NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Wilt TJ, Shamliyan T, Taylor B, et al. Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Feb. (Comparative Effectiveness Reviews, No. 13.)

Cover of Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer

Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer [Internet].

Show details

Appendix DList of Excluded Studies

For Key Questions 1, 2, and 4: Excluded studies are available from the American Urological Association Guideline for the Management of Clinically Localized Prostate Cancer Database. (In press.)

There were 13,888 citations retrieved and reviewed. Of these, 1,764 were selected for winnowing; 759 accepted for further review, and 592 articles, judged potentially eligible, underwent an extraction process. The main reasons (and number of rejected articles) for rejection to narrow articles from 1,764 to 759 were: no outcomes data (435) and T3/T2 contamination (401). Upon further review of the 592 potentially eligible articles, 156 were rejected. Reasons for rejection (and number of rejected articles) included: no outcomes data (31); not local disease (38); T1–T2 patients <50 (7); known duplicate publications (10); other (60).

Question 1. Quality of Life

PCOS

1.
Hoffman RM, Gilliland FD, Penson DF, Stone SN, Hunt WC, Potosky AL. Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer. 2004;101(9):2011–9. Previously published data . [PubMed: 15452835]
2.
Legler J, Potosky AL, Gilliland FD. et al. Validation Study of Retrospective Recall of Disease-Targeted Function: Results From the Prostate Cancer Outcomes Study. Medical Care. 2000;38(8):847–57. Validation study . [PubMed: 10929996]
3.
Penson DF, Feng Z, Kuniyuki A. et al. General Quality of Life 2 Years Following Treatment for Prostate Cancer: What Influences Outcomes? Results From the Prostate Cancer Outcomes Study. J Clin Oncol. 2003;21:1147–54. Not localized prostate cancer . [PubMed: 12637483]
4.
Potosky AL, Harlan LC, Stanford JL. et al. Prostate Cancer Practice Patterns and Quality of Life: the Prostate Cancer Outcomes Study. Journal of the National Cancer Institute. 1999;91(20):1719–24. No outcomes data . [PubMed: 10528021]
5.
Potosky AL, Knopf K, Clegg LX. et al. Quality-of-Life Outcomes After Primary Androgen Deprivation Therapy: Results >From the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19:3750–57. Not localized prostate cancer . [PubMed: 11533098]
6.
Potosky AL, Legler J, Albertsen PC. et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. Journal of the National Cancer Institute. 2000;92(19):1582–92. Previously published data updated . [PubMed: 11018094]
7.
Potosky AL, Reeve BB, Clegg LX. et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. Journal of the National Cancer Institute. 2002;94(6):430–7. Previously published data updated . [PubMed: 11904315]

Non-PCOS

1.
Abdalla I, Basu A, Hellman S. An evidence-based analysis of the management of localized prostate cancer. Cancer Journal. 2002;8(1):40–6. Review article . [PubMed: 11895202]
2.
Abouassaly R, Lane BR, Lakin MM, Klein EA, Gill IS. Ejaculatory urine incontinence after radical prostatectomy. Urology. 2006 Dec;68(6):1248–52. Less than 100 patients per study arm . [PubMed: 17141827]
3.
Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. Journal of Urology. 2005;173(2):533–6. Less than 100 patients per study arm . [PubMed: 15643240]
4.
Ahmad MM. Psychometric evaluation of the Cognitive Appraisal of Health Scale with patients with prostate cancer. Journal of Advanced Nursing. 2005;49(1):78–86. Not comparative treatments . [PubMed: 15610384]
5.
Ahmad MM, Musil CM, Zauszniewski JA, Resnick MI. Prostate cancer: appraisal, coping, and health status. Journal of Gerontological Nursing. 2005;31(10):34–43. Not comparative treatments . [PubMed: 16262089]
6.
Ahmed S, Davies J. Managing the complications of prostate cryosurgery. BJU International. 2005;95(4):480–1. No QOL outcomes . [PubMed: 15705063]
7.
Al-Abany M, Helgason AR, Adolfsson J, Steineck G. Reliability of assessment of urgency and other symptoms indicating anal sphincter, large bowel or urinary dysfunction. Scandinavian Journal of Urology & Nephrology. 2006;40(5):397–408. Not comparative treatments . [PubMed: 17060087]
8.
Alberts SR, Novotny PJ, Sloan JA, Danella J, Bostwick DG, Sebo TJ. et al. Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial. Am J Ther. 2006 Jul–Aug;13(4):291–7. Less than 100 patients per study arm . [PubMed: 16858161]
9.
Albertsen PC. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy. Journal of Urology. 2005;174(5):1969–70. No QOL outcomes . [PubMed: 16217368]
10.
Alexianu M, Weiss GH. Radical prostatectomy versus brachytherapy for early-stage prostate cancer. Journal of Endourology. 2000;14(4):325–8. No QOL outcomes . [PubMed: 10910147]
11.
Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD. Do older men benefit from curative therapy of localized prostate cancer? Journal of Clinical Oncology. 2003;21(17):3318–27. No QOL outcomes . [PubMed: 12947068]
12.
Allen ZA, Merrick GS, Butler WM, Wallner KE, Kurko B, Anderson RL. et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. International Journal of Radiation Oncology, Biology, Physics. 2005;62(4):981–7. No QOL outcomes . [PubMed: 15989998]
13.
Anast JW, Sadetsky N, Pasta DJ, Bassett WW, Latini D, DuChane J. et al. The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE) Journal of Urology. 2005;173(4):1132–8. Not comparative treatments . [PubMed: 15758721]
14.
Anastasiadis AG, Sachdev R, Salomon L, Ghafar MA, Stisser BC, Shabsigh R. et al. Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer. Journal of Cancer Research & Clinical Oncology. 2003;129(12):676–82. Not RCT . [PubMed: 14569465]
15.
Anger JT, Maliski SL, Krupski TL, Kwan L, Gore JL, Fink A. et al. Outcomes in men denied access to a California public assistance program for prostate cancer. Public Health Rep. 2007 Mar–Apr;122(2):217–23. Not comparative treatments . [PMC free article: PMC1820425] [PubMed: 17357364]
16.
Anonymous. Researchers study quality of life after prostate cancer. ONS News 2000;15(8):13. Not prospective or longitudinal survey study or RCT. [PubMed: 12017659]
17.
Anonymous. Patient comfort an important consideration for treating men with prostate cancer. Urologic Nursing 2002;22(4):285. Not prospective or longitudinal survey study or RCT. [PubMed: 12242903]
18.
Anonymous. Bush vs. Kerry: who is healthier? Both candidates are active, so their cardiovascular systems seem to be in tip-top shape. But they've had health problems typical of men their age. Harvard Health Letter 2004;30(1):6–7. Not localized prostate cancer. [PubMed: 15556925]
19.
Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva SJ, Wallace KL. et al. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. Journal of Urology. 2004;172(5 Pt 1):1830–4. CaPSURE data . [PubMed: 15540732]
20.
Arredondo SA, Elkin EP, Marr PL, Latini DM, DuChane J, Litwin MS. et al. Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: data from CaPSURE. Urology. 2006;67(3):559–65. CaPSURE data . [PubMed: 16527580]
21.
Arredondo SA, Latini DM, Sadetsky N, Kawakami J, Pasta DJ, DuChane J. et al. Quality of life for men receiving a second treatment for prostate cancer. Journal of Urology. 2007 Jan;177(1):273–8. discussion 8–9. Not comparative treatments. [PubMed: 17162062]
22.
Ashayeri E, Omogbehin A, Sridhar R, Shankar RA. Strontium 89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience. Journal of the National Medical Association. 2002;94(8):706–11. Not localized prostate cancer . [PMC free article: PMC2594277] [PubMed: 12152927]
23.
Augustin H, Pummer K, Daghofer F, Habermann H, Primus G, Hubmer G. Patient self-reporting questionnaire on urological morbidity and bother after radical retropubic prostatectomy. European Urology. 2002;42(2):112–17. Not comparative treatments . [PubMed: 12160580]
24.
Auvinen A, Vornanen T, Tammela TL, Ala-Opas M, Leppilahti M, Salminen P. et al. A randomized trial of the choice of treatment in prostate cancer: design and baseline characteristics. BJU International. 2001;88(7):708–15. No QOL outcomes . [PubMed: 11890241]
25.
Bacon CG, Giovannucci E, Testa M, Glass TA, Kawachi I. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer. 2002;94(3):862–71. Not comparative treatments . [PubMed: 11857323]
26.
Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. Journal of Urology. 2001;166(5):1804–10. Not prospective or longitudinal survey study . [PubMed: 11586228]
27.
Bailey DE, Mishel MH, Belyea M, Stewart JL, Mohler J. Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nursing. 2004;27(5):339–46. Not comparative treatments . [PubMed: 15525860]
28.
Ball AJ, Gambill B, Fabrizio MD, Davis JW, Given RW, Lynch DF. et al. Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. Journal of Endourology. 2006 Oct;20(10):723–31. Less than 1 year duration or follow-up . [PubMed: 17094746]
29.
Bang H, Jung SH, George SL. Sample size calculation for simulation-based multiple-testing procedures. Journal of Biopharmaceutical Statistics. 2005;15(6):957–67. Not localized prostate cancer . [PubMed: 16279354]
30.
Barqawi A, O'Donnell C, Kumar R, Koul H, Crawford ED. Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW) International Journal of Impotence Research. 2005;17(4):370–4. Not comparative treatments . [PubMed: 15889121]
31.
Barreto F, Dall'Oglio M, Srougi M. Recurrent vesicourethal stenosis after radical prostatectomy: how to treat it? International Braz J Urol. 2005;31(6):552–4. Less than 100 patients per study arm . [PubMed: 16386124]
32.
Basu A, Meltzer D. Value of information on preference heterogeneity and individualized care. Medical Decision Making. 2007 Mar–Apr;27(2):112–27. Not comparative treatments . [PubMed: 17409362]
33.
Batista-Miranda JE, Sevilla-Cecilia C, Torrubia R, Musquera M, Huguet-Perez J, Ponce de Leon X. et al. Quality of life in prostate cancer patients and controls: psychometric validation of the FACTP-4 in Spanish, and relation to urinary symptoms. Archivos Espanoles de Urologia. 2003;56(4):447–54. Not comparative treatments . [PubMed: 12830620]
34.
Befort CA, Zelefsky MJ, Scardino PT, Borrayo E, Giesler RB, Kattan MW. A measure of health-related quality of life among patients with localized prostate cancer: results from ongoing scale development. Clinical Prostate Cancer. 2005;4(2):100–8. Validation study . [PubMed: 16197610]
35.
Ben-Tovim DI, Dougherty ML, Stapleton AM, Pinnock CB. Coping with prostate cancer: a quantitative analysis using a new instrument, the centre for clinical excellence in urological research coping with cancer instrument. Urology. 2002;59(3):383–8. Not prospective or longitudinal survey study or RCT . [PubMed: 11880075]
36.
Berglund G, Petersson LM, Eriksson KC, Wallenius I, Roshanai A, Nordin KM. et al. “Between Men”: a psychosocial rehabilitation programme for men with prostate cancer. Acta Oncologica. 2007;46(1):83–9. Not comparative treatments . [PubMed: 17438709]
37.
Berry W, Friedland D, Fleagle J, Jackson D, Ilegbodu D, Boehm KA. et al. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer. 2006 Sep;5(2):131–7. Not comparative treatments . [PubMed: 17026801]
38.
Bertaccini A, Ceccarelli R, Urbinati M, Galassi P, Vitullo G, De Stefano R. et al. BSP-PC (Bononian Satisfaction Profile—Prostate Cancer): development and validation of a “disease-specific” questionnaire for the evaluation of health-related quality of life in patients with prostate cancer. Archivio Italiano di Urologia, Andrologia. 2003;75(4):187–94. Less than 100 patients per study arm . [PubMed: 15005491]
39.
Bestmann B, Loetters C, Diemer T, Weidner W, Kuchler T, Rohde V. Prostate-specific symptoms of prostate cancer in a German general population. Prostate Cancer & Prostatic Diseases. 2007;10(1):52–9. Not comparative treatments . [PubMed: 17102801]
40.
Bestmann B, Rohde V, Siebmann JU, Galalae R, Weidner W, Kuchler T. Validation of the German prostate-specific module. World Journal of Urology. 2006 Feb;24(1):94–100. Not prospective or longitudinal survey study or RCT . [PubMed: 16421733]
41.
Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Research. 2006;66(2):1234–40. Not localized prostate cancer . [PubMed: 16424063]
42.
Bex A, Otto T, Lummen G, Rubben H. Phase II study of repeated single 24-hour infusion of low-dose 5-fluorouracil for palliation in symptomatic hormone-refractory prostate cancer. Urologia Internationalis. 2002;69(4):273–7. Not localized prostate cancer . [PubMed: 12444282]
43.
Bianco FJ Jr, Riedel ER, Begg CB, Kattan MW, Scardino PT. Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters.[see comment] Journal of Urology. 2005;173(6):2099–103. No QOL outcomes . [PMC free article: PMC1855289] [PubMed: 15879851]
44.
Bidoli E, Talamini R, Bosetti C, Negri E, Maruzzi D, Montella M. et al. Macronutrients, fatty acids, cholesterol and prostate cancer risk. Annals of Oncology. 2005;16(1):152–7. No QOL outcomes . [PubMed: 15598953]
45.
Bisson JI, Chubb HL, Bennett S, Mason M, Jones D, Kynaston H. The prevalence and predictors of psychological distress in patients with early localized prostate cancer. BJU International. 2002;90(1):56–61. Not comparative treatments . [PubMed: 12081771]
46.
Black PC, Basen-Engquist K, Wang X, Swartz RJ, Eddings T, Matin SF. et al. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. BJU International. 2007 Jul;100(1):63–9. Not localized prostate cancer . [PubMed: 17552954]
47.
Blank TO, Bellizzi KM. After prostate cancer: predictors of well-being among long-term prostate cancer survivors. Cancer. 2006;106(10):2128–35. Not localized prostate cancer . [PubMed: 16607648]
48.
Blatt HJ, Abel LJ, Stipetich RL, Galbreath RW, Lief JH, Butler WM. et al. Utilization of a self-administered questionnaire to assess rectal function following prostate brachytherapy. Urologic Nursing. 2001;21(5):356–9. Not comparative treatments . [PubMed: 11998302]
49.
Bloom JR, Stewart SL, Oakley-Girvans I, Banks PJ, Chang S. Family history, perceived risk, and prostate cancer screening among African American men. Cancer Epidemiology, Biomarkers & Prevention. 2006 Nov;15(11):2167–73. Not comparative treatments . [PubMed: 17119042]
50.
Boberg EW, Gustafson DH, Hawkins RP, Offord KP, Koch C, Wen KY. et al. Assessing the unmet information, support and care delivery needs of men with prostate cancer. Patient Education & Counseling. 2003;49(3):233–42. Not comparative treatments . [PubMed: 12642195]
51.
Boccardo F, Rubagotti A, Conti G, Potenzoni D, Manganelli A, Del Monaco D. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. Cancer Chemotherapy & Pharmacology. 2005;56(4):415–20. No QOL outcomes . [PubMed: 15838655]
52.
Bode RK, Lai JS, Dineen K, Heinemann AW, Shevrin D, Von Roenn J. et al. Expansion of a physical function item bank and development of an abbreviated form for clinical research. Journal of Applied Measurement. 2006;7(1):1–15. Not localized prostate cancer . [PubMed: 16385148]
53.
Boehmer U, Babayan RK. Facing erectile dysfunction due to prostate cancer treatment: perspectives of men and their partners. Cancer Investigation. 2004;22(6):840–8. Less than 100 patients per study arm . [PubMed: 15641481]
54.
Bokhour BG, Clark JA, Inui TS, Silliman RA, Talcott JA. Sexuality after treatment for early prostate cancer: exploring the meanings of “erectile dysfunction”.[see comment] Journal of General Internal Medicine. 2001;16(10):649–55. No QOL outcomes . [PMC free article: PMC1495277] [PubMed: 11679031]
55.
Bondy SJ, Iscoe NA, Rothwell DM, Gort EH, Fleshner NE, Paszat LF. et al. Trends in hormonal management of prostate cancer: a population-based study in Ontario. Medical Care. 2001;39(4):384–96. No QOL outcomes . [PubMed: 11329525]
56.
Borchers H, Kirschner-Hermanns R, Brehmer B, Tietze L, Reineke T, Pinkawa M. et al. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results. BJU International. 2004;94(6):805–11. Less than 100 patients per study arm . [PubMed: 15476513]
57.
Bradley EB, Bissonette EA, Theodorescu D. Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer. BJU International. 2004;94(7):1003–9. Not localized prostate cancer . [PubMed: 15541117]
58.
Brandeis J, Pashos CL, Henning JM, Litwin MS. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Cancer. 2000;89(8):1792–9. No QOL outcomes . [PubMed: 11042575]
59.
Brandeis JM, Litwin MS, Burnison CM, Reiter RE. Quality of life outcomes after brachytherapy for early stage prostate cancer. Journal of Urology. 2000;163(3):851–7. Not prospective or longitudinal survey study . [PubMed: 10687991]
60.
Brar R, Maliski SL, Kwan L, Krupski TL, Litwin MS. Changes in quality of life among low-income men treated for prostate cancer. Urology. 2005;66(2):344–9. Not localized prostate cancer . [PubMed: 16040094]
61.
Brasso K, Friis S, Juel K, Jorgensen T, Iversen P. The need for hospital care of patients with clinically localized prostate cancer managed by noncurative intent: a population based registry study. Journal of Urology. 2000;163(4):1150–4. No QOL outcomes . [PubMed: 10737485]
62.
Brehmer B, Kirschner-Hermanns R, Donner A, Reineke T, Knuchel-Clarke R, Jakse G. Efficacy of unilateral nerve sparing in radical perineal prostatectomy. Urologia Internationalis. 2005;74(4):308–14. Not comparative treatments . [PubMed: 15897694]
63.
Brindle LA, Oliver SE, Dedman D, Donovan JL, Neal DE, Hamdy FC. et al. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. BJU International. 2006 Oct;98(4):777–82. Not comparative treatments . [PubMed: 16978272]
64.
Brown CT, O'Flynn E, Van Der Meulen J, Newman S, Mundy AR, Emberton M. The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened? BJU International. 2003;91(1):30–2. Not localized prostate cancer . [PubMed: 12614245]
65.
Bruchovsky N, Klotz LH, Sadar M, Crook JM, Hoffart D, Godwin L. et al. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Molecular Urology. 2000;4(3):191–9. discussion 201. No QOL outcomes. [PubMed: 11062374]
66.
Bruner DW, Hanlon A, Mazzoni S, Raysor S, Konski A, Hanks G. et al. Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 2004;58(1):34–42. Not comparative treatments . [PubMed: 14697418]
67.
Buhler KR, Santucci RA, Royai RA, Whitney SC, Vessella RL, Lange PH. et al. Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model. Prostate. 2000;43(1):63–70. Not human study . [PubMed: 10725867]
68.
Burns SM, Mahalik JR. Physical health, self-reliance, and emotional control as moderators of the relationship between locus of control and mental health among men treated for prostate cancer. J Behav Med. 2006 Dec;29(6):561–72. Not comparative treatments . [PubMed: 16988886]
69.
Burns-Cox N, Basketter V, Higgins B, Holmes S. Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer. International Journal of Urology. 2002;9(8):431–4. Not localized prostate cancer . [PubMed: 12225339]
70.
Buron C, Le Vu B, Cosset JM, Pommier P, Peiffert D, Delannes M. et al. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. International Journal of Radiation Oncology, Biology, Physics. 2007 Mar 1;67(3):812–22. Not localized prostate cancer . [PubMed: 17293235]
71.
Butler WM, Merrick GS, Dorsey AT, Lief JH, Galbreath RW. Modern prostate brachytherapy. Medical Dosimetry. 2000;25(3):149–53. Review article . [PubMed: 11025262]
72.
Caffo O, Fellin G, Bolner A, Coccarelli F, Divan C, Frisinghelli M. et al. Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 2006 Sep 1;66(1):31–7. Not comparative treatments . [PubMed: 16765529]
73.
Calvert NW, Morgan AB, Catto JW, Hamdy FC, Akehurst RL, Mouncey P. et al. Effectiveness and cost-effectiveness of prognostic markers in prostate cancer. British Journal of Cancer. 2003;88(1):31–5. No QOL outcomes . [PMC free article: PMC2376796] [PubMed: 12556955]
74.
Cambio AJ, Ellison LM, Chamie K, deVere White RW, Evans CP. Cost-benefit and outcome analysis: effect of prostate biopsy undergrading. Urology. 2007 Jun;69(6):1152–6. Not comparative treatments . [PubMed: 17572205]
75.
Campbell LC, Keefe FJ, McKee DC, Edwards CL, Herman SH, Johnson LE. et al. Prostate cancer in African Americans: relationship of patient and partner self-efficacy to quality of life. Journal of Pain & Symptom Management. 2004;28(5):433–44. Not localized prostate cancer . [PubMed: 15504620]
76.
Campbell LC, Keefe FJ, Scipio C, McKee DC, Edwards CL, Herman SH. et al. Facilitating research participation and improving quality of life for African American prostate cancer survivors and their intimate partners. A pilot study of telephone-based coping skills training. Cancer. 2007 Jan 15;109(2 Suppl):414–24. Not comparative treatments . [PubMed: 17173280]
77.
Canada AL, Neese LE, Sui D, Schover LR. Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Cancer. 2005;104(12):2689–700. No QOL outcomes . [PubMed: 16294343]
78.
Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosomatic Medicine. 2003;65(4):571–81. Less than 100 patients per study arm . [PubMed: 12883107]
79.
Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology. 2004;29(4):448–74. Less than 100 patients per study arm . [PubMed: 14749092]
80.
Carmack Taylor CL, de Moor C, Basen-Engquist K, Smith MA, Dunn AL, Badr H. et al. Moderator analyses of participants in the Active for Life after cancer trial: implications for physical activity group intervention studies. Ann Behav Med. 2007 Feb;33(1):99–104. Not comparative treatments . [PubMed: 17291175]
81.
Carmack Taylor CL, Demoor C, Smith MA, Dunn AL, Basen-Engquist K, Nielsen I. et al. Active for Life After Cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients. Psycho-Oncology. 2006 Oct;15(10):847–62. Less than 100 patients per study arm . [PubMed: 16447306]
82.
Carmack Taylor CL, Smith MA, de Moor C, Dunn AL, Pettaway C, Sellin R. et al. Quality of life intervention for prostate cancer patients: design and baseline characteristics of the active for life after cancer trial. Controlled Clinical Trials. 2004;25(3):265–85. No QOL outcomes . [PubMed: 15157729]
83.
Cathala N, Brillat F, Mombet A, Lobel E, Prapotnich D, Alexandre L. et al. Patient followup after radical prostatectomy by Internet medical file. Journal of Urology. 2003;170(6 Pt 1):2284–7. Not comparative treatments . [PubMed: 14634397]
84.
Cereceda LE, Flechon A, Droz JP. Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients. Clinical Prostate Cancer. 2003;2(1):34–40. Not localized prostate cancer . [PubMed: 15046682]
85.
Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2003;56(4):1085–92. Not comparative treatments . [PubMed: 12829146]
86.
Chander S, Choo R, Danjoux C, Morton G, Pearse A, Deboer G. et al. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. International Journal of Radiation Oncology, Biology, Physics. 2005;62(3):719–24. Less than 100 patients per study arm . [PubMed: 15936551]
87.
Chapple A, Ziebland S, Shepperd S, Miller R, Herxheimer A, McPherson A. Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study.[see comment] BMJ. 2002;325(7367):737. Not comparative treatments . [PMC free article: PMC128372] [PubMed: 12364299]
88.
Chaussy C, Thuroff S. Results and side effects of high-intensity focused ultrasound in localized prostate cancer. Journal of Endourology. 2001;15(4):437–40. discussion 47–8. No QOL outcomes. [PubMed: 11394458]
89.
Chaussy C, Thuroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Current Urology Reports. 2003;4(3):248–52. No QOL outcomes . [PubMed: 12756090]
90.
Cheli CD, Levine RL, Cambetas DR, Kolker JD, Roberts SB. Age-related reference ranges for complexed prostate-specific antigen and complexed/total prostate-specific antigen ratio: results from East Texas Medical Center Cancer Institute screening campaign. Urology. 2002;60(4 Suppl 1):53–9. Not comparative treatments . [PubMed: 12384164]
91.
Chiu BC, Anderson JR, Corbin D. Predictors of prostate cancer screening among health fair participants. Public Health. 2005;119(8):686–93. Not comparative treatments . [PubMed: 15949522]
92.
Choo R, Do V, Herschorn S, DeBoer G, Danjoux C, Morton G. et al. Urodynamic changes at 18 months post-therapy in patients treated with external beam radiotherapy for prostate carcinoma. International Journal of Radiation Oncology, Biology, Physics. 2002;53(2):290–6. Less than 100 patients per study arm . [PubMed: 12023132]
93.
Chrouser KL, Leibovich BC, Sweat SD, Larson DW, Davis BJ, Tran NV. et al. Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. Journal of Urology. 2005;173(6):1953–7. No QOL outcomes . [PubMed: 15879789]
94.
Clark JA, Bokhour BG, Inui TS, Silliman RA, Talcott JA. Measuring patients' perceptions of the outcomes of treatment for early prostate cancer. Medical Care. 2003;41(8):923–36. Not localized prostate cancer . [PubMed: 12886172]
95.
Clark JA, Inui TS, Silliman RA, Bokhour BG, Krasnow SH, Robinson RA. et al. Patients' perceptions of quality of life after treatment for early prostate cancer. Journal of Clinical Oncology. 2003;21(20):3777–84. Not localized prostate cancer . [PubMed: 14551296]
96.
Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Medical Care. 2001;39(10):1118–30. Validation study . [PubMed: 11567174]
97.
Clark JA, Talcott JA. Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made. Journal of Clinical Oncology. 2006 Sep 20;24(27):4457–63. Not comparative treatments . [PubMed: 16983114]
98.
Cliff AM, MacDonagh RP. Psychosocial morbidity in prostate cancer: I. Design of a new questionnaire. BJU International. 2000;86(7):829–33. Not comparative treatments . [PubMed: 11069409]
99.
Cohen JH, Schoenbach VJ, Kaufman JS, Talcott JA, Schenck AP, Peacock S. et al. Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States) Cancer Causes Control. 2006 Aug;17(6):803–11. No QOL outcomes . [PubMed: 16783608]
100.
Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004;64(2):335–40. No QOL outcomes . [PubMed: 15302490]
101.
Cooperberg MR, Koppie TM, Lubeck DP, Ye J, Grossfeld GD, Mehta SS. et al. How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE. Urology. 2003;61(1):190–6. CaPSURE data . [PubMed: 12559294]
102.
Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. Journal of Clinical Oncology. 2004;22(11):2141–9. CaPSURE data . [PMC free article: PMC2997214] [PubMed: 15169800]
103.
Cormier L, Guillemin F, Valeri A, Fournier G, Cussenot O, Mangin P. et al. Impact of prostate cancer screening on health-related quality of life in at-risk families. Urology. 2002;59(6):901–6. Not comparative treatments . [PubMed: 12031378]
104.
Courneya KS, Segal RJ, Reid RD, Jones LW, Malone SC, Venner PM. et al. Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivors. Journal of Clinical Epidemiology. 2004;57(6):571–9. Not comparative treatments . [PubMed: 15246125]
105.
Crawford ED. Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks. Urology. 2003;62(6 Suppl 1):13–9. Not comparative treatments . [PubMed: 14706504]
106.
Crowe H, Costello AJ. Prostate cancer: perspectives on quality of life and impact of treatment on patients and their partners. Urologic Nursing. 2003;23(4):279–85. Not localized prostate cancer . [PubMed: 14552074]
107.
Dacal K, Sereika SM, Greenspan SL. Quality of life in prostate cancer patients taking androgen deprivation therapy. Journal of the American Geriatrics Society. 2006;54(1):85–90. Not localized prostate cancer . [PubMed: 16420202]
108.
Dahm P, Silverstein AD, Weizer AZ, Young MD, Vieweg J, Albala DM. et al. A longitudinal assessment of bowel related symptoms and fecal incontinence following radical perineal prostatectomy. Journal of Urology. 2003;169(6):2220–4. Not comparative treatments . [PubMed: 12771754]
109.
Dahn JR, Penedo FJ, Gonzalez JS, Esquiabro M, Antoni MH, Roos BA. et al. Sexual functioning and quality of life after prostate cancer treatment: considering sexual desire. Urology. 2004;63(2):273–7. Not localized prostate cancer . [PubMed: 14972470]
110.
Dahn JR, Penedo FJ, Molton I, Lopez L, Schneiderman N, Antoni MH. Physical activity and sexual functioning after radiotherapy for prostate cancer: beneficial effects for patients undergoing external beam radiotherapy. Urology. 2005;65(5):953–8. Not comparative treatments . [PubMed: 15882730]
111.
Dale W, Hemmerich J, Meltzer D. Extending the validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) at the time of prostate biopsy in a racially-mixed population. Psycho-Oncology. 2007 May;16(5):493–8. Not comparative treatments . [PubMed: 17080494]
112.
Dalkin BL, Christopher BA, Shawler D. Health related quality of life outcomes after radical prostatectomy: attention to study design and the patient-based importance of single-surgeon studies. Urologic Oncology. 2006;24(1):28–32. Not comparative treatments . [PubMed: 16414489]
113.
Dalkin BL, Wessells H, Cui H. A national survey of urinary and health related quality of life outcomes in men with an artificial urinary sphincter for post-radical prostatectomy incontinence. Journal of Urology. 2003;169(1):237–9. Not comparative treatments . [PubMed: 12478144]
114.
D'Amico A, Cormack R, Kumar S, Tempany CM. Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer. Journal of Endourology. 2000;14(4):367–70. Not comparative treatments . [PubMed: 10910153]
115.
Daubenmier JJ, Weidner G, Marlin R, Crutchfield L, Dunn-Emke S, Chi C. et al. Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology. 2006;67(1):125–30. Not comparative treatments . [PubMed: 16413347]
116.
Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality.[see comment] Journal of Urology. 2001;166(3):947–52. Not prospective or longitudinal survey study . [PubMed: 11490252]
117.
Davison BJ, Goldenberg SL. Decisional regret and quality of life after participating in medical decision-making for early-stage prostate cancer. BJU International. 2003;91(1):14–7. Less than 100 patients per study arm . [PubMed: 12614242]
118.
Davison BJ, Parker PA, Goldenberg SL. Patients' preferences for communicating a prostate cancer diagnosis and participating in medical decision-making. BJU International. 2004;93(1):47–51. Less than 100 patients per study arm . [PubMed: 14678366]
119.
Deimling GT, Bowman KF, Sterns S, Wagner LJ, Kahana B. Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. Psycho-Oncology. 2006 Apr;15(4):306–20. Not comparative treatments . [PubMed: 16041841]
120.
Deimling GT, Sterns S, Bowman KF, Kahana B. The health of older-adult, long-term cancer survivors. Cancer Nursing. 2005;28(6):415–24. Not comparative treatments . [PubMed: 16330962]
121.
Deinsberger R, Regatschnig R, Kaiser B, Bankl HC. Spinal leptomeningeal metastases from prostate cancer. J Neurooncol. 2006 Feb;76(3):293–7. Not comparative treatments . [PubMed: 16151594]
122.
Deinsberger R, Regatschnig R, Kaiser B, Bankl HC. Spinal leptomeningeal metastases from prostate cancer. Acta Neurochir (Wien) 2006 Apr;148(4):467–71. Not comparative treatments . [PubMed: 16322903]
123.
Deliveliotis C, Liakouras C, Delis A, Skolarikos A, Varkarakis J, Protogerou V. Prostate operations: long-term effects on sexual and urinary function and quality of life. Comparison with an age-matched control population. Urological Research. 2004;32(4):283–9. Not comparative treatments . [PubMed: 15057494]
124.
Demark-Wahnefried W, Clipp EC, McBride C, Lobach DF, Lipkus I, Peterson B. et al. Design of FRESH START: a randomized trial of exercise and diet among cancer survivors. Medicine & Science in Sports & Exercise. 2003;35(3):415–24. Not comparative treatments . [PubMed: 12618570]
125.
Demark-Wahnefried W, Clipp EC, Morey MC, Pieper CF, Sloane R, Snyder DC. et al. Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD. Journal of Clinical Oncology. 2006 Jul 20;24(21):3465–73. Not comparative treatments . [PMC free article: PMC1532928] [PubMed: 16849763]
126.
Demark-Wahnefried W, Morey MC, Clipp EC, Pieper CF, Snyder DC, Sloane R. et al. Leading the Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast and prostate cancer survivors. Controlled Clinical Trials. 2003;24(2):206–23. Not comparative treatments . [PubMed: 12689742]
127.
Demark-Wahnefried W, Peterson B, McBride C, Lipkus I, Clipp E. Current health behaviors and readiness to pursue life-style changes among men and women diagnosed with early stage prostate and breast carcinomas. Cancer. 2000;88(3):674–84. Not comparative treatments . [PubMed: 10649263]
128.
Denis L. Europa uomo. BJU International. 2007 Jun;99(6):1329–30. Not comparative treatments . [PubMed: 17419704]
129.
Denis LJ. Europa Uomo: The European Prostate Cancer Coalition. Archivio Italiano di Urologia, Andrologia. 2006 Dec;78(4):157–60. Not comparative treatments . [PubMed: 17269623]
130.
Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56(2):302–6. Not localized prostate cancer . [PubMed: 10925098]
131.
Descazeaud A, Zerbib M, Hofer MD, Chaskalovic J, Debre B, Peyromaure M. Evolution of health-related quality of life two to seven years after retropubic radical prostatectomy: evaluation by UCLA prostate cancer index. World Journal of Urology. 2005;23(4):257–62. Not comparative treatments . [PubMed: 16136358]
132.
Diefenbach MA, Hamrick N, Uzzo R, Pollack A, Horwitz E, Greenberg R. et al. Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer. Journal of Urology. 2003;170(1):166–9. Not comparative treatments . [PubMed: 12796672]
133.
Djozic J. The nerve sparing radical prostatectomy—a step to better quality of life-surgical aspects. Acta Chirurgica Iugoslavica. 2005;52(4):63–7. Not comparative treatments . [PubMed: 16673598]
134.
Do V, Choo R, Deboer G, Herschorn S, Danjoux C, Chen CH. et al. Urodynamic findings 3 months after radiotherapy in patients treated with conformal external beam radiotherapy for prostate carcinoma.[see comment] BJU International. 2002;90(1):62–7. Not comparative treatments . [PubMed: 12081772]
135.
Docherty A, Brothwell CPD, Symons M. The impact of inadequate knowledge on patient and spouse experience of prostate cancer. Cancer Nursing. 2007 Jan–Feb;30(1):58–63. Less than 100 patients per study arm . [PubMed: 17235222]
136.
Donnelly BJ, Saliken JC, Ernst DS, Ali-Ridha N, Brasher PM, Robinson JW. et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology. 2002;60(4):645–9. Not comparative treatments . [PubMed: 12385926]
137.
Downs TM, Sadetsky N, Pasta DJ, Grossfeld GD, Kane CJ, Mehta SS. et al. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer—data from CaPSURE.[see comment] Journal of Urology. 2003;170(5):1822–7. CaPSURE data . [PubMed: 14532784]
138.
Dunsmuir WD, McFarlane JP, Tan A, Dowling C, Downie J, Kourambas J. et al. Gyrus bipolar electrovaporization vs transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y follow-up. Prostate Cancer & Prostatic Diseases. 2003;6(2):182–6. Not localized prostate cancer . [PubMed: 12806380]
139.
Durham J, Low M, McLeod D. Screening for prostate cancer: a survey of New Zealand general practitioners.[see comment] New Zealand Medical Journal. 2003;116(1176):U476. Not comparative treatments . [PubMed: 12835804]
140.
Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003;62(Suppl 1):55–62. No QOL outcomes . [PubMed: 14747042]
141.
Egawa S, Shimura S, Irie A, Kitano M, Nishiguchi I, Kuwao S. et al. Toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Japanese Journal of Clinical Oncology. 2001;31(11):541–7. Less than 100 patients per study arm . [PubMed: 11773262]
142.
Eggener SE, Stern JA, Jain PM, Oram S, Ai J, Cai X. et al. Enhancement of intermittent androgen ablation by “off-cycle” maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate. 2006;66(5):495–502. Not human study . [PubMed: 16372330]
143.
Elkin EB, Cowen ME, Cahill D, Steffel M, Kattan MW. Preference assessment method affects decision-analytic recommendations: a prostate cancer treatment example.[see comment] Medical Decision Making. 2004;24(5):504–10. No QOL outcomes . [PubMed: 15358999]
144.
Eller LS, Lev EL, Gejerman G, Colella J, Esposito M, Lanteri V. et al. Prospective study of quality of life of patients receiving treatment for prostate cancer. Nursing Research. 2006;55(2 Suppl):S28–36. Less than 1 year duration or follow-up . [PubMed: 16601630]
145.
Ellerby JH, McKenzie J, McKay S, Gariepy GJ, Kaufert JM. Bioethics for clinicians: 18. Aboriginal cultures.[see comment] CMAJ Canadian Medical Association Journal. 2000;163(7):845–50. Not localized prostate cancer . [PMC free article: PMC80510] [PubMed: 11033715]
146.
Elstein AS, Chapman GB, Chmiel JS, Knight SJ, Chan C, Nadler RB. et al. Agreement between prostate cancer patients and their clinicians about utilities and attribute importance. Health Expectations. 2004;7(2):115–25. No QOL outcomes . [PMC free article: PMC5060221] [PubMed: 15117386]
147.
Elstein AS, Chapman GB, Knight SJ. Patients' values and clinical substituted judgments: the case of localized prostate cancer. Health Psychology. 2005;24(4 Suppl):S85–92. No QOL outcomes . [PubMed: 16045424]
148.
Enger SM, Van den Eeden SK, Sternfeld B, Loo RK, Quesenberry CP Jr, Rowell S. et al. California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting. BMC Public Health. 2006;6:172. Not comparative treatments . [PMC free article: PMC1569841] [PubMed: 16813653]
149.
Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ. et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. Journal of Clinical Oncology. 2003;21(17):3335–42. Not localized prostate cancer . [PubMed: 12947070]
150.
Eskicorapci SY, Karabulut E, Turkeri L, Baltaci S, Cal C, Toktas G. et al. Validation of 2001 Partin tables in Turkey: a multicenter study. European Urology. 2005;47(2):185–9. No QOL outcomes . [PubMed: 15661412]
151.
Eton DT, Lai JS, Cella D, Reeve BB, Talcott JA, Clark JA. et al. Data pooling and analysis to build a preliminary item bank: an example using bowel function in prostate cancer. Evaluation & the Health Professions. 2005;28(2):142–59. No QOL outcomes . [PubMed: 15851770]
152.
Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors. Cancer. 2001;92(6):1451–9. Less than 1 year duration or follow-up . [PMC free article: PMC2610318] [PubMed: 11745222]
153.
Eton DT, Lepore SJ, Helgeson VS. Psychological distress in spouses of men treated for early-stage prostate carcinoma. Cancer. 2005;103(11):2412–8. Not comparative treatments . [PMC free article: PMC2610316] [PubMed: 15858824]
154.
Evans BR, Peterson BL, Demark-Wahnefried W. No difference in response rate to a mailed survey among prostate cancer survivors using conditional versus unconditional incentives. Cancer Epidemiology, Biomarkers & Prevention. 2004;13(2):277–8. No QOL outcomes . [PubMed: 14973100]
155.
Faithfull S, Corner J, Meyer L, Huddart R, Dearnaley D. Evaluation of nurse-led follow up for patients undergoing pelvic radiotherapy. British Journal of Cancer. 2001;85(12):1853–64. Not comparative treatments . [PMC free article: PMC2364007] [PubMed: 11747326]
156.
Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. European Urology. 2005;47(4):449–54. discussion 54–5. Not localized prostate cancer. [PubMed: 15774240]
157.
Fearing A, Bell D, Newton M, Lambert S. Prostate screening health beliefs and practices of African American men. ABNF Journal. 2000;11(6):141–4. Not comparative treatments . [PubMed: 11760286]
158.
Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM, Bruner DW. et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. International Journal of Radiation Oncology, Biology, Physics. 2005;62(4):956–64. Not comparative treatments . [PubMed: 15989995]
159.
Feneley MR, Brewster S. Opportunities and outcomes in early prostate cancer: a commentary on policy, patient perspectives, trials and strategies. BJU International. 2003;91(3):177–8. Review article . [PubMed: 12580998]
160.
Ferrero JM, Chamorey E, Oudard S, Dides S, Lesbats G, Cavaglione G. et al. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer. 2006 Aug 15;107(4):738–45. Not comparative treatments . [PubMed: 16826591]
161.
Ficarra V, Novara G, Galfano A, Stringari C, Baldassarre R, Cavalleri S. et al. Twelve-month self-reported quality of life after retropubic radical prostatectomy: a prospective study with Rand 36-Item Health Survey (Short Form-36) BJU International. 2006;97(2):274–8. Not comparative treatments . [PubMed: 16430628]
162.
Ficarra V, Righetti R, D'Amico A, Pilloni S, Balzarro M, Schiavone D. et al. General state of health and psychological well-being in patients after surgery for urological malignant neoplasms. Urologia Internationalis. 2000;65(3):130–4. Less than 100 patients per study arm . [PubMed: 11054029]
163.
Fillion L, Gelinas C, Simard S, Savard J, Gagnon P. Validation evidence for the French Canadian adaptation of the Multidimensional Fatigue Inventory as a measure of cancer-related fatigue. Cancer Nursing. 2003;26(2):143–54. Validation study . [PubMed: 12660563]
164.
Filocamo MT, Li Marzi V, Del Popolo G, Cecconi F, Villari D, Marzocco M. et al. Pharmacologic treatment in postprostatectomy stress urinary incontinence. European Urology. 2007 Jun;51(6):1559–64. Less than 100 patients per study arm . [PubMed: 16942833]
165.
Finne P, Stenman UH, Maattanen L, Makinen T, Tammela TL, Martikainen P. et al. The Finnish trial of prostate cancer screening: where are we now? BJU International. 2003;92(Suppl 2):22–6. Not comparative treatments . [PubMed: 14983949]
166.
Finney G, Haynes AM, Cross P, Brenner P, Boyn A, Stricker P. Cross-sectional analysis of sexual function after prostate brachytherapy. Urology. 2005;66(2):377–81. Not comparative treatments . [PubMed: 16098365]
167.
Fisher M. The endothelin-1 antagonist, atrasentan, improves time to progression and quality of life in hormone-refractory prostate cancer. Clinical Prostate Cancer. 2002;1(2):79–80. Not localized prostate cancer . [PubMed: 15046697]
168.
Fleshner N, Dranitsaris G, Finelli A, Tsihlias J, Bell D, Gleave M. et al. Surgical wait times for patients with urological cancers: a survey of Canadian surgeons. Canadian Journal of Urology. 2006 Jun;13(Suppl 3):3–13. Not comparative treatments . [PubMed: 16818006]
169.
Fossa SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW. et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. Journal of Clinical Oncology. 2001;19(1):62–71. Not localized prostate cancer . [PubMed: 11134196]
170.
Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma.[see comment] Cancer. 2002;95(2):287–95. Not prospective or longitudinal survey study . [PubMed: 12124828]
171.
Fowler JE Jr, Viadur Study G. Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer. Urology. 2001;58(3):430–4. Not comparative treatments . [PubMed: 11549494]
172.
Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. Journal of Urology. 2007 Jun;177(6):2151–6. discussion 6. Not prospective or longitudinal survey study or RCT. [PubMed: 17509305]
173.
Fransson P. Recall of pretreatment symptoms among men treated with radiotherapy for prostate cancer. Acta Oncologica. 2005;44(4):355–61. Not comparative treatments . [PubMed: 16120544]
174.
Fransson P, Tavelin B, Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy-induced side effects. Supportive Care in Cancer. 2001;9(3):187–98. Less than 100 patients per study arm . [PubMed: 11401103]
175.
Freedland SJ, Haffner MC, Landis PK, Saigal CS, Carter HB. Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy. Urology. 2005;65(6):1131–6. Not comparative treatments . [PubMed: 15913722]
176.
Froehner M, Koch R, Litz R, Oehlschlaeger S, Wirth MP. Which conditions contributing to the Charlson score predict survival after radical prostatectomy? Journal of Urology. 2004;171(2 Pt 1):697–9. No QOL outcomes . [PubMed: 14713789]
177.
Froehner M, Litz R, Manseck A, Hakenberg OW, Leike S, Albrecht DM. et al. Relationship of comorbidity, age and perioperative complications in patients undergoing radical prostatectomy. Urologia Internationalis. 2001;67(4):283–8. No QOL outcomes . [PubMed: 11741129]
178.
Gacci M, Livi L, Paiar F, Detti B, Litwin MS, Bartoletti R. et al. Quality of life after radical treatment of prostate cancer: validation of the Italian version of the University of California-Los Angeles Prostate Cancer Index. Urology. 2005;66(2):338–43. Not localized prostate cancer . [PubMed: 16098363]
179.
Galalae RM, Loch T, Riemer B, Rzehak P, Kuchler T, Kimmig B. et al. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer. Strahlentherapie und Onkologie. 2004;180(9):582–9. Not comparative treatments . [PubMed: 15378189]
180.
Galbraith ME, Arechiga A, Ramirez J, Pedro LW. Prostate cancer survivors' and partners' selfreports of health-related quality of life, treatment symptoms, and marital satisfaction 2.5–5.5 years after treatment. Oncology Nursing Forum 2005;Online. 32(2):E30–41. Previously published data. [PubMed: 15759059]
181.
Gall TL. The role of religious coping in adjustment to prostate cancer. Cancer Nursing. 2004;27(6):454–61. Not comparative treatments . [PubMed: 15632786]
182.
Gall TL. Relationship with God and the quality of life of prostate cancer survivors. Quality of Life Research. 2004;13(8):1357–68. Not comparative treatments . [PubMed: 15503831]
183.
Gaston KE, Kouba E, Moore DT, Pruthi RS. The use of erythropoietin in patients undergoing radical prostatectomy: effects on hematocrit, transfusion rates and quality of life. Urologia Internationalis. 2006;77(3):211–5. Less than 100 patients per study arm . [PubMed: 17033207]
184.
Gattellari M, Ward JE. Will men attribute fault to their GP for adverse effects arising from controversial screening tests? An Australian study using scenarios about PSA screening. Journal of Medical Screening. 2004;11(4):165–9. Not comparative treatments . [PubMed: 15563771]
185.
Geinitz H, Zimmermann FB, Thamm R, Erber C, Muller T, Keller M. et al. Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer. Radiotherapy & Oncology. 2006 Jun;79(3):341–7. Not comparative treatments . [PubMed: 16733072]
186.
Ghavamian R, Zincke H. Technique for nerve dissection. Seminars in Urologic Oncology. 2000;18(1):43–5. Not comparative treatments . [PubMed: 10719930]
187.
Giard N, Lichtenstein P, Yashin AI. A multistate model for the genetic analysis of the ageing process. Statistics in Medicine. 2002;21(17):2511–26. Not comparative treatments . [PubMed: 12205696]
188.
Giesler RB, Given B, Given CW, Rawl S, Monahan P, Burns D. et al. Improving the quality of life of patients with prostate carcinoma: a randomized trial testing the efficacy of a nurse-driven intervention. Cancer. 2005;104(4):752–62. Not comparative treatments . [PubMed: 15986401]
189.
Giesler RB, Miles BJ, Cowen ME, Kattan MW. Assessing quality of life in men with clinically localized prostate cancer: development of a new instrument for use in multiple settings. Quality of Life Research. 2000;9(6):645–65. Validation study . [PubMed: 11236855]
190.
Gilling PJ, Kennett KM, Fraundorfer MR. Holmium laser resection v transurethral resection of the prostate: results of a randomized trial with 2 years of follow-up. Journal of Endourology. 2000;14(9):757–60. Not localized prostate cancer . [PubMed: 11110572]
191.
Given B, Given C, Azzouz F, Stommel M. Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nursing Research. 2001;50(4):222–32. Not localized prostate cancer . [PubMed: 11480531]
192.
Goeman L, Salomon L, La De Taille A, Vordos D, Hoznek A, Yiou R. et al. Long-term functional and oncological results after retroperitoneal laparoscopic prostatectomy according to a prospective evaluation of 550 patients. World Journal of Urology. 2006 Aug;24(3):281–8. Not comparative treatments . [PubMed: 16508788]
193.
Gohagan JK, Prorok PC, Hayes RB, Kramer BS, Prostate LCaOCSTPT. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Controlled Clinical Trials 2000;21(6 Suppl):251S–72S. Not comparative treatments. [PubMed: 11189683]
194.
Gomella LG, Albertsen PC, Benson MC, Forman JD, Soloway MS. The use of video-based patient education for shared decision-making in the treatment of prostate cancer. Seminars in Urologic Oncology. 2000;18(3):182–7. No QOL outcomes . [PubMed: 10975489]
195.
Gomha MA, Boone TB. Artificial urinary sphincter for post-prostatectomy incontinence in men who had prior radiotherapy: a risk and outcome analysis.[see comment] Journal of Urology. 2002;167(2 Pt 1):591–6. No QOL outcomes . [PubMed: 11792924]
196.
Gore JL, Krupski T, Kwan L, Fink A, Litwin MS. Mental health of low income uninsured men with prostate cancer. Journal of Urology. 2005;173(4):1323–6. Not comparative treatments . [PubMed: 15758790]
197.
Gore JL, Krupski T, Kwan L, Maliski S, Litwin MS. Partnership status influences quality of life in low-income, uninsured men with prostate cancer. Cancer. 2005;104(1):191–8. Not comparative treatments . [PubMed: 15912494]
198.
Gore JL, Penson DF, Litwin MS. Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer. Nat Clin Pract Urol. 2006 Aug;3(8):449–52. Not comparative treatments . [PubMed: 16902521]
199.
Gotay CC. Quality of life research in Hawaii's cancer survivors. Hawaii Medical Journal. 2001;60(7):189. Not localized prostate cancer . [PubMed: 11496533]
200.
Gotay CC, Holup JL, Pagano I. Ethnic differences in quality of life among early breast and prostate cancer survivors.[see comment] Psycho-Oncology. 2002;11(2):103–13. Not localized prostate cancer . [PubMed: 11921326]
201.
Gralla O, Haas F, Knoll N, Hadzidiakos D, Tullmann M, Romer A. et al. Fast-track surgery in laparoscopic radical prostatectomy: basic principles. World Journal of Urology. 2007 Apr;25(2):185–91. Less than 100 patients per study arm . [PubMed: 17171563]
202.
Gralnek D, Wessells H, Cui H, Dalkin BL. Differences in sexual function and quality of life after nerve sparing and nonnerve sparing radical retropubic prostatectomy. Journal of Urology. 2000;163(4):1166–9. discussion 9–70. Not prospective or longitudinal survey study. [PubMed: 10737488]
203.
Gray RE, Wassersug RJ, Sinding C, Barbara AM, Trosztmer C, Fleshner N. The experiences of men receiving androgen deprivation treatment for prostate cancer: a qualitative study. Canadian Journal of Urology. 2005;12(4):2755–63. Less than 100 patients per study arm . [PubMed: 16197599]
204.
Green HJ, Pakenham KI, Headley BC, Gardiner RA. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psycho-Oncology. 2002;11(5):401–14. Not localized prostate cancer . [PubMed: 12228873]
205.
Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN. et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.[see comment] BJU International. 2004;93(7):975–9. Less than 100 patients per study arm . [PubMed: 15142146]
206.
Greene KL, Cowan JE, Cooperberg MR, Meng MV, DuChane J, Carroll PR. et al. Who is the average patient presenting with prostate cancer? Urology. 2005;66(5 Suppl):76–82. CaPSURE data . [PubMed: 16194711]
207.
Grein U, Meyer WW. Local recurrent cancer after radical prostatectomy and incontinence. Is the artificial urinary sphincter a useful therapeutic option? Urologia Internationalis. 2001;66(1):9–12. Not comparative treatments . [PubMed: 11150943]
208.
Gudbergsson SB, Fossa SD, Borgeraas E, Dahl AA. A comparative study of living conditions in cancer patients who have returned to work after curative treatment. Supportive Care in Cancer. 2006 Oct;14(10):1020–9. Not comparative treatments . [PubMed: 16572315]
209.
Guirguis-Blake J. Screening for prostate cancer. Am Fam Physician. 2007 Feb 1;75(3):336–7. Not comparative treatments . [PubMed: 17304863]
210.
Gwede CK, Pow-Sang J, Seigne J, Heysek R, Helal M, Shade K. et al. Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer. 2005;104(7):1381–90. No QOL outcomes . [PubMed: 16080181]
211.
Hack TF, Pickles T, Bultz BD, Ruether JD, Degner LF. Impact of providing audiotapes of primary treatment consultations to men with prostate cancer: a multi-site, randomized, controlled trial. Psycho-Oncology. 2007 Jun;16(6):543–52. Not comparative treatments . [PubMed: 16991107]
212.
Hallberg O. Adverse health indicators correlating with sparsely populated areas in Sweden. Eur J Cancer Prev. 2007 Feb;16(1):71–6. Not comparative treatments . [PubMed: 17220707]
213.
Hammadeh MY, Madaan S, Hines J, Philp T. 5-year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. Urology. 2003;61(6):1166–71. Not localized prostate cancer . [PubMed: 12809891]
214.
Hamrick N, Diefenbach MA. Religion and spirituality among patients with localized prostate cancer. Palliat Support Care. 2006 Dec;4(4):345–55. Not comparative treatments . [PubMed: 17133894]
215.
Hara I, Kawabata G, Miyake H, Nakamura I, Hara S, Okada H. et al. Comparison of quality of life following laparoscopic and open prostatectomy for prostate cancer. Journal of Urology. 2003;169(6):2045–8. Not localized prostate cancer . [PubMed: 12771715]
216.
Harden J, Schafenacker A, Northouse L, Mood D, Smith D, Pienta K, et al. Couples' experiences with prostate cancer: focus group research. Oncology Nursing Forum 2002;Online. 29(4):701–9. Less than 100 patients per study arm. [PubMed: 12011916]
217.
Harden JK, Northouse LL, Mood DW. Qualitative analysis of couples' experience with prostate cancer by age cohort. Cancer Nursing. 2006 Sep–Oct;29(5):367–77. Not comparative treatments . [PubMed: 17006110]
218.
Harrod HL. A piece of my mind. An essay on desire. JAMA. 2003;289(7):813–4. Review article . [PubMed: 12588245]
219.
Hashine K, Azuma K, Koizumi T, Sumiyoshi Y. Health-related quality of life and treatment outcomes for men with prostate cancer treated by combined external-beam radiotherapy and hormone therapy. International Journal of Clinical Oncology. 2005;10(1):45–50. Not comparative treatments . [PubMed: 15729601]
220.
Hedestig O, Sandman PO, Tomic R, Widmark A. Living after radical prostatectomy for localized prostate cancer: a qualitative analysis of patient narratives. Acta Oncologica. 2005;44(7):679–86. Less than 100 patients per study arm . [PubMed: 16227157]
221.
Hedestig O, Sandman PO, Tomic R, Widmark A. Living after external beam radiotherapy of localized prostate cancer: a qualitative analysis of patient narratives. Cancer Nursing. 2005;28(4):310–7. Less than 100 patients per study arm . [PubMed: 16046895]
222.
Hedestig O, Sandman PO, Widmark A. Living with untreated localized prostate cancer: a qualitative analysis of patient narratives.[see comment] Cancer Nursing. 2003;26(1):55–60. Less than 100 patients per study arm . [PubMed: 12556713]
223.
Heidenreich A, Sommer F, Ohlmann CH, Schrader AJ, Olbert P, Goecke J. et al. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Cancer. 2004;101(5):948–56. Not localized prostate cancer . [PubMed: 15329902]
224.
Helgeson VS, Lepore SJ, Eton DT. Moderators of the benefits of psychoeducational interventions for men with prostate cancer. Health Psychology. 2006 May;25(3):348–54. Not comparative treatments . [PMC free article: PMC2678168] [PubMed: 16719606]
225.
Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J. et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer. 2003;98(8):1603–10. Not localized prostate cancer . [PubMed: 14534875]
226.
Henderson A, Andreyev HJN, Stephens R, Dearnaley D. Patient and physician reporting of symptoms and health-related quality of life in trials of treatment for early prostate cancer: considerations for future studies. Clin Oncol (R Coll Radiol) 2006 Dec;18(10):735–43. Review article . [PubMed: 17168208]
227.
Hervouet S, Savard J, Simard S, Ivers H, Laverdiere J, Vigneault E. et al. Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery. Journal of Pain & Symptom Management. 2005;30(5):474–84. Not localized prostate cancer . [PubMed: 16310621]
228.
Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, Niedermann G. et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells—a pilot study. Prostate. 2007 Apr 1;67(5):500–8. Not localized prostate cancer . [PubMed: 17262804]
229.
Hindley RG, Mostafid AH, Brierly RD, Harrison NW, Thomas PJ, Fletcher MS. The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate. BJU International. 2001;88(3):217–20. Not localized prostate cancer . [PubMed: 11488732]
230.
Hoffman RM, Gilliland FD, Penson DF, Stone SN, Hunt WC, Potosky AL. Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer. 2004;101(9):2011–9. Previously published data . [PubMed: 15452835]
231.
Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, Han M, Sanda MG. Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. Urology. 2002;59(4):480–4. Not comparative treatments . [PubMed: 11927294]
232.
Hollenbeck BK, Dunn RL, Wei JT, Montie JE, Sanda MG. Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. Journal of Urology. 2003;169(4):1453–7. Not comparative treatments . [PubMed: 12629382]
233.
Hollenbeck BK, Wei JT, Sanda MG, Dunn RL, Sandler HM. Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer. Urology. 2004;63(5):946–50. Not comparative treatments . [PubMed: 15134986]
234.
Holmes-Rovner M, Stableford S, Fagerlin A, Wei JT, Dunn RL, Ohene-Frempong J. et al. Evidence-based patient choice: a prostate cancer decision aid in plain language. BMC Medical Informatics & Decision Making. 2005;5(1):16. No QOL outcomes . [PMC free article: PMC1168900] [PubMed: 15963238]
235.
Hon NHY, Brathwaite D, Hussain Z, Ghiblawi S, Brace H, Hayne D. et al. A prospective, randomized trial comparing conventional transurethral prostate resection with PlasmaKinetic vaporization of the prostate: physiological changes, early complications and long-term followup. Journal of Urology. 2006 Jul;176(1):205–9. Less than 100 patients per study arm . [PubMed: 16753403]
236.
Hong JH, Jeon SS, Lee HM, Choi YH, Kim S, Choi HY. The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales in men with prostate cancer: reliability and validity of the Korean version. J Korean Med Sci. 2006 Apr;21(2):295–9. Not comparative treatments . [PMC free article: PMC2734007] [PubMed: 16614517]
237.
Hoyle DW. Confronting prostate cancer: a personal reflection. N C Med J. 2006 Mar–Apr;67(2):128–9. Not prospective or longitudinal survey study or RCT . [PubMed: 16752716]
238.
Hsu EI, Hong EK, Lepor H. Influence of body weight and prostate volume on intraoperative, perioperative, and postoperative outcomes after radical retropubic prostatectomy. Urology. 2003;61(3):601–6. Not comparative treatments . [PubMed: 12639655]
239.
Hu JC, Elkin EP, Krupski TL, Gore J, Litwin MS. The effect of postprostatectomy external beam radiotherapy on quality of life: results from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer. 2006 Jul 15;107(2):281–8. CaPSURE data . [PubMed: 16779794]
240.
Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR. et al. Predicting quality of life after radical prostatectomy: results from CaPSURE.[see comment] Journal of Urology. 2004;171(2 Pt 1):703–7. discussion 7–8. CaPSURE data. [PubMed: 14713791]
241.
Hu JC, Kwan L, Saigal CS, Litwin MS. Regret in men treated for localized prostate cancer. Journal of Urology. 2003;169(6):2279–83. Not comparative treatments . [PubMed: 12771770]
242.
Hughes Halbert C, Weathers B, Delmoor E. Developing an academic-community partnership for research in prostate cancer. Journal of Cancer Education. 2006;21(2):99–103. No QOL outcomes . [PubMed: 17020523]
243.
Hunt-Shanks TT, Blanchard CM, Baker F, Hann D, Roberts CS, McDonald J. et al. Exercise use as complementary therapy among breast and prostate cancer survivors receiving active treatment: examination of exercise intention. Integrative Cancer Therapies. 2006 Jun;5(2):109–16. Not comparative treatments . [PubMed: 16685075]
244.
Hurwitz MD, Cormack R, Tempany CM, Kumar S, D'Amico AV. Three-dimensional real-time magnetic resonance-guided interstitial prostate brachytherapy optimizes radiation dose distribution resulting in a favorable acute side effect profile in patients with clinically localized prostate cancer. Techniques in Urology. 2000;6(2):89–94. Not comparative treatments . [PubMed: 10798806]
245.
Ishihara M, Suzuki H, Akakura K, Komiya A, Imamoto T, Tobe T. et al. Baseline health-related quality of life in the management of prostate cancer. International Journal of Urology. 2006 Jul;13(7):920–5. Not comparative treatments . [PubMed: 16882056]
246.
Jacobsen NEB, Moore KN, Estey E, Voaklander D. Open versus laparoscopic radical prostatectomy: a prospective comparison of postoperative urinary incontinence rates. Journal of Urology. 2007 Feb;177(2):615–9. Not prospective or longitudinal survey study or RCT . [PubMed: 17222646]
247.
Jakobsson L. Indwelling catheter treatment and health-related quality of life in men with prostate cancer in comparison with men with benign prostatic hyperplasia. Scandinavian Journal of Caring Sciences. 2002;16(3):264–71. Not comparative treatments . [PubMed: 12191038]
248.
Jakobsson L, Hallberg IR, Loven L. Experiences of micturition problems, indwelling catheter treatment and sexual life consequences in men with prostate cancer. Journal of Advanced Nursing. 2000;31(1):59–67. Not comparative treatments . [PubMed: 10632794]
249.
Jakobsson L, Loven L, Hallberg IR. Micturition problems in relation to quality of life in men with prostate cancer or benign prostatic hyperplasia: comparison with men from the general population. Cancer Nursing. 2004;27(3):218–29. Not comparative treatments . [PubMed: 15238809]
250.
Janda M, Gerstner N, Obermair A, Fuerst A, Wachter S, Dieckmann K. et al. Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer. 2000;89(6):1322–8. Not localized prostate cancer . [PubMed: 11002229]
251.
Jarow JP. Puboprostatic ligament sparing radical retropubic prostatectomy. Seminars in Urologic Oncology. 2000;18(1):28–32. Not comparative treatments . [PubMed: 10719927]
252.
Jayadevappa R, Bloom BS, Fomberstein SC, Wein AJ, Malkowicz SB. Health related quality of life and direct medical care cost in newly diagnosed younger men with prostate cancer. Journal of Urology. 2005;174(3):1059–64. discussion 64. Less than 100 patients per study arm. [PubMed: 16094058]
253.
Jayadevappa R, Chhatre S, Whittington R, Bloom BS, Wein AJ, Malkowicz SB. Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy. BJU International. 2006;97(5):955–62. Not localized prostate cancer . [PubMed: 16643477]
254.
Jayadevappa R, Johnson JC, Chhatre S, Wein AJ, Malkowicz SB. Ethnic variation in return to baseline values of patient-reported outcomes in older prostate cancer patients. Cancer. 2007 Jun 1;109(11):2229–38. Not comparative treatments . [PubMed: 17443664]
255.
Jenkins R, Schover LR, Fouladi RT, Warneke C, Neese L, Klein EA. et al. Sexuality and health-related quality of life after prostate cancer in African-American and white men treated for localized disease. Journal of Sex & Marital Therapy. 2004;30(2):79–93. Not comparative treatments . [PubMed: 14742098]
256.
Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.[see comment] BJU International. 2005;96(1):48–53. Less than 100 patients per study arm . [PubMed: 15963119]
257.
Jepson R, Clegg A, Forbes C, Lewis R, Sowden A, Kleijnen J. The determinants of screening uptake and interventions for increasing uptake: a systematic review. Health Technology Assessment (Winchester, England) 2000;4(14):i–vii. Review article . [PubMed: 10984843]
258.
Jo Y, Hiratsuka J, Fujii T, Takenaka A, Fujisawa M. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c–T3bN0M0 prostate cancer. Urology. 2004;64(3):556–60. Not localized prostate cancer . [PubMed: 15351592]
259.
Jo Y, Junichi H, Tomohiro F, Yoshinari I, Masato F. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life. BJU International. 2005;96(1):43–7. Not localized prostate cancer . [PubMed: 15963118]
260.
Johannsen M, Gneveckow U, Eckelt L, Feussner A, Waldofner N, Scholz R. et al. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. International Journal of Hyperthermia. 2005;21(7):637–47. No QOL outcomes . [PubMed: 16304715]
261.
Johannsen M, Gneveckow U, Taymoorian K, Thiesen B, Waldofner N, Scholz R. et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. International Journal of Hyperthermia. 2007 May;23(3):315–23. Less than 100 patients per study arm . [PubMed: 17523023]
262.
Johnstone PA, Gray C, Powell CR. Quality of life in T1–3N0 prostate cancer patients treated with radiation therapy with minimum 10-year follow-up. International Journal of Radiation Oncology, Biology, Physics. 2000;46(4):833–8. Not localized prostate cancer . [PubMed: 10705003]
263.
Joly F, Alibhai SMH, Galica J, Park A, Yi QL, Wagner L. et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. Journal of Urology. 2006 Dec;176(6 Pt 1):2443–7. Less than 100 patients per study arm . [PubMed: 17085125]
264.
Joseph HJ, Thibault GP, Ruttle-King J. Perceived stress and quality of life among prostate cancer survivors. Mil Med. 2006 May;171(5):425–9. Not comparative treatments . [PubMed: 16761894]
265.
Jurczok A, Zacharias M, Wagner S, Hamza A, Fornara P. Prospective non-randomized evaluation of four mediators of the systemic response after extraperitoneal laparoscopic and open retropubic radical prostatectomy. BJU International. 2007 Jun;99(6):1461–6. Not localized prostate cancer . [PubMed: 17537217]
266.
Kaasa S, Brenne E, Lund JA, Fayers P, Falkmer U, Holmberg M. et al. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy × 1) versus multiple fractions (3 Gy × 10) in the treatment of painful bone metastases. Radiotherapy & Oncology. 2006 Jun;79(3):278–84. Not localized prostate cancer . [PubMed: 16793154]
267.
Kaiho Y, Nakagawa H, Ikeda Y, Namiki S, Numahata K, Satoh M. et al. Intraoperative electrophysiological confirmation of urinary continence after radical prostatectomy. Journal of Urology. 2005;173(4):1139–42. Not comparative treatments . [PubMed: 15758722]
268.
Kakehi Y, Kamoto T, Ogawa O, Arai Y, Litwin MS, Suzukamo Y. et al. Development of Japanese version of the UCLA Prostate Cancer Index: a pilot validation study. International Journal of Clinical Oncology. 2002;7(5):306–11. Validation study . [PubMed: 12402065]
269.
Kakehi Y, Takegami M, Suzukamo Y, Namiki S, Arai Y, Kamoto T. et al. Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite. Journal of Urology. 2007 May;177(5):1856–61. Less than 100 patients per study arm . [PubMed: 17437836]
270.
Kalkner KM, Acosta S, Thorsson O, Frederiksen H, Nilsson A, Gustavsson B. et al. Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer. Prostate Cancer & Prostatic Diseases. 2006;9(1):92–8. Not localized prostate cancer . [PubMed: 16231013]
271.
Kang SH, Kim JW, Bae JH, Park HS, Moon DG, Yoon DK. et al. Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy: quality of life in high-risk prostate cancer patients. Asian J Androl. 2006 Sep;8(5):629–36. Less than 100 patients per study arm . [PubMed: 16847531]
272.
Kao GD, Devine P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer. 2000;88(3):615–9. Less than 100 patients per study arm . [PubMed: 10649255]
273.
Kao J, Turian J, Meyers A, Hamilton RJ, Smith B, Vijayakumar S. et al. Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer. British Journal of Radiology. 2004;77(914):129–36. Less than 100 patients per study arm . [PubMed: 15010385]
274.
Ka'opua LSL, Gotay CC, Boehm PS. Spiritually based resources in adaptation to long-term prostate cancer survival: perspectives of elderly wives. Health Soc Work. 2007 Feb;32(1):29–39. Less than 100 patients per study arm . [PubMed: 17432739]
275.
Karakiewicz PI, Kattan MW, Tanguay S, Elhilali MM, Bazinet M, Scardino PT. et al. Cross-cultural validation of the UCLA prostate cancer index. Urology. 2003;61(2):302–7. Validation study . [PubMed: 12597935]
276.
Karakiewicz PI, Tanguay S, Kattan MW, Elhilali MM, Aprikian AG. Erectile and urinary dysfunction after radical prostatectomy for prostate cancer in Quebec: a population-based study of 2415 men. European Urology. 2004;46(2):188–94. Not comparative treatments . [PubMed: 15245812]
277.
Kasimis B, Wilding G, Kreis W, Feuerman M, Chang V, Hwang S. et al. Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D2) prostate cancer.[see comment] Cancer Investigation. 2000;18(7):602–8. Not localized prostate cancer . [PubMed: 11036467]
278.
Kattan MW, Fearn PA, Miles BJ. Time trade-off utility modified to accommodate degenerative and life-threatening conditions. Proceedings / AMIA Annual Symposium 2001:304–8. Not comparative treatments. [PMC free article: PMC2243360] [PubMed: 11825200]
279.
Katz D, Koppie TM, Wu D, Meng MV, Grossfeld GD, Sadesky N. et al. Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups. Journal of Urology. 2002;168(5):2092–6. Not comparative treatments . [PubMed: 12394716]
280.
Katz G, Rodriguez R. Use of a modified American Urological Association Symptom Score for the evaluation of the quality of life of patients with prostate cancer. Urology. 2001;57(1):112–6. Validation study . [PubMed: 11164154]
281.
Katz G, Rodriguez R. Changes in continence and health-related quality of life after curative treatment and watchful waiting of prostate cancer. Urology. 2007 Jun;69(6):1157–60. Less than 100 patients per study arm . [PubMed: 17572206]
282.
Kaul S, Savera A, Badani K, Fumo M, Bhandari A, Menon M. Functional outcomes and oncological efficacy of Vattikuti Institute prostatectomy with Veil of Aphrodite nerve-sparing: an analysis of 154 consecutive patients. BJU International. 2006;97(3):467–72. Not comparative treatments . [PubMed: 16469009]
283.
Key TJ, Allen N, Appleby P, Overvad K, Tjonneland A, Miller A. et al. Fruits and vegetables and prostate cancer: no association among 1104 cases in a prospective study of 130544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC) International Journal of Cancer. 2004;109(1):119–24. Not comparative treatments . [PubMed: 14735477]
284.
Kim SP, Knight SJ, Tomori C, Colella KM, Schoor RA, Shih L. et al. Health literacy and shared decision making for prostate cancer patients with low socioeconomic status. Cancer Investigation. 2001;19(7):684–91. Not comparative treatments . [PubMed: 11577809]
285.
Kim Y, Roscoe JA, Morrow GR. The effects of information and negative affect on severity of side effects from radiation therapy for prostate cancer. Supportive Care in Cancer. 2002;10(5):416–21. Not comparative treatments . [PubMed: 12136225]
286.
Kinsinger DP, Penedo FJ, Antoni MH, Dahn JR, Lechner S, Schneiderman N. Psychosocial and sociodemographic correlates of benefit-finding in men treated for localized prostate cancer. Psycho-Oncology. 2006 Nov;15(11):954–61. Not comparative treatments . [PubMed: 16523528]
287.
Kirby R. Case study: management of lymph node-positive disease detected at radical prostatectomy. Prostate Cancer & Prostatic Diseases. 2005;8(3):287–9. Less than 100 patients per study arm . [PubMed: 15940288]
288.
Kirschner-Hermanns R, Jakse G. Quality of life following radical prostatectomy. Frontiers of Radiation Therapy & Oncology. 2002;36:99–105. Not comparative treatments . [PubMed: 11842760]
289.
Klabunde CN, Reeve BB, Harlan LC, Davis WW, Potosky AL. Do patients consistently report comorbid conditions over time?: results from the prostate cancer outcomes study. Medical Care. 2005;43(4):391–400. No QOL outcomes . [PubMed: 15778642]
290.
Knight SJ, Latini DM, Hart SL, Sadetsky N, Kane CJ, DuChane J. et al. Education predicts quality of life among men with prostate cancer cared for in the Department of Veterans Affairs: a longitudinal quality of life analysis from CaPSURE. Cancer. 2007 May 1;109(9):1769–76. CaPSURE data . [PubMed: 17380491]
291.
Knight SJ, Siston AK, Chmiel JS, Slimack N, Elstein AS, Chapman GB. et al. Ethnic variation in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans. Clinical Prostate Cancer. 2004;3(1):31–7. No QOL outcomes . [PubMed: 15279688]
292.
Ko CM, Malcarne VL, Varni JW, Roesch SC, Banthia R, Greenbergs HL. et al. Problem-solving and distress in prostate cancer patients and their spousal caregivers. Supportive Care in Cancer. 2005;13(6):367–74. Not comparative treatments . [PMC free article: PMC1599706] [PubMed: 15657688]
293.
Kobayashi T, Nishizawa K, Mitsumori K. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer. Scandinavian Journal of Urology & Nephrology. 2006;40(3):198–203. No QOL outcomes . [PubMed: 16809259]
294.
Kolodziej M, Neubauer MA, Rousey SR, Pluenneke RE, Perrine G, Mull S. et al. Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer. Clin Genitourin Cancer. 2006 Sep;5(2):155–61. Not comparative treatments . [PubMed: 17026805]
295.
Konski A, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck JR. et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 2006 Oct 1;66(2):408–15. Not comparative treatments . [PubMed: 16887291]
296.
Korfage IJ, de Koning HJ, Habbema JDF, Schroder FH, Essink-Bot ML. Side-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy controls? BJU International. 2007 Apr;99(4):801–6. Less than 100 patients per study arm . [PubMed: 17233804]
297.
Korfage IJ, de Koning HJ, Roobol M, Schroder FH, Essink-Bot ML. Prostate cancer diagnosis: the impact on patients' mental health. European Journal of Cancer. 2006;42(2):165–70. Not comparative treatments . [PubMed: 16326098]
298.
Korfage IJ, Essink-Bot ML, Borsboom GJ, Madalinska JB, Kirkels WJ, Habbema JD. et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. International Journal of Cancer. 2005;116(2):291–6. Not localized prostate cancer . [PubMed: 15800919]
299.
Korfage IJ, Essink-Bot ML, Madalinska JB, Kirkels WJ, Litwin MS, de Koning HJ. Measuring disease specific quality of life in localized prostate cancer: the Dutch experience. Quality of Life Research. 2003;12(4):459–64. Validation study . [PubMed: 12797718]
300.
Korfage IJ, Hak T, de Koning HJ, Essink-Bot ML. Patients' perceptions of the side-effects of prostate cancer treatment—a qualitative interview study. Soc Sci Med. 2006 Aug;63(4):911–9. Less than 100 patients per study arm . [PubMed: 16798130]
301.
Kornblith AB, Herndon JE 2nd, Zuckerman E, Godley PA, Savarese D, Vogelzang NJ. et al. The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Annals of Oncology. 2001;12(5):633–41. Not localized prostate cancer . [PubMed: 11432621]
302.
Koroukian SM, Murray P, Madigan E. Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. Journal of Clinical Oncology. 2006;24(15):2304–10. Not localized prostate cancer . [PubMed: 16710028]
303.
Kouba E, Hubbard JS, Moore D, Wallen EM, Pruthi RS. A prospective evaluation of the short-term impact and recovery of health-related quality of life in men undergoing radical prostatectomy. BJU International. 2007 Jan;99(1):72–6. Not comparative treatments . [PubMed: 17227494]
304.
Krahn M, Ritvo P, Irvine J, Tomlinson G, Bezjak A, Trachtenberg J. et al. Construction of the Patient-Oriented Prostate Utility Scale (PORPUS): a multiattribute health state classification system for prostate cancer. Journal of Clinical Epidemiology. 2000;53(9):920–30. Design study . [PubMed: 11004418]
305.
Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A. et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Medical Care. 2003;41(1):153–64. Not localized prostate cancer . [PubMed: 12544552]
306.
Kronenwetter C, Weidner G, Pettengill E, Marlin R, Crutchfield L, McCormac P. et al. A qualitative analysis of interviews of men with early stage prostate cancer: the Prostate Cancer Lifestyle Trial. Cancer Nursing. 2005;28(2):99–107. Less than 100 patients per study arm . [PubMed: 15815179]
307.
Krupski T, Bissonette EA, Petroni GR, Theodorescu D. The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapy. European Urology. 2003;43(5):467–72. Not localized prostate cancer . [PubMed: 12705988]
308.
Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology. 2000;55(5):736–42. Not localized prostate cancer . [PubMed: 10792092]
309.
Krupski TL, Bergman J, Kwan L, Litwin MS. Quality of prostate carcinoma care in a statewide public assistance program. Cancer. 2005;104(5):985–92. Quality of care study . [PubMed: 16047332]
310.
Krupski TL, Fink A, Kwan L, Maliski S, Connor SE, Clerkin B. et al. Health-related quality-of-life in low-income, uninsured men with prostate cancer. Journal of Health Care for the Poor & Underserved. 2005;16(2):375–90. Not localized prostate cancer . [PubMed: 15937399]
311.
Krupski TL, Kwan L, Fink A, Sonn GA, Maliski S, Litwin MS. Spirituality influences health related quality of life in men with prostate cancer. Psycho-Oncology. 2006 Feb;15(2):121–31. Not comparative treatments . [PubMed: 15880458]
312.
Krupski TL, Saigal CS, Litwin MS. Variation in continence and potency by definition.[see comment] Journal of Urology. 2003;170(4 Pt 1):1291–4. Validation study . [PubMed: 14501744]
313.
Kubler HR, Tseng TY, Sun L, Vieweg J, Harris MJ, Dahm P. Impact of nerve sparing technique on patient self-assessed outcomes after radical perineal prostatectomy. Journal of Urology. 2007 Aug;178(2):488–92. discussion 92. Not comparative treatments. [PubMed: 17561133]
314.
Kumar V, Toussi H, Marr C, Hough C, Javle P. The benefits of radical prostatectomy beyond cancer control in symptomatic men with prostate cancer. BJU International. 2004;93(4):507–9. Less than 100 patients per study arm . [PubMed: 15008719]
315.
Kupelian PA, Willoughby TR. Short-course, intensity-modulated radiotherapy for localized prostate cancer. Cancer Journal. 2001;7(5):421–6. Not comparative treatments . [PubMed: 11693901]
316.
Kuriyama M, Takahashi Y, Sahashi M, Ono Y, Tanaka T, Shimizu H. et al. Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Japanese Journal of Clinical Oncology. 2001;31(1):18–24. Not localized prostate cancer . [PubMed: 11256836]
317.
Kwiatkowski M, Huber A, Moschopulos M, Lehmann K, Wernli M, Hafeli A. et al. Prostate cancer screening: results of a prospective trial in Canton Aargau, Switzerland. Swiss Medical Weekly. 2004;134(3940):580–5. Not comparative treatments . [PubMed: 15592949]
318.
Lambert S, Fearing A, Bell D, Newton M. A comparative study of prostate screening health beliefs and practices between African American and Caucasian men. ABNF Journal. 2002;13(3):61–3. Not comparative treatments . [PubMed: 12108142]
319.
Larson G, Pappas N, Hassoun B. Prostate cancer treatment with ultrasound-guided transperineal brachytherapy: analysis of the treatment results of our first 150 patients. Journal - Oklahoma State Medical Association. 2000;93(8):391–6. Not comparative treatments . [PubMed: 10979616]
320.
Latini DM, Chan JM, Cowan JE, Arredondo SA, Kane CJ, Penson DF. et al. Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE. Urology. 2006 Dec;68(6):1242–7. CaPSURE data . [PubMed: 17141841]
321.
Lebeau T, Perrotte P, Valiquette L, Benard F, McCormack M, Saad F. et al. Validation of prostate cancer index and SF-12 short forms. Canadian Journal of Urology. 2005;12(6):2873–9. Validation study . [PubMed: 16401372]
322.
Lee D. Clinical trials of atrasentan in hormone-refractory prostate cancer. Clinical Prostate Cancer. 2003;2(2):84–6. Not localized prostate cancer . [PubMed: 15040868]
323.
Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman SM. Design considerations for efficient prostate cancer chemoprevention trials. Urology. 2001;57(4 Suppl 1):205–12. Not comparative treatments . [PubMed: 11295629]
324.
Lee WR, McQuellon RP, Harris-Henderson K, Case LD, McCullough DL. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 2000;46(1):77–81. Not comparative treatments . [PubMed: 10656376]
325.
Lee WR, McQuellon RP, McCullough DL. A prospective analysis of patient-reported quality of life after prostate brachytherapy. Seminars in Urologic Oncology. 2000;18(2):147–51. Not comparative treatments . [PubMed: 10875457]
326.
Legler J, Potosky AL, Gilliland FD, Eley JW, Stanford JL. Validation study of retrospective recall of disease-targeted function: results from the prostate cancer outcomes study. Medical Care. 2000;38(8):847–57. Validation study . [PubMed: 10929996]
327.
Legler JM, Davis WW, Potosky AL, Hoffman RM. Latent variable modelling of recovery trajectories: sexual function following radical prostatectomy. Statistics in Medicine. 2004;23(18):2875–93. Not comparative treatments . [PubMed: 15344192]
328.
Lehrer S, Cesaretti J, Stone NN, Stock RG. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. BJU International. 2006 Nov;98(5):979–81. Not comparative treatments . [PubMed: 17034599]
329.
Leibovici D, Lee AK, Cheung RM, Spiess PE, Kuban DA, Rosser CJ. et al. Symptomatic local recurrence of prostate carcinoma after radiation therapy. Cancer. 2005;103(10):2060–6. Not comparative treatments . [PubMed: 15822114]
330.
Leitzmann MF. Is there a link between macronutrient intake and prostate cancer? Nature Clinical Practice Oncology. 2005;2(4):184–5. Review article . [PubMed: 16264928]
331.
Lepore SJ, Helgeson VS, Eton DT, Schulz R. Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions. Health Psychology. 2003;22(5):443–52. Not comparative treatments . [PMC free article: PMC2593114] [PubMed: 14570527]
332.
Lertakyamanee J, Ruksamanee EO, Tantiwong A, Boonsuk K, Nilpradab I, Vorakijpokatorn P. et al. The risk and effectiveness of transurethral resection of prostate. Journal of the Medical Association of Thailand. 2002;85(12):1288–95. Not comparative treatments . [PubMed: 12678166]
333.
Lev EL, Eller LS, Gejerman G, Lane P, Owen SV, White M. et al. Quality of life of men treated with brachytherapies for prostate cancer. Health & Quality of Life Outcomes. 2004;2:28. Less than 100 patients per study arm . [PMC free article: PMC442132] [PubMed: 15198803]
334.
Lev EL, Eller LS, Kolassa J, Gejerman G, Colella J, Lane P. et al. Exploratory factor analysis: strategies used by patients to promote health. World Journal of Urology. 2007 Mar;25(1):87–93. No QOL outcomes . [PubMed: 17066263]
335.
Lewinshtein DJ, Perrotte P, Lebeau T, Ramirez A, Benayoun S, Karakiewicz PI. Normal urinary and sexual function in men without evidence of prostate cancer from Montreal, Canada. BJU International. 2006 Jun;97(6):1273–7. Not localized prostate cancer . [PubMed: 16686725]
336.
Lieberman R. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials. Urology. 2001;57(4 Suppl 1):224–9. Not comparative treatments . [PubMed: 11295633]
337.
Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007 Aug;28(8):623–30. Not localized prostate cancer . [PubMed: 17625384]
338.
Liepe K, Runge R, Kotzerke J. Systemic radionuclide therapy in pain palliation. American Journal of Hospice & Palliative Care. 2005;22(6):457–64. Not localized prostate cancer . [PubMed: 16323716]
339.
Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology. 2003;62(4):707–13. Not localized prostate cancer . [PubMed: 14550448]
340.
Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR. et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007 Jun 1;109(11):2239–47. Less than 100 patients per study arm . [PubMed: 17455209]
341.
Litwin MS, Greenfield S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007 May 1;109(9):1777–83. CaPSURE data . [PubMed: 17354226]
342.
Litwin MS, Lubeck DP, Spitalny GM, Henning JM, Carroll PR. Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer. 2002;95(1):54–60. CaPSURE data . [PubMed: 12115317]
343.
Litwin MS, Lubeck DP, Stoddard ML, Pasta DJ, Flanders SC, Henning JM. Quality of life before death for men with prostate cancer: results from the CaPSURE database. Journal of Urology. 2001;165(3):871–5. CaPSURE data . [PubMed: 11176489]
344.
Litwin MS, Melmed GY, Nakazon T. Life after radical prostatectomy: a longitudinal study.[see comment] Journal of Urology. 2001;166(2):587–92. Not comparative treatments . [PubMed: 11458073]
345.
Litwin MS, Pasta DJ, Yu J, Stoddard ML, Flanders SC. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Journal of Urology. 2000;164(6):1973–7. CaPSURE data . [PubMed: 11061894]
346.
Litwin MS, Sadetsky N, Pasta DJ, Lubeck DP. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. Journal of Urology. 2004;172(2):515–9. CaPSURE data . [PubMed: 15247718]
347.
Livingston P, White V, Hayman J, Hill D. How acceptable is a referral and telephone-based outcall programme for men diagnosed with cancer? A feasibility study. Eur J Cancer Care (Engl) 2006 Dec;15(5):467–75. Not comparative treatments . [PubMed: 17177905]
348.
Livsey JE, Routledge J, Burns M, Swindell R, Davidson SE, Cowan RA. et al. Scoring of treatment-related late effects in prostate cancer. Radiotherapy & Oncology. 2002;65(2):109–21. Not comparative treatments . [PubMed: 12443807]
349.
Lock M, Loblaw DA, Choo R, Imrie K. Disseminated intravascular coagulation and PC-SPES: a case report and literature review. Canadian Journal of Urology. 2001;8(4):1326–9. Review article . [PubMed: 11564276]
350.
Lowe FC. Goals for benign prostatic hyperplasia therapy. Urology. 2002;59(2 Suppl 1):1–2. Not localized prostate cancer . [PubMed: 11832306]
351.
Lubeck DP, Kim H, Grossfeld G, Ray P, Penson DF, Flanders SC. et al. Health related quality of life differences between black and white men with prostate cancer: data from the cancer of the prostate strategic urologic research endeavor.[see comment] Journal of Urology. 2001;166(6):2281–5. CaPSURE data . [PubMed: 11696752]
352.
Lubeck DP, Litwin MS, Henning JM, Mathias SD, Bloor L, Carroll PR. An instrument to measure patient satisfaction with healthcare in an observational database: results of a validation study using data from CaPSURE. American Journal of Managed Care. 2000;6(1):70–6. CaPSURE data . [PubMed: 11009748]
353.
Ma G, Troxel AB, Heitjan DF. An index of local sensitivity to nonignorable drop-out in longitudinal modelling. Statistics in Medicine. 2005;24(14):2129–50. Review article . [PubMed: 15909292]
354.
Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer.[see comment] Journal of Clinical Oncology. 2001;19(6):1619–28. Not localized prostate cancer . [PubMed: 11250990]
355.
Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH. Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate. 2001;46(2):87–97. Not comparative treatments . [PubMed: 11170136]
356.
Maier S, Reich E, Martin R, Bachem M, Altug V, Hautmann RE. et al. Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines. International Journal of Cancer. 2000;88(2):245–51. Not localized prostate cancer . [PubMed: 11004676]
357.
Malcarne VL, Banthia R, Varni JW, Sadler GR, Greenbergs HL, Ko CM. Problem-solving skills and emotional distress in spouses of men with prostate cancer. Journal of Cancer Education. 2002;17(3):150–4. Not comparative treatments . [PubMed: 12243220]
358.
Malik A, Mukhtar H. Prostate cancer prevention through pomegranate fruit. Cell Cycle. 2006;5(4):371–3. Not comparative treatments . [PubMed: 16479165]
359.
Maliski SL, Kwan L, Krupski T, Fink A, Orecklin JR, Litwin MS. Confidence in the ability to communicate with physicians among low-income patients with prostate cancer. Urology. 2004;64(2):329–34. Not comparative treatments . [PubMed: 15302489]
360.
Maliski SL, Kwan L, Orecklin JR, Saigal CS, Litwin MS. Predictors of fatigue after treatment for prostate cancer. Urology. 2005;65(1):101–8. No QOL outcomes . [PubMed: 15667873]
361.
Mangar SA, Sydes MR, Tucker HL, Coffey J, Sohaib SA, Gianolini S. et al. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397) Radiotherapy & Oncology. 2006 Sep;80(3):355–62. No QOL outcomes . [PubMed: 16949694]
362.
Mark HF, Samy M, Santoro K, Mark S, Feldman D. Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer. Experimental & Molecular Pathology. 2000;68(1):65–9. Not localized prostate cancer . [PubMed: 10640455]
363.
Marley J. Can quality-of-life measures help in the care of urology patients? Professional Nurse. 2002;18(4):229–31. Review article . [PubMed: 12518618]
364.
Massey P. Intravenous nutrient therapy eliminated androgen deprivation therapy-induced hot flashes in two men with prostate cancer. J Soc Integr Oncol. 2006;4(4):153–6. Not comparative treatments . [PubMed: 17022923]
365.
Matsuura N, Kamae I, Nakamura H, Maruo T. Utility and treatment decisions: 15 clinical cases in Japan. Journal of Evaluation in Clinical Practice. 2001;7(4):419–30. Less than 100 patients per study arm . [PubMed: 11737533]
366.
Maung K. Zoledronic acid is effective in the treatment of prostate cancer patients with bone metastases. Clinical Prostate Cancer. 2002;1(1):12–3. Not localized prostate cancer . [PubMed: 15046707]
367.
McBride CM, Clipp E, Peterson BL, Lipkus IM, Demark-Wahnefried W. Psychological impact of diagnosis and risk reduction among cancer survivors. Psycho-Oncology. 2000;9(5):418–27. Not localized prostate cancer . [PubMed: 11038480]
368.
McElveen TL, Waterman FM, Kim H, Dicker AP. Factors predicting for urinary incontinence after prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2004;59(5):1395–404. Not comparative treatments . [PubMed: 15275725]
369.
McGovern PM, Gross CR, Krueger RA, Engelhard DA, Cordes JE, Church TR. False-positive cancer screens and health-related quality of life. Cancer Nursing. 2004;27(5):347–52. Not comparative treatments . [PubMed: 15525861]
370.
McLaughlin PW, Troyer S, Berri S, Narayana V, Meirowitz A, Roberson PL. et al. Functional anatomy of the prostate: implications for treatment planning. International Journal of Radiation Oncology, Biology, Physics. 2005;63(2):479–91. No QOL outcomes . [PubMed: 16168840]
371.
McPherson CP, Swenson KK, Kjellberg J. Quality of life in patients with prostate cancer. Seminars in Oncology Nursing. 2001;17(2):138–46. Review article . [PubMed: 11383245]
372.
Mehta SS, Lubeck DP, Pasta DJ, Litwin MS. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. Journal of Urology. 2003;170(5):1931–3. CaPSURE data . [PubMed: 14532810]
373.
Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carroll PR. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. Journal of Urology. 2003;170(6 Pt 1):2279–83. CaPSURE data . [PubMed: 14634396]
374.
Merrick GS, Butler WM. Rectal function following permanent prostate brachytherapy. West Virginia Medical Journal. 2004;100(1):18–20. Not comparative treatments . [PubMed: 15119492]
375.
Merrick GS, Butler WM, Dorsey AT, Galbreath RW, Blatt H, Lief JH. Rectal function following prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2000;48(3):667–74. Not comparative treatments . [PubMed: 11020562]
376.
Merrick GS, Butler WM, Galbreath RW, Stipetich RL, Abel LJ, Lief JH. Erectile function after permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2002;52(4):893–902. Not comparative treatments . [PubMed: 11958881]
377.
Merrick GS, Butler WM, Wallner K, Galbreath RW, Anderson RL, Kurko BS. et al. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Urology. 2002;60(1):104–8. Not comparative treatments . [PubMed: 12100933]
378.
Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Lief JH. Brachytherapy-related dysuria. BJU International. 2005;95(4):597–602. Not comparative treatments . [PubMed: 15705087]
379.
Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Gutman S. et al. Long-term rectal function after permanent prostate brachytherapy.[see comment] Cancer Journal. 2007 Mar–Apr;13(2):95–104. Not comparative treatments . [PubMed: 17476137]
380.
Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS. et al. Erectile function after prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2005;62(2):437–47. Not comparative treatments . [PubMed: 15890585]
381.
Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, Cleavinger S. Rectal function following brachytherapy with or without supplemental external beam radiation: results of two prospective randomized trials. Brachytherapy. 2003;2(3):147–57. No QOL outcomes . [PubMed: 15062137]
382.
Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH. Long-term urinary quality of life after permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2003;56(2):454–61. Not comparative treatments . [PubMed: 12738320]
383.
Merrick GS, Butler WM, Wallner KE, Galbreath RW, Murray B, Zeroski D. et al. Dysuria after permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2003;55(4):979–85. Not comparative treatments . [PubMed: 12605976]
384.
Merrick GS, Butler WM, Wallner KE, Hines AL, Allen Z. Late rectal function after prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2003;57(1):42–8. Not comparative treatments . [PubMed: 12909214]
385.
Merrick GS, Butler WM, Wallner KE, Lief JH, Anderson RL, Smeiles BJ. et al. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. International Journal of Radiation Oncology, Biology, Physics. 2002;54(4):1055–62. Less than 100 patients per study arm . [PubMed: 12419431]
386.
Merrick GS, Butler WM, Wallner KE, Murray BC, Allen Z, Galbreath RW. Influence of hormonal therapy on late rectal function after permanent prostate brachytherapy with or without supplemental external beam radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 2004;58(1):68–74. No QOL outcomes . [PubMed: 14697422]
387.
Merrill RM. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah. Preventive Medicine. 2001;33(6):646–52. Not comparative treatments . [PubMed: 11716662]
388.
Merrill RM, Perego UA, Heiner SW. Age, lifestyle, health risk indicators, and prostate-specific antigen scores in men participating in the world senior games. Urologic Oncology. 2002;7(3):105–9. Not localized prostate cancer . [PubMed: 12474543]
389.
Meyer JP, Gillatt DA, Lockyer R, Macdonagh R. The effect of erectile dysfunction on the quality of life of men after radical prostatectomy. BJU International. 2003;92(9):929–31. Not comparative treatments . [PubMed: 14632849]
390.
Michalski JM, Winter K, Purdy JA, Wilder R, Perez CA, Roach M. et al. Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. Seminars in Radiation Oncology. 2002;12(1 Suppl 1):75–80. Not comparative treatments . [PubMed: 11917289]
391.
Michalski JM, Winter K, Purdy JA, Wilder RB, Perez CA, Roach M. et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. International Journal of Radiation Oncology, Biology, Physics. 2003;56(1):192–8. Not comparative treatments . [PubMed: 12694838]
392.
Miften MM, Beavis AW, Marks LB. Influence of dose calculation model on treatment plan evaluation in conformal radiotherapy: a three-case study. Medical Dosimetry. 2002;27(1):51–7. Less than 100 patients per study arm . [PubMed: 12019966]
393.
Miller DC, Litwin MS, Sanda MG, Montie JE, Dunn RL, Resh J. et al. Use of quality indicators to evaluate the care of patients with localized prostate carcinoma. Cancer. 2003;97(6):1428–35. No QOL outcomes . [PubMed: 12627506]
394.
Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM. et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. Journal of Clinical Oncology. 2005;23(12):2772–80. Not localized prostate cancer . [PubMed: 15837992]
395.
Miller DC, Wei JT, Dunn RL, Montie JE, Pimentel H, Sandler HM. et al. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. Urology. 2006 Jul;68(1):166–71. No QOL outcomes . [PubMed: 16844457]
396.
Miller NL, Bissonette EA, Bahnson R, Wilson J, Theodorescu D. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy. Cancer. 2003;97(5):1203–10. Not prospective or longitudinal survey study . [PubMed: 12599226]
397.
Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP. et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 2007 Feb 15;109(4):802–10. Less than 100 patients per study arm . [PubMed: 17219443]
398.
Moinpour CM, Lovato LC, Thompson IM Jr, Ware JE Jr, Ganz PA, Patrick DL. et al. Profile of men randomized to the prostate cancer prevention trial: baseline health-related quality of life, urinary and sexual functioning, and health behaviors. Journal of Clinical Oncology. 2000;18(9):1942–53. Not comparative treatments . [PubMed: 10784636]
399.
Mols F, van de Poll-Franse LV, Vingerhoets AJJM, Hendrikx A, Aaronson NK, Houterman S. et al. Long-term quality of life among Dutch prostate cancer survivors: results of a population-based study. Cancer. 2006 Nov 1;107(9):2186–96. Not localized prostate cancer . [PubMed: 17013914]
400.
Monahan PO, Champion V, Rawl S, Giesler RB, Given B, Given CW. et al. What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer: 4-weeks-post-treatment depressive symptoms or type of treatment? Quality of Life Research. 2007 Apr;16(3):399–411. Not localized prostate cancer . [PubMed: 17091363]
401.
Monga U, Kerrigan AJ, Thornby J, Monga TN, Zimmermann KP. Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy. Journal of Rehabilitation Research & Development. 2005;42(3):391–9. Less than 100 patients per study arm . [PubMed: 16187251]
402.
Montgomery JS, Gayed BA, Hollenbeck BK, Daignault S, Sanda MG, Montie JE. et al. Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy. Journal of Urology. 2006 Jul;176(1):257–61. discussion 61–2. Not comparative treatments. [PubMed: 16753415]
403.
Movsas B, Scott C, Watkins-Bruner D. Pretreatment factors significantly influence quality of life in cancer patients: a Radiation Therapy Oncology Group (RTOG) analysis. International Journal of Radiation Oncology, Biology, Physics. 2006 Jul 1;65(3):830–5. Less than 100 patients per study arm . [PubMed: 16564646]
404.
Muanza TM, Albert PS, Smith S, Godette D, Crouse NS, Cooley-Zgela T. et al. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 2005;62(5):1316–21. Not comparative treatments . [PubMed: 16029787]
405.
Mulhall JP, Morgentaler A. Penile rehabilitation should become the norm for radical prostatectomy patients. J Sex Med. 2007 May;4(3):538–43. Review article . [PubMed: 17498093]
406.
Mulholland TL, Huynh PN, Huang RR, Wong C, Diokno AC, Peters KM. Urinary incontinence after radical retropubic prostatectomy is not related to patient body mass index. Prostate Cancer & Prostatic Diseases. 2006;9(2):153–9. Not comparative treatments . [PubMed: 16505832]
407.
Namiki S, Ishidoya S, Saito S, Satoh M, Tochigi T, Ioritani N. et al. Natural history of voiding function after radical retropubic prostatectomy. Urology. 2006 Jul;68(1):142–7. Not comparative treatments . [PubMed: 16777193]
408.
Namiki S, Ishidoya S, Tochigi T, Kawamura S, Kuwahara M, Terai A. et al. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: comparison with conventional and conformal radiotherapy. Japanese Journal of Clinical Oncology. 2006 Apr;36(4):224–30. Less than 100 patients per study arm . [PubMed: 16537689]
409.
Namiki S, Kuwahara M, Ioritani N, Akito T, Arai Y. An evaluation of urinary function after radical prostatectomy in Japanese men: concordance with definitions of urinary continence. BJU International. 2005;95(4):530–3. Not comparative treatments . [PubMed: 15705074]
410.
Namiki S, Saito S, Nakagawa H, Sanada T, Yamada A, Arai Y. Impact of unilateral sural nerve graft on recovery of potency and continence following radical prostatectomy: 3-year longitudinal study. Journal of Urology. 2007 Jul;178(1):212–6. discussion 6. Less than 100 patients per study arm. [PubMed: 17499797]
411.
Namiki S, Saito S, Satoh M, Ishidoya S, Kawamura S, Tochigi T. et al. Quality of life after radical prostatectomy in Japanese men: 2 year longitudinal study. Japanese Journal of Clinical Oncology. 2005;35(9):551–8. Not comparative treatments . [PubMed: 16141296]
412.
Namiki S, Saito S, Tochigi T, Ioritani N, Terai A, Arai Y. Impact of salvage therapy for biochemical recurrence on health-related quality of life following radical prostatectomy. International Journal of Urology. 2007 Mar;14(3):186–91. Not comparative treatments . [PubMed: 17430252]
413.
Namiki S, Saito S, Tochigi T, Kuwahara M, Ioritani N, Yoshimura K. et al. Impact of hormonal therapy prior to radical prostatectomy on the recovery of quality of life. International Journal of Urology. 2005;12(2):173–81. Not localized prostate cancer . [PubMed: 15733112]
414.
Namiki S, Satoh T, Baba S, Ishiyama H, Hayakawa K, Saito S. et al. Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study. Urology. 2006 Dec;68(6):1230–6. Less than 100 patients per study arm . [PubMed: 17141839]
415.
Namiki S, Takegami M, Kakehi Y, Suzukamo Y, Fukuhara S, Arai Y. Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer. Journal of Urology. 2007 Aug;178(2):473–7. discussion 7. Less than 100 patients per study arm. [PubMed: 17561164]
416.
Namiki S, Tochigi T, Kuwahara M, Ioritani N, Terai A, Numata I. et al. Health related quality of life in Japanese men after radical prostatectomy or radiation therapy for localized prostate cancer. International Journal of Urology. 2004;11(8):619–27. Not localized prostate cancer . [PubMed: 15285752]
417.
Namiki S, Tochigi T, Kuwahara M, Ioritani N, Yoshimura K, Terai A. et al. Recovery of health related quality of life after radical prostatectomy in japanese men: a longitudinal study. International Journal of Urology. 2004;11(9):742–9. Not comparative treatments . [PubMed: 15379938]
418.
Namiki S, Tochigi T, Kuwahara M, Ohnuma T, Ioritani N, Soma F. et al. Health-related quality of life after radical prostatectomy in Japanese men with localized prostate cancer. International Journal of Urology. 2003;10(12):643–50. Not comparative treatments . [PubMed: 14633067]
419.
Naoe M, Ogawa Y, Shichijo T, Fuji K, Fukagai T, Yoshida H. Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer. Prostate Cancer & Prostatic Diseases. 2006;9(3):275–8. Less than 100 patients per study arm . [PubMed: 16786037]
420.
Natsume O, Kondo H, Cho M, Fujimoto K, Ozono S, Hirao Y. The impact of radical prostatectomy on patient well-being: a prospective urodynamic study focused on detrusor function. Hinyokika Kiyo - Acta Urologica Japonica. 2004;50(1):1–6. Not comparative treatments . [PubMed: 15032007]
421.
Naughton CK, Miller DC, Yan Y. Impact of transrectal ultrasound guided prostate biopsy on quality of life: a prospective randomized trial comparing 6 versus 12 cores. Journal of Urology. 2001;165(1):100–3. Not comparative treatments . [PubMed: 11125374]
422.
Newton F, Burney S, Frydenberg M, Millar J, Ng K. Assessing mood and general health-related quality of life among men treated in Australia for localized prostate cancer. International Journal of Urology 2007 Apr Apr;14(4):311–6. Less than 100 patients per study arm. [PubMed: 17470160]
423.
Newton FJ, Burney S, Millar JL, Frydenberg M, Ng KT. Disease-specific quality of life among patients with localized prostate cancer: an Australian perspective. BJU International. 2006 Jun;97(6):1179–83. Less than 100 patients per study arm . [PubMed: 16686708]
424.
Nishimura K, Yamaguchi Y, Yamanaka M, Ichikawa Y, Nagano S. Climacteric-like disorders in prostate cancer patients treated with LHRH agonists. Archives of Andrology. 2005;51(1):41–8. Not comparative treatments . [PubMed: 15764416]
425.
Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. International Journal of Urology. 2004;11(9):735–41. Not comparative treatments . [PubMed: 15379937]
426.
Noguchi M, Itoh K, Yao A, Mine T, Yamada A, Obata Y. et al. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate. 2005;63(1):1–12. Not localized prostate cancer . [PubMed: 15378520]
427.
Noguchi M, Shimada A, Yahara J, Suekane S, Noda S. Early catheter removal 3 days after radical retropubic prostatectomy. International Journal of Urology. 2004;11(11):983–8. Not comparative treatments . [PubMed: 15509202]
428.
Norderhaug IN, Sandberg S, Fossa SD, Forland F, Malde K, Kvinnsland S. et al. Health technology assessment and implications for clinical practice: the case of prostate cancer screening.[see comment][erratum appears in Scand J Clin Lab Invest. 2004;64(8):757] Scandinavian Journal of Clinical & Laboratory Investigation. 2003;63(5):331–8. Not comparative treatments . [PubMed: 14599155]
429.
North West Uro-Oncology G. A preliminary report on a patient-preference study to compare treatment options in early prostate cancer. BJU International 2002;90(3):253–6. No QOL outcomes. [PubMed: 12133061]
430.
Northouse LL, Rosset T, Phillips L, Mood D, Schafenacker A, Kershaw T. Research with families facing cancer: the challenges of accrual and retention. Res Nurs Health. 2006 Jun;29(3):199–211. Not comparative treatments . [PubMed: 16676337]
431.
O'Connell B, Baker L, Munro I. The nature and impact of incontinence in men who have undergone prostate surgery and implications for nursing practice. Contemp Nurse. 2007 Feb;24(1):65–78. Not comparative treatments . [PubMed: 17348784]
432.
Oefelein MG. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. Journal of Urology. 2003;169(1):251–5. Not localized prostate cancer . [PubMed: 12478147]
433.
Ohyama C, Tsuchiya N, Habuchi T, Sato K, Satoh S, Shimoda N. et al. Rectosigmoidal bladder utilizing intussuscepted ileal segment: a surgical technique for urinary diversion and experiences in 30 patients.[see comment] International Journal of Urology. 2004;11(6):379–85. Not localized prostate cancer . [PubMed: 15157206]
434.
Olmi P. Limits to the radiation therapy due to age. Tumori. 2002;88(1 Suppl 1):S95–7. Review article . [PubMed: 11989940]
435.
Olver I, Keefe D, Myers M. Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer. Internal Medicine Journal. 2005;35(7):405–8. Less than 100 patients per study arm . [PubMed: 15958110]
436.
Onik G. The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation. A review. Technology in Cancer Research & Treatment. 2004;3(4):365–70. Review article . [PubMed: 15270587]
437.
Onik G, Narayan P, Vaughan D, Dineen M, Brunelle R. Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology. 2002;60(1):109–14. Less than 100 patients per study arm . [PubMed: 12100934]
438.
Ozasa K, Nakao M, Watanabe Y, Hayashi K, Miki T, Mikami K. et al. Association of serum phytoestrogen concentration and dietary habits in a sample set of the JACC Study. Journal of Epidemiology. 2005;15(Suppl 2):S196–202. Not localized prostate cancer . [PubMed: 16127234]
439.
Pagano S, Gotay CC. Modeling quality of life in cancer patients as a unidimensional construct. Hawaii Medical Journal. 2006;65(3):76–80. Not localized prostate cancer . [PubMed: 16724449]
440.
Passik SD, Kirsh KL. A pilot examination of the impact of cancer patients' fatigue on their spousal caregivers. Palliat Support Care. 2005 Dec;3(4):273–9. Not localized prostate cancer . [PubMed: 17039982]
441.
Patel VR, Thaly R, Shah K. Robotic radical prostatectomy: outcomes of 500 cases. BJU International. 2007 May;99(5):1109–12. Not comparative treatments . [PubMed: 17437441]
442.
Patel VR, Tully AS, Holmes R, Lindsay J. Robotic radical prostatectomy in the community setting—the learning curve and beyond: initial 200 cases. Journal of Urology. 2005;174(1):269–72. Not comparative treatments . [PubMed: 15947662]
443.
Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ. Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. Journal of the American Dietetic Association. 2003;103(3):323–8. Not localized prostate cancer . [PubMed: 12616253]
444.
Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ. et al. Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. Journal of Alternative & Complementary Medicine. 2002;8(4):477–85. Not localized prostate cancer . [PubMed: 12230908]
445.
Pearce A, Choo R, Danjoux C, Morton G, Loblaw DA, Szumacher E. et al. Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy. International Journal of Radiation Oncology, Biology, Physics. 2006;65(1):78–83. Not comparative treatments . [PubMed: 16563657]
446.
Pelucchi C, Galeone C, Talamini R, Negri E, Parpinel M, Franceschi S. et al. Dietary folate and risk of prostate cancer in Italy.[see comment] Cancer Epidemiology, Biomarkers & Prevention. 2005;14(4):944–8. Not comparative treatments . [PubMed: 15824168]
447.
Penedo FJ, Dahn JR, Molton I, Gonzalez JS, Kinsinger D, Roos BA. et al. Cognitive-behavioral stress management improves stress-management skills and quality of life in men recovering from treatment of prostate carcinoma. Cancer. 2004;100(1):192–200. Not comparative treatments . [PubMed: 14692040]
448.
Penedo FJ, Dahn JR, Shen BJ, Schneiderman N, Antoni MH. Ethnicity and determinants of quality of life after prostate cancer treatment. Urology. 2006;67(5):1022–7. No QOL outcomes . [PubMed: 16698362]
449.
Penedo FJ, Molton I, Dahn JR, Shen BJ, Kinsinger D, Traeger L. et al. A randomized clinical trial of group-based cognitive-behavioral stress management in localized prostate cancer: development of stress management skills improves quality of life and benefit finding. Ann Behav Med. 2006 Jun;31(3):261–70. Less than 100 patients per study arm . [PubMed: 16700640]
450.
Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D. et al. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study.[see comment] Journal of Clinical Oncology. 2003;21(6):1147–54. Not localized prostate cancer . [PubMed: 12637483]
451.
Penson DF, Latini DM, Lubeck DP, Wallace K, Henning JM, Lue T. Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the ExCEED data base.[see comment] Journal of Urology. 2003;169(4):1458–61. Not comparative treatments . [PubMed: 12629383]
452.
Penson DF, Stoddard ML, Pasta DJ, Lubeck DP, Flanders SC, Litwin MS. The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. Journal of Clinical Epidemiology. 2001;54(4):350–8. Not comparative treatments . [PubMed: 11297885]
453.
Perczek RE, Burke MA, Carver CS, Krongrad A, Terris MK. Facing a prostate cancer diagnosis: who is at risk for increased distress? Cancer. 2002;94(11):2923–9. Not comparative treatments . [PubMed: 12115380]
454.
Perdona S, Autorino R, De Placido S, D'Armiento M, Gallo A, Damiano R. et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncology. 2005;6(5):295–300. Not comparative treatments . [PubMed: 15863377]
455.
Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope. 2000;110(4):593–602. Not localized prostate cancer . [PubMed: 10764003]
456.
Pickard AS, Hung SY, McKoy JM, Witt WP, Arseven A, Sharifi R. et al. Opportunities for disease state management in prostate cancer. Disease Management. 2005;8(4):235–44. Not comparative treatments . [PubMed: 16117718]
457.
Pietrow PK, Parekh DJ, Smith JA Jr, Shyr Y, Cookson MS. Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence. Journal of Urology. 2001;166(6):2286–90. Not localized prostate cancer . [PubMed: 11696753]
458.
Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Eble MJ. Low-grade toxicity after conformal radiation therapy for prostate cancer—impact of bladder volume. International Journal of Radiation Oncology, Biology, Physics. 2006;64(3):835–41. Not comparative treatments . [PubMed: 16289911]
459.
Pinkawa M, Fischedick K, Gagel B, Piroth MD, Borchers H, Jakse G. et al. Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer. Urology. 2006 Jul;68(1):104–9. Not comparative treatments . [PubMed: 16806434]
460.
Pinkawa M, Fischedick K, Piroth MD, Gagel B, Borchers H, Jakse G. et al. Health-related quality of life after permanent interstitial brachytherapy for prostate cancer: correlation with postimplant CT scan parameters. Strahlentherapie und Onkologie. 2006 Nov;182(11):660–5. Less than 100 patients per study arm . [PubMed: 17072524]
461.
Pinsky PF, Miller A, Kramer BS, Church T, Reding D, Prorok P. et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol. 2007 Apr 15;165(8):874–81. Not comparative treatments . [PubMed: 17244633]
462.
Plante MK, Bunnell ML, Trotter SJ, Jackson TL, Esenler AC, Zvara P. Transurethral prostatic tissue ablation via a single needle delivery system: initial experience with radio-frequency energy and ethanol. Prostate Cancer & Prostatic Diseases. 2002;5(3):183–8. Not localized prostate cancer . [PubMed: 12496979]
463.
Ponholzer A, Brossner C, Struhal G, Marszalek M, Madersbacher S. Lower urinary tract symptoms, urinary incontinence, sexual function and quality of life after radical prostatectomy and external beam radiation therapy: real life experience in Austria. World Journal of Urology. 2006 Aug;24(3):325–30. Not localized prostate cancer . [PubMed: 16688458]
464.
Ponholzer A, Struhal G, Madersbacher S. Frequent use of complementary medicine by prostate cancer patients. European Urology. 2003;43(6):604–8. Not localized prostate cancer . [PubMed: 12767359]
465.
Porterfield H. UsToo PC-SPES surveys: review of studies and update of previous survey results. Molecular Urology. 2000;4(3):289–91. discussion 93. Not comparative treatments. [PubMed: 11062386]
466.
Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS. et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. Journal of Clinical Oncology. 2001;19(17):3750–7. Not localized prostate cancer . [PubMed: 11533098]
467.
Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS. et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.[see comment] Journal of the National Cancer Institute. 2000;92(19):1582–92. Previously published data updated . [PubMed: 11018094]
468.
Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC. et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy.[see comment] Journal of the National Cancer Institute. 2002;94(6):430–7. Previously published data updated . [PubMed: 11904315]
469.
Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW. Potency after permanent prostate brachytherapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 2001;50(5):1235–42. Not comparative treatments . [PubMed: 11483334]
470.
Poulakis V, Witzsch U, de Vries R, Dillenburg W, Becht E. Laparoscopic radical prostatectomy in men older than 70 years of age with localized prostate cancer: comparison of morbidity, reconvalescence, and short-term clinical outcomes between younger and older men. European Urology. 2007 May;51(5):1341–8. discussion 9. Less than 100 patients per study arm. [PubMed: 17184898]
471.
Powel LL, Clark JA. The value of the marginalia as an adjunct to structured questionnaires: experiences of men after prostate cancer surgery. Quality of Life Research. 2005;14(3):827–35. Not comparative treatments . [PubMed: 16022075]
472.
Rago RP, Einstein A Jr, Lush R, Beer TM, Ko YJ, Henner WD. et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemotherapy & Pharmacology. 2003;51(4):297–305. Not localized prostate cancer . [PubMed: 12721757]
473.
Ramsawh HJ, Morgentaler A, Covino N, Barlow DH, DeWolf WC. Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy. Journal of Urology. 2005;174(4 Pt 1):1395–8. Not comparative treatments . [PubMed: 16145445]
474.
Ramsden AR, Thurairaja R, Persad R, Chodak GW. Current trends in the management of radical retropubic prostatectomy: is short-stay RRP feasible in the United Kingdom? Prostate Cancer & Prostatic Diseases. 2004;7(1):50–3. Not comparative treatments . [PubMed: 14999239]
475.
Rao J, Koay SK, Lau WK, Cheng CW. Patient-reported urinary continence (third-party interview): results of post-radical retropubic prostatectomy in Singaporeans. Asian Journal of Surgery. 2005;28(3):207–10. Not comparative treatments . [PubMed: 16024318]
476.
Reed SD, Radeva JI, Glendenning GA, Saad F, Schulman KA. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer.[see comment] Journal of Urology. 2004;171(4):1537–42. No QOL outcomes . [PubMed: 15017215]
477.
Reeve BB, Potosky AL, Willis GB. Should function and bother be measured and reported separately for prostate cancer quality-of-life domains? Urology. 2006 Sep;68(3):599–603. Not comparative treatments . [PubMed: 16979720]
478.
Rehman J, Ragab MM, Venkatesh R, Landman J, Lee D, Chen C. et al. Laparoscopic radical prostatectomy: Washington University initial experience and prospective evaluation of quality of life. Journal of Endourology. 2004;18(3):277–87. Not comparative treatments . [PubMed: 15225395]
479.
Reis F, Netto NR Jr, Reinato JA, Thiel M, Zani E. The impact of prostatectomy and brachytherapy in patients with localized prostate cancer. International Urology & Nephrology. 2004;36(2):187–90. No QOL outcomes . [PubMed: 15368690]
480.
Richman MB, Forman EH, Bayazit Y, Einstein DB, Resnick MI, Stovsky MD. A novel computer based expert decision making model for prostate cancer disease management.[see comment] Journal of Urology. 2005 Dec;174(6):2310–8. No QOL outcomes . [PubMed: 16280831]
481.
Ritvo P, Irvine J, Naglie G, Tomlinson G, Bezjak A, Matthew A. et al. Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer. Journal of Clinical Epidemiology. 2005;58(5):466–74. Not localized prostate cancer . [PubMed: 15845333]
482.
Roberts KJ, Lepore SJ, Helgeson V. Social-cognitive correlates of adjustment to prostate cancer. Psycho-Oncology. 2006 Mar;15(3):183–92. Less than 100 patients per study arm . [PMC free article: PMC2610315] [PubMed: 15929030]
483.
Robinson JW, Donnelly BJ, Coupland K, Siever JE, Saliken JC, Scott C. et al. Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. Urologic Oncology. 2006 Nov–Dec;24(6):472–86. Less than 100 patients per study arm . [PubMed: 17138127]
484.
Robinson JW, Donnelly BJ, Saliken JC, Weber BA, Ernst S, Rewcastle JC. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology. 2002;60(2 Suppl 1):12–8. Not comparative treatments . [PubMed: 12206843]
485.
Rodgers JK, Sawhney R, Chaudhary U, Bissada NK. Quality of life in men with localized prostate cancer treated by radical prostatectomy or radiotherapy. Archives of Andrology. 2006;52(2):129–33. Not prospective or longitudinal survey study . [PubMed: 16443590]
486.
Rodrigues G, Bauman G, Lock M, D'Souza D, Mahon J. Psychometric properties of a prostate cancer radiation late toxicity questionnaire. Health & Quality of Life Outcomes. 2007;5:29. Not comparative treatments . [PMC free article: PMC1894787] [PubMed: 17540022]
487.
Rodrigues G, Bezjak A, Osoba D, Catton P, Tsuji D, Taylor D. et al. The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer. Quality of Life Research. 2004;13(7):1235–46. Not comparative treatments . [PubMed: 15473502]
488.
Rogers CG, Su LM, Link RE, Sullivan W, Wagner A, Pavlovich CP. Age stratified functional outcomes after laparoscopic radical prostatectomy. Journal of Urology. 2006 Dec;176(6 Pt 1):2448–52. Not comparative treatments . [PubMed: 17085126]
489.
Roos IA. Reacting to the diagnosis of prostate cancer: patient learning in a community of practice. Patient Education & Counseling. 2003;49(3):219–24. Not comparative treatments . [PubMed: 12642193]
490.
Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Preventive Medicine. 2004;38(6):732–44. Not comparative treatments . [PubMed: 15193893]
491.
Ross LE, Uhler RJ, Williams KN. Awareness and use of the prostate-specific antigen test among African-American men. Journal of the National Medical Association. 2005;97(7):963–71. Not comparative treatments . [PMC free article: PMC2569321] [PubMed: 16080666]
492.
Ross PL, Littenberg B, Fearn P, Scardino PT, Karakiewicz PI, Kattan MW. Paper standard gamble: a paper-based measure of standard gamble utility for current health. International Journal of Technology Assessment in Health Care. 2003;19(1):135–47. Not comparative treatments . [PubMed: 12701946]
493.
Ruthman JL, Ferrans CE. Efficacy of a video for teaching patients about prostate cancer screening and treatment. American Journal of Health Promotion. 2004;18(4):292–5. Not comparative treatments . [PubMed: 15011928]
494.
Sadler GR, Ko CM, Malcarne VL, Banthia R, Gutierrez I, Varni JW. Costs of recruiting couples to a clinical trial. Contemp Clin Trials. 2007 Jul;28(4):423–32. No QOL outcomes . [PMC free article: PMC2819400] [PubMed: 17218166]
495.
Saigal CS, Gornbein J, Nease R, Litwin MS. Predictors of utilities for health states in early stage prostate cancer. Journal of Urology. 2001;166(3):942–6. Not comparative treatments . [PubMed: 11490251]
496.
Saigal CS, Gornbein J, Reid K, Litwin MS. Stability of time trade-off utilities for health states associated with the treatment of prostate cancer. Quality of Life Research. 2002;11(5):405–14. Not comparative treatments . [PubMed: 12113388]
497.
Saito S, Namiki S, Numahata K, Satoh M, Ishidoya S, Ito A. et al. Relevance of postcatheter removal incontinence to postoperative urinary function after radical prostatectomy. International Journal of Urology. 2006 Sep;13(9):1191–6. Less than 100 patients per study arm . [PubMed: 16984551]
498.
Salminen E, Portin R, Korpela J, Backman H, Parvinen LM, Helenius H. et al. Androgen deprivation and cognition in prostate cancer. British Journal of Cancer. 2003;89(6):971–6. No QOL outcomes . [PMC free article: PMC2376935] [PubMed: 12966411]
499.
Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clinical Cancer Research. 2004;10(22):7575–82. No QOL outcomes . [PubMed: 15569988]
500.
Salomon L, Anastasiadis A, Saint F, De La Taille A, Chopin D, Abbou CC. Introducing a new, simple scoring system to evaluate oncological and functional outcome after radical prostatectomy. Scandinavian Journal of Urology & Nephrology. 2003;37(5):392–5. Not comparative treatments . [PubMed: 14594687]
501.
Salomon L, Saint F, Anastasiadis AG, Sebe P, Chopin D, Abbou CC. Combined reporting of cancer control and functional results of radical prostatectomy. European Urology. 2003;44(6):656–60. Not comparative treatments . [PubMed: 14644116]
502.
Sanchez-Ortiz RF, Broderick GA, Rovner ES, Wein AJ, Whittington R, Malkowicz SB. Erectile function and quality of life after interstitial radiation therapy for prostate cancer. International Journal of Impotence Research. 2000;12(Suppl 3):S18–24. Not comparative treatments . [PubMed: 11002395]
503.
Sandblom G, Carlsson P, Sennfalt K, Varenhorst E. A population-based study of pain and quality of life during the year before death in men with prostate cancer. British Journal of Cancer. 2004;90(6):1163–8. Not comparative treatments . [PMC free article: PMC2409660] [PubMed: 15026796]
504.
Sandblom G, Carlsson P, Sigsjo P, Varenhorst E. Pain and health-related quality of life in a geographically defined population of men with prostate cancer. British Journal of Cancer. 2001;85(4):497–503. Not comparative treatments . [PMC free article: PMC2364104] [PubMed: 11506486]
505.
Sanders S, Pedro LW, Bantum EOC, Galbraith ME. Couples surviving prostate cancer: Long-term intimacy needs and concerns following treatment. Clin J Oncol Nurs. 2006 Aug;10(4):503–8. Not comparative treatments . [PubMed: 16927903]
506.
Sanderson KM, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G. et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. Journal of Urology. 2006 Nov;176(5):2025–31. discussion 31–2. Not comparative treatments. [PubMed: 17070244]
507.
Santis WF, Hoffman MA, Dewolf WC. Early catheter removal in 100 consecutive patients undergoing radical retropubic prostatectomy. BJU International. 2000;85(9):1067–8. Not comparative treatments . [PubMed: 10848696]
508.
Sarma AV, McLaughlin JC, Jacobsen SJ, Logie J, Dolin P, Dunn RL. et al. Longitudinal changes in lower urinary tract symptoms among a cohort of black American men: the Flint Men's Health Study. Urology. 2004;64(5):959–65. Not localized prostate cancer . [PubMed: 15533486]
509.
Sarosdy MF. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy.[see comment] Cancer. 2004;101(4):754–60. Less than 100 patients per study arm . [PubMed: 15305406]
510.
Savard J, Simard S, Hervouet S, Ivers H, Lacombe L, Fradet Y. Insomnia in men treated with radical prostatectomy for prostate cancer. Psycho-Oncology. 2005;14(2):147–56. Not comparative treatments . [PubMed: 15386779]
511.
Schmid HP, Morant R, Bernhard J, Maibach R. Swiss Group for Clinical Cancer R. Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma. European Urology. 2003;43(1):28–30. Not localized prostate cancer . [PubMed: 12507540]
512.
Scholz MC, Jennrich RI, Strum SB, Johnson HJ, Guess BW, Lam RY. Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period. Journal of Urology. 2006;175(5):1673–8. Not comparative treatments . [PubMed: 16600727]
513.
Schroder FH, Wildhagen MF. Rotterdam Study Group of the 'European Randomised Study of Screening for Prostate C. Screening for prostate cancer: evidence and perspectives. BJU International. 2001;88(8):811–7. Not comparative treatments . [PubMed: 11736853]
514.
Schuster TG, Marcovich R, Sheffield J, Montie JE, Lee CT. Radical cystectomy for bladder cancer after definitive prostate cancer treatment. Urology. 2003;61(2):342–7. discussion 7. Not localized prostate cancer. [PubMed: 12597943]
515.
Sciarra A, Cardi A, Salvatori G, D'Eramo G, Mariotti G, Di Silverio F. Which patients with prostate cancer are actually candidates for hormone therapy? International Braz J Urol. 2004;30(6):455–65. Not comparative treatments . [PubMed: 15663802]
516.
Seftel A. Sexual, psychological and dyadic qualities of the prostate cancer ‘couple’ Journal of Urology. 2005;174(5):1939. Review article . [PubMed: 16217353]
517.
Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG. et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.[see comment] Journal of Clinical Oncology. 2003;21(9):1653–9. Not comparative treatments . [PubMed: 12721238]
518.
Seki N, Tatsugami K, Naito S. Holmium laser enucleation of the prostate: comparison of outcomes according to prostate size in 97 Japanese patients. Journal of Endourology. 2007 Feb;21(2):192–6. Not comparative treatments . [PubMed: 17338621]
519.
Selek U, Cheung R, Lii M, Allen P, Steadham RE, Vantreese TR Jr. et al. Erectile dysfunction and radiation dose to penile base structures: a lack of correlation.[see comment] International Journal of Radiation Oncology, Biology, Physics. 2004;59(4):1039–46. Not comparative treatments . [PubMed: 15234037]
520.
Selli C, De Antoni P, Moro U, Macchiarella A, Giannarini G, Crisci A. Role of bladder neck preservation in urinary continence following radical retropubic prostatectomy. Scandinavian Journal of Urology & Nephrology. 2004;38(1):32–7. Not comparative treatments . [PubMed: 15204424]
521.
Sennfalt K, Carlsson P, Sandblom G, Varenhorst E. The estimated economic value of the welfare loss due to prostate cancer pain in a defined population. Acta Oncologica. 2004;43(3):290–6. No QOL outcomes . [PubMed: 15244254]
522.
Shah SH. A patient with dementia and cancer: to feed via percutaneous endoscopic gastrostomy tube or not? Palliat Med. 2006 Oct;20(7):711–4. Not localized prostate cancer . [PubMed: 17060270]
523.
Shapiro PJ, Coyne JC, Kruus LK, Palmer SC, Vaughn DJ, Malkowicz SB. Interest in services among prostate cancer patients receiving androgen deprivation therapy. Psycho-Oncology. 2004;13(8):512–25. No QOL outcomes . [PubMed: 15295773]
524.
Sharkey J, Cantor A, Solc Z, Huff W, Chovnick SD, Behar RJ. et al. Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer. Current Urology Reports. 2002;3(3):250–7. No QOL outcomes . [PubMed: 12084197]
525.
Sheriff SK, Shohara RA, Dumican SB, Small EJ, Carroll PR, Chan JM. Lifestyle correlates of health perception and treatment satisfaction in a clinical cohort of men with prostate cancer. Clinical Prostate Cancer. 2005;3(4):239–45. Not comparative treatments . [PubMed: 15882480]
526.
Simon HB. On call. September 11 was an emotional day for all of us, but September 12 was a confusing day for me. I read two newspapers that reported on research in the New England Journal of Medicine. The New York Times headline said: “Prostate cancer surgery found to cut death risk,” but the Washington Post announced: “Studies find no advantage to prostate cancer surgery.” Which was right? Harvard Mens Health Watch. 2002;7(5):8. Review article . [PubMed: 12499134]
527.
Singh H, Maskarinec G, Shumay DM. Understanding the motivation for conventional and complementary/alternative medicine use among men with prostate cancer. Integrative Cancer Therapies. 2005;4(2):187–94. Not comparative treatments . [PubMed: 15911931]
528.
Sloan JA, Varricchio C. Quality of Life endpoints in prostate chemoprevention trials. Urology. 2001;57(4 Suppl 1):235–40. Not comparative treatments . [PubMed: 11295635]
529.
Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB. et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. Journal of Clinical Oncology. 2000;18(7):1440–50. Not localized prostate cancer . [PubMed: 10735891]
530.
Smith DP, Supramaniam R, King MT, Ward J, Berry M, Armstrong BK. Age, health, and education determine supportive care needs of men younger than 70 years with prostate cancer. Journal of Clinical Oncology. 2007 Jun 20;25(18):2560–6. Not comparative treatments . [PubMed: 17577034]
531.
Smith DS, Carvalhal GF, Schneider K, Krygiel J, Yan Y, Catalona WJ. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer. 2000;88(6):1454–63. Not comparative treatments . [PubMed: 10717630]
532.
Smith DS, Krygiel J, Nease RF Jr, Sumner W 2nd, Catalona WJ. Patient preferences for outcomes associated with surgical management of prostate cancer. Journal of Urology. 2002;167(5):2117–22. Not comparative treatments . [PubMed: 11956454]
533.
Soloway CT, Soloway MS, Kim SS, Kava BR. Sexual, psychological and dyadic qualities of the prostate cancer ‘couple’ BJU International. 2005;95(6):780–5. Not comparative treatments . [PubMed: 15794782]
534.
Soumarova R, Homola L, Stursa M, Perkova H. Acute toxicity of conformal high dose interstitial brachytherapy boost in prostate cancer. Neoplasma. 2006;53(5):410–7. Not localized prostate cancer . [PubMed: 17013535]
535.
Speight JL, Elkin EP, Pasta DJ, Silva S, Lubeck DP, Carroll PR. et al. Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: data from CaPSURE. International Journal of Radiation Oncology, Biology, Physics. 2004;60(4):1066–75. CaPSURE data . [PubMed: 15519776]
536.
Spry NA, Kristjanson L, Hooton B, Hayden L, Neerhut G, Gurney H. et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. European Journal of Cancer. 2006 May;42(8):1083–92. Not comparative treatments . [PubMed: 16632343]
537.
Srinualnad S, Charoenkraikamol C, Toraksa S, Uiprasertkul M, Amornvesukit T, Taweemonkongsap T. et al. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day) Journal of the Medical Association of Thailand. 2006;89(1):37–42. Not comparative treatments . [PubMed: 16583579]
538.
Staff I, Salner A, Bohannon R, Panatieri P, Maljanian R. Disease-specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three-dimensional conformal radiotherapy. Cancer. 2003;98(11):2335–43. Not comparative treatments . [PubMed: 14635067]
539.
Stamogiannou I, Grunfeld EA, Denison K, Muir G. Beliefs about illness and quality of life among men with erectile dysfunction. International Journal of Impotence Research. 2005;17(2):142–7. Not localized prostate cancer . [PubMed: 15014554]
540.
Stavridis S, Georgiev V, Popov Z, Penev M, Lekovski Lj, Stankov O. et al. Radical retropubic prostatectomy for prostate carcinoma; first results of the Clinic of Urology in Skopje. Acta Chirurgica Iugoslavica. 2005;52(4):37–40. Not comparative treatments . [PubMed: 16673592]
541.
Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P. Prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer. Urology. 2004;63(4):751–6. Less than 100 patients per study arm . [PubMed: 15072894]
542.
Steginga SK, Pinnock C, Gardner M, Gardiner RA, Dunn J. Evaluating peer support for prostate cancer: the Prostate Cancer Peer Support Inventory. BJU International. 2005;95(1):46–50. Not comparative treatments . [PubMed: 15663527]
543.
Steiner MS, Pound CR. Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia.[see comment] Clinical Prostate Cancer. 2003;2(1):24–31. Not localized prostate cancer . [PubMed: 15046680]
544.
Stewart SL, King JB, Thompson TD, Friedman C, Wingo PA. Cancer mortality surveillance—United States, 1990-2000. Morbidity & Mortality Weekly Report 2004;Surveillance Summaries. 53(3):1–108. No QOL outcomes. [PubMed: 15179359]
545.
Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Medical Care. 2005;43(4):347–55. Not comparative treatments . [PubMed: 15778638]
546.
Stojanovic S, Radosvic-Jelic Lj, Tulic C, Popov I, Babic D, Acimovic M. et al. Radical radiotherapy for localized prostate cancer in elderly. Acta Chirurgica Iugoslavica. 2005;52(4):103–7. Not comparative treatments . [PubMed: 16673605]
547.
Stommel M, Kurtz ME, Kurtz JC, Given CW, Given BA. A longitudinal analysis of the course of depressive symptomatology in geriatric patients with cancer of the breast, colon, lung, or prostate. Health Psychology. 2004;23(6):564–73. Not localized prostate cancer . [PubMed: 15546224]
548.
Stone NN, Stock RG. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. Brachytherapy. 2003;2(1):32–9. Not comparative treatments . [PubMed: 15062161]
549.
Stone NN, Stock RG. Practical considerations in permanent brachytherapy for localized adenocarcinoma of the prostate. Urologic Clinics of North America. 2003;30(2):351–62. Not comparative treatments . [PubMed: 12735510]
550.
Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology. 2007 Feb;69(2):338–42. Not comparative treatments . [PubMed: 17320674]
551.
Stone P, Hardy J, Huddart R, A'Hern R, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. European Journal of Cancer. 2000;36(9):1134–41. Not comparative treatments . [PubMed: 10854947]
552.
Stone P, Richards M, A'Hern R, Hardy J. Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. Journal of Pain & Symptom Management. 2001;22(6):1007–15. Not localized prostate cancer . [PubMed: 11738163]
553.
Stranzl H, Gabor S, Mayer R, Prettenhofer U, Wurzinger G, Hackl A. Fractionated intraluminal HDR 192Ir brachytherapy as palliative treatment in patients with endobronchial metastases from non-bronchogenic primaries. Strahlentherapie und Onkologie. 2002;178(8):442–5. Not localized prostate cancer . [PubMed: 12240550]
554.
Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger HJ, Gasser T. et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88.[erratum appears in J Clin Oncol. 2005 Feb 1;23(4):936] Journal of Clinical Oncology. 2004;22(20):4109–18. Not localized prostate cancer . [PubMed: 15483020]
555.
Sullivan LD, Weir MJ, Kinahan JF, Taylor DL. A comparison of the relative merits of radical perineal and radical retropubic prostatectomy. BJU International. 2000;85(1):95–100. Less than 100 patients per study arm . [PubMed: 10619954]
556.
Sunny L, Hopfgarten T, Adolfsson J, Steineck G. Economic conditions and marriage quality of men with prostate cancer. BJU International. 2007 Jun;99(6):1391–7. Not comparative treatments . [PubMed: 17355370]
557.
Sweeney CJ. ECOG: CHAARTED—ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clin. 2006 Aug;4(8):588–90. Not localized prostate cancer . [PubMed: 17111557]
558.
Sydes MR, Stephens RJ, Moore AR, Aird EG, Bidmead AM, Fallowfield LJ. et al. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy & Oncology. 2004;72(2):199–211. No QOL outcomes . [PubMed: 15297138]
559.
Symon Z, Daignault S, Symon R, Dunn RL, Sanda MG, Sandler HM. Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy. Urology. 2006 Dec;68(6):1224–9. Less than 100 patients per study arm . [PubMed: 17141840]
560.
Talcott JA, Clark JA, Manola J, Mitchell SP. Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understand. Journal of Urology. 2006 Oct;176(4 Pt 1):1558–63. discussion 63–4. Previously published data. [PubMed: 16952681]
561.
Talcott JA, Manola J, Clark JA, Kaplan I, Beard CJ, Mitchell SP. et al. Time course and predictors of symptoms after primary prostate cancer therapy. Journal of Clinical Oncology. 2003;21(21):3979–86. Not RCT . [PubMed: 14581420]
562.
Tangen CM, Goodman PJ, Crowley JJ, Thompson IM. Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology. 2004;171(2 Pt 2):S64–7. No QOL outcomes . [PubMed: 14713757]
563.
Tannor BB, Ross L. Physician-patient discussions about prostate-specific antigen test use among African-American men. Journal of the National Medical Association. 2006;98(4):532–8. Not comparative treatments . [PMC free article: PMC2569217] [PubMed: 16623065]
564.
Taussky D, Schneider U, Rousson V, Pescia R. Patient-reported toxicity correlated to dose-volume histograms of the rectum in radiotherapy of the prostate. American Journal of Clinical Oncology. 2003;26(5):e144–9. Not comparative treatments . [PubMed: 14528089]
565.
Taylor KL, Shelby R, Gelmann E, McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial.[see comment] Journal of the National Cancer Institute. 2004;96(14):1083–94. Not localized prostate cancer . [PubMed: 15265970]
566.
Templeton H, Coates V. Evaluation of an evidence-based education package for men with prostate cancer on hormonal manipulation therapy. Patient Education & Counseling. 2004;55(1):55–61. Not comparative treatments . [PubMed: 15476990]
567.
Terret C, Albrand G, Droz JP. Geriatric assessment in elderly patients with prostate cancer. Clinical Prostate Cancer. 2004;2(4):236–40. Not comparative treatments . [PubMed: 15072607]
568.
Tewari A, Kaul S, Menon M. Robotic radical prostatectomy: a minimally invasive therapy for prostate cancer. Current Urology Reports. 2005;6(1):45–8. Not comparative treatments . [PubMed: 15610696]
569.
Tewari A, Menon M. Vattikuti Institute prostatectomy: surgical technique and current results. Current Urology Reports. 2003;4(2):119–23. Not comparative treatments . [PubMed: 12648428]
570.
Tewari A, Srivasatava A, Menon M. Members of the VIPT. A prospective comparison of radical retropubic and robot-assisted prostatectomy: experience in one institution. BJU International. 2003;92(3):205–10. Not RCT . [PubMed: 12887468]
571.
Thompson RH, Slezak JM, Webster WS, Lieber MM. Radical prostatectomy for octogenarians: how old is too old? Urology. 2006 Nov;68(5):1042–5. Not comparative treatments . [PubMed: 17095073]
572.
Thornton AA, Perez MA. Posttraumatic growth in prostate cancer survivors and their partners. Psycho-Oncology. 2006 Apr;15(4):285–96. Not comparative treatments . [PubMed: 16035136]
573.
Thuroff S, Chaussy C. High-intensity focused ultrasound: complications and adverse events. Molecular Urology. 2000;4(3):183–7. discussion 9. Not comparative treatments. [PubMed: 11062373]
574.
Tiffany NM, Wersinger EM, Garzotto M, Beer TM. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.[see comment] Urology. 2004;63(5):934–9. Not localized prostate cancer . [PubMed: 15134984]
575.
Truong PT, Berthelet E, Lee JC, Petersen R, Lim JTW, Gaul CA. et al. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy. Canadian Journal of Urology. 2006 Jun;13(3):3139–46. Not comparative treatments . [PubMed: 16813705]
576.
Tsai HK, Manola J, Abner A, Talcott JA, D'Amico AV, Beard C. Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy. Urologic Oncology. 2005;23(4):230–7. Less than 100 patients per study arm . [PubMed: 16018937]
577.
Turk IA, Deger S, Morgan WR, Davis JW, Schellhammer PF, Loening SA. Sural nerve graft during laparoscopic radical prostatectomy. Initial experience. Urologic Oncology. 2002;7(5):191–4. Not comparative treatments . [PubMed: 12644215]
578.
Uchida T, Baba S, Irie A, Soh S, Masumori N, Tsukamoto T. et al. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: a multicenter study. Hinyokika Kiyo - Acta Urologica Japonica. 2005;51(10):651–8. Not comparative treatments . [PubMed: 16285617]
579.
Ueda T, Suzuki H, Akakura K, Ishihara M, Kamiya N, Komiya A. et al. Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer. Hinyokika Kiyo - Acta Urologica Japonica. 2006 Jul;52(7):515–21. Not comparative treatments . [PubMed: 16910582]
580.
Ukoli FA, Lynch BS, Adams-Campbell LL. Radical prostatectomy and quality of life among African Americans. Ethn Dis. 2006;16(4):988–93. Not comparative treatments . [PubMed: 17061757]
581.
Unger JM, LeBlanc M, Thompson IM, Coltman CA Jr. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. Urologic Oncology. 2004;22(4):362–8. Not comparative treatments . [PubMed: 15283898]
582.
Valdimarsdottir U, Helgason AR, Furst CJ, Adolfsson J, Steineck G. The unrecognised cost of cancer patients' unrelieved symptoms:a nationwide follow-up of their surviving partners. British Journal of Cancer. 2002;86(10):1540–5. Not localized prostate cancer . [PMC free article: PMC2746591] [PubMed: 12085201]
583.
Valdimarsdottir U, Helgason AR, Furst CJ, Adolfsson J, Steineck G. Long-term effects of widowhood after terminal cancer: a Swedish nationwide follow-up. Scandinavian Journal of Public Health. 2003;31(1):31–6. Not localized prostate cancer . [PubMed: 12623522]
584.
Vale J. Erectile dysfunction following radical therapy for prostate cancer. Radiotherapy & Oncology. 2000;57(3):301–5. Review article . [PubMed: 11104890]
585.
van Andel G, Kurth KH. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. European Urology. 2003;44(2):209–14. Not localized prostate cancer . [PubMed: 12875940]
586.
Van Andel G, Visser AP, Hulshof MC, Horenblas S, Kurth KH. Health-related quality of life and psychosocial factors in patients with prostate cancer scheduled for radical prostatectomy or external radiation therapy. BJU International. 2003;92(3):217–22. Not localized prostate cancer . [PubMed: 12887470]
587.
van Andel G, Visser AP, Zwinderman AH, Hulshof MC, Horenblas S, Kurth KH. A prospective longitudinal study comparing the impact of external radiation therapy with radical prostatectomy on health related quality of life (HRQOL) in prostate cancer patients. Prostate. 2004;58(4):354–65. Less than 100 patients per study arm . [PubMed: 14968436]
588.
van Dis FW, Mols F, Vingerhoets AJJM, Ferrell B, van de Poll-Franse LV. A validation study of the Dutch version of the Quality of Life-Cancer Survivor (QOL-CS) questionnaire in a group of prostate cancer survivors. Quality of Life Research. 2006 Dec;15(10):1607–12. Not localized prostate cancer . [PubMed: 16826441]
589.
Van Gellekom MP, Moerland MA, Van Vulpen M, Wijrdeman HK, Battermann JJ. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. International Journal of Radiation Oncology, Biology, Physics. 2005;63(3):772–80. Not comparative treatments . [PubMed: 15964707]
590.
van Haarst EP, Heldeweg EA, Newling DW, Schlatmann TJ. A cross-sectional study of the international prostate symptom scores related to age and gender in Dutch adults reporting no voiding complaints. European Urology. 2005;47(3):334–9. Not comparative treatments . [PubMed: 15716197]
591.
Van Steen K, Curran D, Molenberghs G. Sensitivity analysis of longitudinal binary quality of life data with drop-out: an example using the EORTC QLQ-C30. Statistics in Medicine. 2001;20(24):3901–20. Not localized prostate cancer . [PubMed: 11782042]
592.
van Tol-Geerdink JJ, Stalmeier PFM, van Lin ENJT, Schimmel EC, Huizenga H, van Daal WAJ. et al. Do patients with localized prostate cancer treatment really want more aggressive treatment? Journal of Clinical Oncology. 2006 Oct 1;24(28):4581–6. Not localized prostate cancer . [PubMed: 17008699]
593.
Visser A, van Andel G, Willems P, Voogt E, Dijkstra A, Rovers P. et al. Changes in health-related quality of life of men with prostate cancer 3 months after diagnosis: the role of psychosocial factors and comparisment with benign prostate hyperplasia patients. Patient Education & Counseling. 2003;49(3):225–32. Not comparative treatments . [PubMed: 12642194]
594.
Voerman B, Fischer M, Visser A, Garssen B, van Andel G, Bensing J. Health-related quality of life in Dutch men with prostate cancer. J Psychosoc Oncol. 2006;24(2):49–64. Not localized prostate cancer . [PubMed: 17046806]
595.
Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH. et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist. 2004;9(6):687–95. Not localized prostate cancer . [PubMed: 15561812]
596.
Vojkovic SJ, Kristjanson LJ. Case study report of two palliative care patients receiving intracerebroventricular (ICV) analgesia. Journal of Palliative Care. 2003;19(4):280–3. Not localized prostate cancer . [PubMed: 14959600]
597.
Vordermark D, Schwab M, Flentje M, Sailer M, Kolbl O. Chronic fatigue after radiotherapy for carcinoma of the prostate: correlation with anorectal and genitourinary function. Radiotherapy & Oncology. 2002;62(3):293–7. Not localized prostate cancer . [PubMed: 12175560]
598.
Vordermark D, Wulf J, Markert K, Baier K, Kolbl O, Beckmann G. et al. 3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey. Acta Oncologica. 2006;45(6):708–16. Less than 100 patients per study arm . [PubMed: 16938814]
599.
Votron L, D'Hoore W, Swine C, Daisne JF, Scalliet P. The opinion of general practitioners on the treatment of prostate and breast cancer in elderly people: results of a survey based on clinical models. Clinical Oncology (Royal College of Radiologists) 2004;16(7):474–8. Not localized prostate cancer . [PubMed: 15490809]
600.
Wahlgren T, Brandberg Y, Haggarth L, Hellstrom M, Nilsson S. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25. International Journal of Radiation Oncology, Biology, Physics. 2004;60(1):51–9. Not comparative treatments . [PubMed: 15337539]
601.
Wallace M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncology Nursing Forum 2003;Online. 30(2):303–9. Not comparative treatments. [PubMed: 12692664]
602.
Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate.[see comment] Journal of Urology. 2000;163(6):1802–7. Not comparative treatments . [PubMed: 10799186]
603.
Walsh PC. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Journal of Urology. 2000;163(1):370. CaPSURE data . [PubMed: 10604391]
604.
Walsh PC, Marschke PL. Intussusception of the reconstructed bladder neck leads to earlier continence after radical prostatectomy. Urology. 2002;59(6):934–8. Not comparative treatments . [PubMed: 12031385]
605.
Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006 Nov 15;296(19):2336–42. Not comparative treatments . [PubMed: 17105796]
606.
Wang H, Huang E, Dale W, Campbell T, Ignacio L, Kopnick M. et al. Self-assessed health-related quality of life in men who have completed radiotherapy for prostate cancer: instrument validation and its relation to patient-assessed bother of symptoms. International Journal of Cancer. 2000;90(3):163–72. Not comparative treatments . [PubMed: 10900429]
607.
Wang L, Hricak H, Kattan MW, Chen HN, Kuroiwa K, Eisenberg HF. et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology. 2007 Jan;242(1):182–8. Not localized prostate cancer . [PubMed: 17090712]
608.
Wang LG, Mencher SK, McCarron JP, Ferrari AC. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review. Oncology Reports. 2004;11(6):1325–9. Less than 100 patients per study arm . [PubMed: 15138573]
609.
Warde P, Tsuji D, Bristow R. A randomized phase III study of neoadjuvant hormonal therapy in patients with localized prostate cancer. Clin Genitourin Cancer. 2006 Dec;5(3):235–7. No QOL outcomes . [PubMed: 17239279]
610.
Ward-Smith P. Brachytherapy for prostate cancer: the patient's perspective. Urologic Nursing. 2003;23(3):213–7. Not comparative treatments . [PubMed: 12861739]
611.
Ward-Smith P, Kapitan D. Quality of life among men treated with radiation therapy for prostate cancer. Urologic Nursing. 2005;25(4):263–8. Not comparative treatments . [PubMed: 16225343]
612.
Ward-Smith P, Wittkopp D, Sheldon JM. Quality of life among men treated with brachytherapy for prostate cancer. Urologic Nursing. 2004;24(2):95–9. Not comparative treatments . [PubMed: 15131916]
613.
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905. Validation study . [PubMed: 11113727]
614.
Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS. et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer.[see comment] Journal of Clinical Oncology. 2002;20(2):557–66. Not prospective or longitudinal survey study . [PubMed: 11786586]
615.
Wernicke AG, Valicenti R, Dieva K, Houser C, Pequignot E. Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 2004;60(5):1357–63. Not comparative treatments . [PubMed: 15590165]
616.
Widmark A, Fossa SD, Lundmo P, Damber JE, Vaage S, Damber L. et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3.[see comment] Urology. 2003;61(1):145–51. No QOL outcomes . [PubMed: 12559286]
617.
Wilkinson S, Gomella LG, Smith JA, Brawer MK, Dawson NA, Wajsman Z. et al. Attitudes and use of complementary medicine in men with prostate cancer. Journal of Urology. 2002;168(6):2505–9. Not localized prostate cancer . [PubMed: 12441950]
618.
Willener R, Hantikainen V. Individual quality of life following radical prostatectomy in men with prostate cancer. Urologic Nursing. 2005;25(2):88–90. Not comparative treatments . [PubMed: 15900977]
619.
Windsor PM, Nicol KF, Potter J. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer. 2004;101(3):550–7. Not comparative treatments . [PubMed: 15274068]
620.
Winquist E, Waldron T, Berry S, Ernst DS, Hotte S, Lukka H. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. BMC Cancer. 2006;6:112. Review article . [PMC free article: PMC1550253] [PubMed: 16670021]
621.
Wiygul JB, Evans BR, Peterson BL, Polascik TJ, Walther PJ, Robertson CN. et al. Supplement use among men with prostate cancer. Urology. 2005;66(1):161–6. Not localized prostate cancer . [PubMed: 15992901]
622.
Woel R, Beard C, Chen MH, Hurwitz M, Loffredo M, McMahon E. et al. Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization. International Journal of Radiation Oncology, Biology, Physics. 2005;62(2):392–6. Not comparative treatments . [PubMed: 15890580]
623.
Wu S. Sickness and preventive medical behavior. Journal of Health Economics. 2003;22(4):675–89. Not localized prostate cancer . [PubMed: 12842321]
624.
Wust P, von Borczyskowski DW, Henkel T, Rosner C, Graf R, Tilly W. et al. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy. Radiotherapy & Oncology. 2004;73(1):39–48. Not comparative treatments . [PubMed: 15465144]
625.
Xu K, Ling MT, Wang X, Wong YC. Evidence of a novel biomarker, alphas1-Casein, a milk protein, in benign prostate hyperplasia. Prostate Cancer & Prostatic Diseases. 2006;9(3):293–7. Not localized prostate cancer . [PubMed: 16683014]
626.
Yang BK, Crisci A, Young MD, Silverstein AD, Peterson BL, Dahm P. Cross-sectional survey of long-term quality of life after radical perineal prostatectomy. Urology. 2005;65(1):120–5. Not comparative treatments . [PubMed: 15667876]
627.
Yang BK, Young MD, Calingaert B, Albala DM, Vieweg J, Murphy BC. et al. Prospective and longitudinal patient self-assessment of health-related quality of life following radical perineal prostatectomy. Journal of Urology. 2004;172(1):264–8. Not comparative treatments . [PubMed: 15201791]
628.
Yokomizo A, Kawamoto H, Nihei K, Ishizuka N, Kakehi Y, Tobisu K. et al. Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401. Japanese Journal of Clinical Oncology. 2005;35(1):34–6. No QOL outcomes . [PubMed: 15681602]
629.
Yoshimura K, Arai Y, Ichioka K, Matsui Y, Ogura K, Terai A. A 3-y prospective study of health-related and disease-specific quality of life in patients with nonmetastatic prostate cancer treated with radical prostatectomy or external beam radiotherapy. Prostate Cancer & Prostatic Diseases. 2004;7(2):144–51. Less than 100 patients per study arm . [PubMed: 15111981]
630.
Yoshimura K, Ichioka K, Terada N, Terai A, Arai Y. Use of complementary and alternative medicine by patients with localized prostate carcinoma: study at a single institute in Japan. International Journal of Clinical Oncology. 2003;8(1):26–30. Not comparative treatments . [PubMed: 12601539]
631.
Young MD, Weizer AZ, Silverstein AD, Crisci A, Albala DM, Vieweg J. et al. Urinary continence and quality of life in the first year after radical perineal prostatectomy. Journal of Urology. 2003;170(6 Pt 1):2374–8. Not comparative treatments . [PubMed: 14634420]
632.
Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L. et al. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer. 2006;106(9):1865–74. No QOL outcomes . [PubMed: 16568450]
633.
Zhang AY, Strauss GJ, Siminoff LA. Intervention of urinary incontinence and quality of life outcome in prostate cancer patients. J Psychosoc Oncol. 2006;24(2):17–30. Less than 100 patients per study arm . [PubMed: 17046804]
634.
Zisman A, Leibovici D, Kleinmann J, Cooper A, Siegel Y, Lindner A. The impact of prostate biopsy on patient well-being: a prospective study of voiding impairment. Journal of Urology. 2001;166(6):2242–6. Not comparative treatments . [PubMed: 11696744]

Proton beam radiation therapy (PBRT), high-intensity focused ultrasound (HIFU), intensity modulated radiation therapy (IMRT), cryosurgery, and laparoscopic/robotic surgery

1.
Austin-Seymour M, Urie M, Munzenrider J. et al. Considerations in fractionated proton radiation therapy: clinical potential and results. Radiother Oncol. 1990 Jan;17(1):29–35. Not eligible outcomes . [PubMed: 2157240]
2.
Banerjee S, Das T, Chakraborty S. et al. 177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. Nuclear Medicine & Biology. 2004;31(6):753–9. Not eligible exposure . [PubMed: 15246366]
3.
Brahme A. Individualizing cancer treatment: biological optimization models in treatment planning and delivery. Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):327–37. Review . [PubMed: 11173125]
4.
Casciani E, Polettini E, Bertini L. et al. Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiologia Medica. 2004;108(56):530–41. Not eligible exposure . [PubMed: 15722999]
5.
Cella L, Lomax A, Miralbell R. Potential role of intensity modulated proton beams in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):217–23. Not eligible outcomes . [PubMed: 11163518]
6.
Chabanova E, Logager V, Thomsen H. Combined MR examination of prostate: is it reliable? Acta Radiologica. 2004;45(5):591–3. Not eligible exposure . [PubMed: 15515525]
7.
Chan I, Wells W 3rd, Mulkern RV. et al. Detection of prostate cancer by integration of line-scan diffusion, T2-mapping and T2-weighted magnetic resonance imaging; a multichannel statistical classifier. Med Phys. 2003 Sep;30(9):2390–8. Not eligible exposure . [PubMed: 14528961]
8.
Cheng LL, Burns MA, Taylor JL. et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Research. 2005;65(8):3030–4. Not eligible exposure . [PubMed: 15833828]
9.
Crook J, Toi A, McLean M. et al. The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy. Brachytherapy. 2002;1(3):131–7. Not eligible outcomes . [PubMed: 15090275]
10.
Delen S, Eyben J. Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy. Nederlands Tijdschrift voor Geneeskunde. 2006;150(43):2401. Not English language . [PubMed: 17100134]
11.
Ficarra V, Antoniolli SZ, Novara G. et al. Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int. 2006 Dec;98(6):1193–8. Case series, 30 patients . [PubMed: 17125477]
12.
Fourkal E, Li JS, Xiong W. et al. Intensity modulated radiation therapy using laser-accelerated protons: a Monte Carlo dosimetric study. Phys Med Biol. 2003 Dec 21;48(24):3977–4000. Not eligible outcomes . [PubMed: 14727747]
13.
Fricke ST, Rodriguez O, Vanmeter J. et al. In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate cancer models. Prostate. 2006;66(7):708–17. Not human study . [PubMed: 16425198]
14.
Fujita T, Teh BS, Timme TL. et al. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):84–90. Not eligible outcomes . [PubMed: 16472937]
15.
Futterer JJ, Heijmink SWTPJ, Scheenen TWJ. et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241(2):449–58. Not eligible exposure . [PubMed: 16966484]
16.
Futterer JJ, Scheenen TWJ, Heijmink SWTPJ. et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Investigative Radiology. 2007;42(2):116–22. Not eligible exposure . [PubMed: 17220729]
17.
Galbraith ME, Ramirez JM, Pedro LW. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol Nurs Forum. 2001 Apr;28(3):551–60. Case series . [PubMed: 11338762]
18.
Gelet A, Chapelon JY, Poissonnier L. et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology. 2004 Apr;63(4):625–9. Not eligible target population . [PubMed: 15072864]
19.
Gonzalez-Gronow M, Misra UK, Gawdi G, Pizzo SV. Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells. Journal of Biological Chemistry. 2005;280(29):27173–8. Not eligible exposure . [PubMed: 15911629]
20.
Hara I, Murakami M, Kagawa K. et al. Experience with conformal proton therapy for early prostate cancer. American Journal of Clinical Oncology. 2004;27(4):323–7. Less than 50 subjects per study arm . [PubMed: 15289722]
21.
Hartford AC, Niemierko A, Adams JA. et al. Conformal irradiation of the prostate: estimating long-term rectal bleeding risk using dose-volume histograms. Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):721–30. Case series study . [PubMed: 8948358]
22.
Hoffelt SC, Marshall LM, Garzotto M. et al. A comparison of CT scan to transrectal ultrasound-measured prostate volume in untreated prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):29–32. Not eligible outcomes . [PubMed: 12909212]
23.
Hricak H. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol. 2005;78(Spec No 2):S103–11. Not eligible exposure . [PubMed: 16306632]
24.
Humez S, Monet M, van Coppenolle F, Delcourt P, Prevarskaya N. The role of intracellular pH in cell growth arrest induced by ATP. American Journal of Physiology - Cell Physiology. 2004;287(6):C1733–46. Not eligible exposure . [PubMed: 15355852]
25.
Hurwitz MD, Kaplan ID, Hansen JL. et al. Association of rectal toxicity with thermal dose parameters in treatment of locally advanced prostate cancer with radiation and hyperthermia. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):913–8. Not eligible exposure . [PubMed: 12095557]
26.
Illing RO, Leslie TA, Kennedy JE. et al. Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: A proposed standard for the conduct of therapy. BJU Int. 2006 Dec;98(6):1187–92. Case series, 34 patients . [PubMed: 17125476]
27.
Isidoro A, Martinez M, Fernandez PL. et al. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochemical Journal. 2004;378(Pt 1):17–20. Not prostate cancer . [PMC free article: PMC1223948] [PubMed: 14683524]
28.
Johansson B, Ridderheim M, Glimelius B. The potential of proton beam radiation therapy in prostate cancer, other urological cancers and gynaecological cancers. Acta Oncologica. 2005;44(8):890–5. Review . [PubMed: 16332598]
29.
Kagei K, Tokuuye K, Sugahara S. et al. Initial experience of proton beam therapy at the new facility of the University of Tsukuba. Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica. 2004;64(4):225–30. Not English language . [PubMed: 15211886]
30.
Kiessling F, Huber PE, Grobholz R. et al. Dynamic magnetic resonance tomography and proton magnetic resonance spectroscopy of prostate cancers in rats treated by radiotherapy. Investigative Radiology. 2004;39(1):34–44. Not human study . [PubMed: 14701987]
31.
Kline EE, Treat EG, Averna TA, Davis MS, Smith AY, Sillerud LO. Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection. Journal of Urology. 2006;176(5):2274–9. Not eligible exposure . [PubMed: 17070311]
32.
Kline RP, Wu EX, Petrylak DP. et al. Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging. Clin Cancer Res. 2000 Jun;6(6):2146–56. Not eligible target population . [PubMed: 10873063]
33.
Kodibagkar VD, Cui W, Merritt ME, Mason RP. Novel 1H NMR approach to quantitative tissue oximetry using hexamethyldisiloxane. Magnetic Resonance in Medicine. 2006;55(4):743–8. Not eligible exposure . [PubMed: 16506157]
34.
Kondrat'ev BV, Vinogradov VM, Shalek RA, Ialynych NN, Kopaneva MV. Proton irradiation of the pituitary gland for alleviating pain in patients with disseminated prostate cancer. Voprosy Onkologii. 2006;52(1):92–4. Not English language . [PubMed: 16715713]
35.
Kumar R, Kumar M, Jagannathan NR, Gupta NP, Hemal AK. Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate. Urological Research. 2004;32(1):36–40. Not eligible exposure . [PubMed: 14534764]
36.
Kumar V, Jagannathan NR, Kumar R. et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magnetic Resonance Imaging. 2006;24(5):541–8. Not eligible exposure . [PubMed: 16735174]
37.
Kurhanewicz J, Vigneron DB, Hricak H. et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology. 1996 Aug;200(2):489–96. Not eligible exposure . [PubMed: 8685346]
38.
Kwock L, Smith JK, Castillo M. et al. Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. Lancet Oncology. 2006;7(10):859–68. Not eligible exposure . [PubMed: 17012048]
39.
Lawton CA, DeSilvio M, Lee WR. et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05) Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):39–47. Not eligible outcomes . [PubMed: 17084551]
40.
Lee J, Yamaguchi T, Abe A. et al. Clinical evaluation of choline measurement by proton MR spectroscopy in patients with malignant tumors. Radiation Medicine. 2004;22(3):148–54. Not eligible exposure . [PubMed: 15287529]
41.
Lee M, Wynne C, Webb S. et al. A comparison of proton and megavoltage X-ray treatment planning for prostate cancer. Radiother Oncol. 1994 Dec;33(3):239–53. Not eligible outcomes . [PubMed: 7716264]
42.
Lichy MP, Pintaske J, Kottke R. et al. 3D proton MR spectroscopic imaging of prostate cancer using a standard spine coil at 1.5 T in clinical routine: a feasibility study. European Radiology. 2005;15(4):653–60. Not eligible exposure . [PubMed: 15627193]
43.
Liney GP, Turnbull LW, Lowry M. et al. In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI. Magn Reson Imaging. 1997;15(10):1177–86. Not eligible exposure . [PubMed: 9408138]
44.
Manenti G, Squillaci E, Carlani M, Mancino S, Di Roma M, Simonetti G. Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience. Radiologia Medica. 2006;111(1):22–32. Not eligible exposure . [PubMed: 16623302]
45.
Merrick GS, Butler WM, Wallner KE. et al. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis. Brachytherapy. 2005;4(4):241–51. Not eligible outcomes . [PubMed: 16344253]
46.
Michalski JM. Radiation therapy in the management of locally advanced prostate cancer. Current Urology Reports. 2006;7(3):217–24. Review . [PubMed: 16630525]
47.
Mock U, Bogner J, Georg D, Auberger T, Potter R. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy. Strahlentherapie und Onkologie. 2005;181(7):448–55. Not eligible outcomes . [PubMed: 15995838]
48.
Morakkabati-Spitz N, Bastian PJ, Meissner A. et al. MR techniques for noninvasive diagnosis of prostate cancer. Urologe A. 2006;45(6):702–5. Not English language . [PubMed: 16788787]
49.
Moyers MF, Miller DW. Range, range modulation, and field radius requirements for proton therapy of prostate cancer. Technol Cancer Res Treat. 2003 Oct;2(5):445–7. Not eligible outcomes . [PubMed: 14529309]
50.
Mueller-Lisse UG, Vigneron DB, Hricak H. et al. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology. 2001 Nov;221(2):380–90. Not eligible exposure . [PubMed: 11687679]
51.
Murayama S, Fuji H, Yamashita H. et al. Initial clinical experience of proton therapy at Shizuoka Cancer Center. Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica. 2005;65(4):424–31. Not English language . [PubMed: 16334397]
52.
Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncologica. 2004;43(4):316–81. Review . [PubMed: 15303499]
53.
Ogino T. Proton beam therapy. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 2006;33(4):450–4. Not English language . [PubMed: 16612152]
54.
Paganetti H, Niemierko A, Ancukiewicz M. et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):407–21. Not eligible outcomes . [PubMed: 12023146]
55.
Parivar F, Hricak H, Shinohara K. et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology. 1996 Oct;48(4):594–9. Not eligible exposure . [PubMed: 8886066]
56.
Petros JA, Baumann AK, Ruiz-Pesini E. et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(3):719–24. Not eligible exposure . [PMC free article: PMC545582] [PubMed: 15647368]
57.
Pickles T, Pollack A. The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer. Can J Urol. 2006;13(Suppl 2):68–71. Review . [PubMed: 16672133]
58.
Pisani LJ, Ross AB, Diederich CJ. et al. Effects of spatial and temporal resolution for MR image-guided thermal ablation of prostate with transurethral ultrasound. Journal of Magnetic Resonance Imaging. 2005;22(1):109–18. Not eligible exposure . [PubMed: 15971190]
59.
Portalez D, Malavaud B, Herigault G. et al. Predicting prostate cancer with dynamic endorectal coil MR and proton spectroscopic MR imaging. Journal de Radiologie. 2004;85(12 Pt 1):1999–2004. Not English language . [PubMed: 15692410]
60.
Pucar D, Koutcher JA, Shah A. et al. Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clinical Prostate Cancer. 2004;3(3):174–81. Not eligible exposure . [PubMed: 15636684]
61.
Ronson BB, Yonemoto LT, Rossi CJ, Slater JM, Slater JD. Patient tolerance of rectal balloons in conformal radiation treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 2006;64(5):1367–70. Not eligible outcomes . [PubMed: 16488552]
62.
Ross AB, Diederich CJ, Nau WH. et al. Highly directional transurethral ultrasound applicators with rotational control for MRI-guided prostatic thermal therapy. Physics in Medicine & Biology. 2004;49(2):189–204. Not eligible exposure . [PubMed: 15083666]
63.
Sacco DE, Daller M, Grocela JA. et al. Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention. BJU Int. 2003 Mar;91(4):345–9. Not eligible exposure . [PubMed: 12603412]
64.
Sahab ZJ, Suh Y, Sang QXA. Isoelectric point-based prefractionation of proteins from crude biological samples prior to two-dimensional gel electrophoresis. Journal of Proteome Research. 2005;4(6):2266–72. Not eligible exposure . [PubMed: 16335975]
65.
Scheenen TWJ, Gambarota G, Weiland E. et al. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T. Magnetic Resonance in Medicine. 2005;53(6):1268–74. Not eligible exposure . [PubMed: 15906304]
66.
Scheenen TWJ, Klomp DWJ, Roll SA, Futterer JJ, Barentsz JO, Heerschap A. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magnetic Resonance in Medicine. 2004;52(1):80–8. Not eligible exposure . [PubMed: 15236370]
67.
Schneider U, Lomax A, Pemler P. et al. The impact of IMRT and proton radiotherapy on secondary cancer incidence. Strahlentherapie und Onkologie. 2006;182(11):647–52. Case series . [PubMed: 17072522]
68.
Schulte RW, Li T. Innovative strategies for image-guided proton treatment of prostate cancer. Technology in Cancer Research & Treatment. 2006;5(2):91–100. Review . [PubMed: 16551129]
69.
Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25(8):953–64. Review . [PubMed: 17350944]
70.
Shah SK, Lui PD, Baldwin DD, Ruckle HC. Urothelial carcinoma after external beam radiation therapy for prostate cancer. Journal of Urology. 2006;175(6):2063–6. Not eligible exposure . [PubMed: 16697804]
71.
Shukla-Dave A, Hricak H, Eberhardt SC. et al. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings—initial observations. Radiology. 2004;231(3):717–24. Not eligible exposure . [PubMed: 15163811]
72.
Slater JD, Yonemoto LT, Rossi CJ Jr. et al. Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):299–304. Duplicate report . [PubMed: 9788407]
73.
Smyslov AI, Konchili IN, Lebedev LA, Khmelevski EB. Comparative analysis of dose distribution in photon and proton therapy of prostate cancer. Meditsinskaia Tekhnika 2006(5):16–20. Not English language. [PubMed: 17133938]
74.
Sovak M, Seligson AL, Konas M. et al. Herbal composition PC-SPES for management of prostate cancer: identification of active principles. J Natl Cancer Inst. 2002 Sep 4;94(17):1275–81. Not eligible exposure . [PubMed: 12208892]
75.
Squillaci E, Manenti G, Mancino S. et al. MR spectroscopy of prostate cancer. Initial clinical experience. Journal of Experimental & Clinical Cancer Research. 2005;24(4):523–30. Not eligible exposure . [PubMed: 16471314]
76.
Thomas SJ. Margins for treatment planning of proton therapy. Physics in Medicine & Biology. 2006;51(6):1491–501. Not eligible outcomes . [PubMed: 16510958]
77.
Timmermann B, Schuck A, Niggli F, Weiss M, Lomax A, Goitein G. “Spot-scanning” proton therapy for rhabdomyosarcomas of early childhood. First experiences at PSI. Strahlentherapie und Onkologie. 2006;182(11):653–9. Not English language . [PubMed: 17072523]
78.
Uchida T, Sanghvi NT, Gardner TA. et al. Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report. Urology. 2002 Mar;59(3):394–8. Case series, 20 patients . [PubMed: 11880077]
79.
Vallancien G, Prapotnich D, Cathelineau X. et al. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol. 2004 Jun;171(6 Pt 1):2265–7. Case series, 30 patients . [PubMed: 15126799]
80.
Wambersie A, Hendry J, Gueulette J, Gahbauer R, Potter R, Gregoire V. Radiobiological rationale and patient selection for high-LET radiation in cancer therapy. Radiother Oncol. 2004;73(Suppl 2):S1–14. Review . [PubMed: 15971301]
81.
Wust P, Cho CH, Hildebrandt B, Gellermann J. Thermal monitoring: invasive, minimal-invasive and non-invasive approaches. International Journal of Hyperthermia. 2006;22(3):255–62. Review . [PubMed: 16754347]
82.
Yamaguchi T, Lee J, Uemura H. et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. European Journal of Nuclear Medicine & Molecular Imaging. 2005;32(7):742–8. Not eligible exposure . [PubMed: 16052370]
83.
Yeboah C, Sandison GA. Optimized treatment planning for prostate cancer comparing IMPT, VHEET and 15 MV IMXT. Phys Med Biol. 2002 Jul 7;47(13):2247–61. Not eligible outcomes . [PubMed: 12164585]
84.
Yeboah C, Sandison GA, Chvetsov AV. Intensity and energy modulated radiotherapy with proton beams: variables affecting optimal prostate plan. Med Phys. 2002 Feb;29(2):176–89. Not eligible outcomes . [PubMed: 11865989]
85.
Zakian KL, Sircar K, Hricak H. et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234(3):804–14. Not eligible exposure . [PubMed: 15734935]
86.
Zhang X, Dong L, Lee AK. et al. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. International Journal of Radiation Oncology, Biology, Physics. 2007;67(2):620–9. Not eligible exposure . [PMC free article: PMC1945214] [PubMed: 17236979]

Question 3. Provider Characteristics Associated with Patient Outcomes

1.
Results of 12-year study show brachytherapy is as effective as surgery. Rep Med Guidel Outcomes Res. Jul 20 2000;11(15):10, 12. News. [PubMed: 11771565]
2.
Antiandrogen therapy and side effects following radical prostatectomy. Clin J Oncol Nurs. Jul–Aug 2000;4(4):179–180. Review. [PubMed: 11261099]
3.
Prostate cancer surgery: busier is better. Harv Mens Health Watch. Feb 2003;7(7):7–8. Review. [PubMed: 12604444]
4.
Abbas F, Siddiqui K, Biyabani SR. et al. Early surgical results with intent to treat by radical retropubic prostatectomy for clinically localized prostate cancer. J Pak Med Assoc. 2002 May;52(5):200–205. Not eligible exposure . [PubMed: 12174491]
5.
Abbou CC, Salomon L, Hoznek A. et al. Laparoscopic radical prostatectomy: preliminary results. Urology. 2000 May;55(5):630–634. No provider characteristics . [PubMed: 10792066]
6.
Abdalla I, Basu A, Hellman S. An evidence-based analysis of the management of localized prostate cancer. Cancer J. 2002 Jan–Feb;8(1):40–46. Review . [PubMed: 11895202]
7.
Abrahamsson PA. The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument for. Eur Urol. 1996;29(Suppl 2):27–30. Review . [PubMed: 8717458]
8.
Adolfsson J, Steineck G, Whitmore WF Jr. Recent results of management of palpable clinically localized prostate cancer. Cancer. 1993 Jul 15;72(2):310–322. Review . [PubMed: 8319164]
9.
Ahlgren G, Pedersen K, Lundberg S. et al. Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy. Urology. 1999 Aug;54(2):329–334. Not eligible exposure . [PubMed: 10443734]
10.
Akaza H. Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer. BJU Int. 2004 Jan;93(1):42–46. Not eligible exposure . [PubMed: 14678365]
11.
Akdas A, Tarcan T, Turkeri L. et al. The impact of prostate-specific antigen, its density and the Gleason score in the prediction of extracapsular disease in prostate carcinoma. Eur Urol. 1997;31(3):311–316. Not eligible exposure . [PubMed: 9129922]
12.
Akporiaye LE. Early results of transurethral vaporisation of prostate in Nigeria. West Afr J Med. 2004 Apr–Jun;23(2):139–141. Not eligible exposure . [PubMed: 15287293]
13.
Akyol M, Kilicarslan H, Goze F. et al. Granuloma annulare associated with prostate carcinoma. J Eur Acad Dermatol Venereol. 2003 Jul;17(4):464–465. Review . [PubMed: 12834464]
14.
Albertsen PC, Hanley JA, Barrows GH. et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005 Sep 7;97(17):1248–1253. Not eligible exposure . [PubMed: 16145045]
15.
Alibhai SM, Klotz LH. A systematic review of randomized trials in localized prostate cancer. Can J Urol. 2004 Feb;11(1):2110–2117. Review . [PubMed: 15003149]
16.
Alibhai SM, Naglie G, Nam R. et al. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol. 2003 Sep 1;21(17):3318–3327. Not eligible exposure . [PubMed: 12947068]
17.
Altwein JE. Enhancing the efficacy of radical prostatectomy in locally advanced prostate cancer. Urol Int. 1998;60(Suppl 2):2–10. discussion 35. Review. [PubMed: 9607552]
18.
Amling CL, Lerner SE, Martin SK. et al. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol. 1999 Mar;161(3):857–862. discussion 862–853. Not eligible exposure. [PubMed: 10022701]
19.
Anast JW, Sadetsky N, Pasta DJ. et al. The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE) J Urol. 2005 Apr;173(4):1132–1138. Not eligible exposure . [PubMed: 15758721]
20.
Anastasiadis AG, Benson MC, Rosenwasser MP. et al. Cavernous nerve graft reconstruction during radical prostatectomy or radical cystectomy: safe and technically feasible. Prostate Cancer Prostatic Dis. 2003;6(1):56–60. Not eligible exposure . [PubMed: 12664067]
21.
Andersson J, Ekman P, Egevad L. et al. Relatively high risk of treatment failure after prostatectomy: tumour grade, histopathological stage and the preoperative serum PSA level are key prognosticators. Scand J Urol Nephrol. 2001 Dec;35(6):453–458. Not eligible exposure . [PubMed: 11848423]
22.
Andersson SO, Johansson JE, Windahl T. Neodymium-YAG laser treatment in localized prostatic cancer. High rate of local failure. Scand J Urol Nephrol. 1993;27(4):485–487. Not eligible exposure . [PubMed: 8159921]
23.
Andriole GL. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Eur Urol. 1997;32(Suppl 3):65–69. Review . [PubMed: 9267788]
24.
Ansari MS, Nabi G, Aron M. Solitary radial head metastasis with wrist drop: a rare presentation of metastatic prostate cancer. Urol Int. 2003;70(1):77–79. Not eligible target population . [PubMed: 12635643]
25.
Anscher MS, Robertson CN, Prosnitz R. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):37–43. Not eligible exposure. [PubMed: 7543893]
26.
Ansong S. Re: Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol. 1997 Jan;157(1):269–270. Comment . [PubMed: 8976276]
27.
Antiphon P, Hoznek A, Benyoussef A. et al. Complete solo laparoscopic radical prostatectomy: initial experience. Urology. 2003 Apr;61(4):724–728. discussion 728–729. Not eligible exposure. [PubMed: 12670553]
28.
Aprikian AG, Fair WR, Reuter VE. et al. Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br J Urol. 1994 Nov;74(5):630–636. Not eligible exposure . [PubMed: 7530128]
29.
Arcangeli G, Micheli A, Verna L. et al. Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer. Radiother Oncol. 1995 May;35(2):123–128. Not eligible exposure . [PubMed: 7569020]
30.
Augustin H, Hammerer P, Graefen M. et al. Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. Eur Urol. 2003 Feb;43(2):113–118. Not eligible exposure . [PubMed: 12565767]
31.
Augustin H, Hammerer PG, Blonski J. et al. Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy? Urology. 2003 Jul;62(1):79–85. Not eligible exposure . [PubMed: 12837427]
32.
Augustin H, Pummer K, Daghofer F. et al. Patient self-reporting questionnaire on urological morbidity and bother after radical retropubic prostatectomy. Eur Urol. 2002 Aug;42(2):112–117. Not eligible exposure . [PubMed: 12160580]
33.
Aus G. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment. Scand J Urol Nephrol Suppl. 1994;167:1–41. Not eligible exposure . [PubMed: 7542397]
34.
Aus G, Abrahamsson PA, Ahlgren G. et al. Hormonal treatment before radical prostatectomy: a 3-year followup. J Urol. 1998 Jun;159(6):2013–2016. discussion 2016–2017. Not eligible exposure. [PubMed: 9598509]
35.
Aus G, Becker C, Lilja H. et al. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3) Scand J Urol Nephrol. 2003;37(6):466–470. Not eligible exposure . [PubMed: 14675918]
36.
Ayala G, Wang D, Wulf G. et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 2003 Oct 1;63(19):6244–6251. Not eligible exposure . [PubMed: 14559810]
37.
Bahn DK, Lee F. Cryosurgical ablation therapy for prostate cancer. Arch Ital Urol Androl. 2000 Dec;72(4):302–304. Review . [PubMed: 11221060]
38.
Baniel J, Israilov S, Segenreich E. et al. Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy. BJU Int. 2001 Jul;88(1):58–62. Not eligible exposure . [PubMed: 11446847]
39.
Barqawi AB, Moul JW, Ziada A. et al. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology. 2003 Nov;62(5):872–876. Not eligible exposure . [PubMed: 14624911]
40.
Barrou B, Benoit G, Ouldkaci M. et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother. 2004 May;53(5):453–460. Not eligible exposure . [PubMed: 14760510]
41.
Barry MJ. PSA screening for prostate cancer: the current controversy—a viewpoint. Patient Outcomes Research Team for Prostatic Diseases. Ann Oncol. 1998 Dec;9(12):1279–1282. Review . [PubMed: 9932155]
42.
Barry MJ, Fleming C, Coley CM. et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes. Urology. 1995 Sep;46(3):277–289. Review . [PubMed: 7544931]
43.
Bates TS, Sugiono M, James ED. et al. Is the conservative management of chronic retention in men ever justified? BJU Int. 2003 Oct;92(6):581–583. Not eligible target population . [PubMed: 14511038]
44.
Battermann JJ, van Es CA. The learning curve in prostate seed implantation. Cancer Radiother. 2000 Nov;4(Suppl 1):119s–122s. No provider charactertistics . [PubMed: 11194949]
45.
Baur H, Frimberger M, Altwein JE. Simultaneous radical prostatectomy and partial rectum resection without colostomy. Eur Urol. 1997;31(3):380–381. Not eligible exposure . [PubMed: 9129936]
46.
Beer TM, Bubalo JS. Prevention and management of prostate cancer chemotherapy complications. Urol Clin North Am. 2004 May;31(2):367–378. Review . [PubMed: 15123414]
47.
Beer TM, Lemmon D, Lowe BA. et al. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer. 2003 Mar 1;97(5):1217–1224. Not eligible exposure . [PubMed: 12599228]
48.
Begg CB, Scardino PT. Taking stock of volume-outcome studies. J Clin Oncol. 2003 Feb 1;21(3):393–394. Comment . [PubMed: 12560422]
49.
Bentas W, Wolfram M, Jones J. et al. Robotic technology and the translation of open radical prostatectomy to laparoscopy: the early Frankfurt experience with robotic radical prostatectomy and one year follow-up. Eur Urol. 2003 Aug;44(2):175–181. No provider characteristics . [PubMed: 12875935]
50.
Bergstralh EJ, Myers RP. Re: Radical surgery for advanced prostate cancer and for radiation failures. J Urol. 1993 Jun;149(6):1560. Comment . [PubMed: 8501814]
51.
Bhandari A, McIntire L, Kaul SA. et al. Perioperative complications of robotic radical prostatectomy after the learning curve. J Urol. 2005 Sep;174(3):915–918. No provider characteristics . [PubMed: 16093987]
52.
Bhatnagar V, Stewart ST, Bonney WW. et al. Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time. Urology. 2004 Jan;63(1):103–109. Not eligible exposure . [PubMed: 14751359]
53.
Bhatta-Dhar N, Reuther AM, Zippe C. et al. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology. 2004 Mar;63(3):528–531. Not eligible exposure . [PubMed: 15028451]
54.
Bhayani SB, Pavlovich CP, Hsu TS. et al. Prospective comparison of short-term convalescence: laparoscopic radical prostatectomy versus open radical retropubic prostatectomy. Urology. 2003 Mar;61(3):612–616. Not eligible exposure . [PubMed: 12639657]
55.
Bianco FJ Jr, Scardino PT, Stephenson AJ. et al. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):448–453. Not eligible outcomes . [PubMed: 15890586]
56.
Bissada NK, Gunhan M, Hull JW. Surgical management of localized prostate cancer. J S C Med Assoc. 2000 Feb;96(2):60–64. Review . [PubMed: 10710901]
57.
Blana A, Walter B, Rogenhofer S. et al. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology. 2004 Feb;63(2):297–300. Not eligible exposure . [PubMed: 14972475]
58.
Bloom KD, Richie JP, Schultz D. et al. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. Urology. 2004 Feb;63(2):333–336. Not eligible exposure . [PubMed: 14972484]
59.
Boccon-Gibod L. The management of localised cancer of the prostate. Eur Urol. 1996;29(Suppl 2):62–68. Review . [PubMed: 8717466]
60.
Boccon-Gibod L, Djavan WB, Hammerer P. et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract. 2004 Apr;58(4):382–390. Review . [PubMed: 15161124]
61.
Bochner BH, Figueroa AJ, Skinner EC. et al. Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure. J Urol. 1998 Jul;160(1):29–33. Not eligible exposure . [PubMed: 9628599]
62.
Boczko J, Melman A. Radical perineal prostatectomy in obese patients. Urology. 2003 Sep;62(3):467–469. Not eligible exposure . [PubMed: 12946748]
63.
Bollens R, Sandhu S, Roumeguere T. et al. Laparoscopic radical prostatectomy: the learning curve. Curr Opin Urol. 2005 Mar;15(2):79–82. Review . [PubMed: 15725929]
64.
Bono AV, Celato N, Cova V. et al. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis. 2002;5(2):123–127. Not eligible exposure . [PubMed: 12497001]
65.
Bottke D, Wiegel T, Hocht S. et al. Salvage radiotherapy in patients with persisting prostate-specific antigen after radical prostatectomy for prostate cancer. Oncology. 2003;65(Suppl 1):18–23. Review . [PubMed: 12949429]
66.
Brant LA, Brantt WO, Brown MH. et al. A new minimally invasive open pelvic lymphadenectomy surgical technique for the staging of prostate cancer. Urology. 1996 Mar;47(3):416–421. No provider characteristics . [PubMed: 8633413]
67.
Brawer MK, Stamey TA, Fowler J. et al. Perspectives on prostate cancer diagnosis and treatment: a roundtable. Urology. 2001 Aug;58(2):135–140. Comment . [PubMed: 11489681]
68.
Brehmer B, Borchers H, Kirschner-Hermanns R. et al. Perioperative morbidity of the extended radical perineal prostatectomy. Eur Urol. 2001 Aug;40(2):139–143. No provider characteristics . [PubMed: 11528190]
69.
Brehmer B, Kirschner-Hermanns R, Donner A. et al. Efficacy of unilateral nerve sparing in radical perineal prostatectomy. Urol Int. 2005;74(4):308–314. Not eligible exposure . [PubMed: 15897694]
70.
Brierly RD, Hindley RG, Challacombe BJ. et al. “Urological cold shower”—a novel treatment for intraoperative erection. Urology. 2003 Feb;61(2):462. Not eligible exposure . [PubMed: 12597976]
71.
Brink S. Prostate cancer: kinder cuts mean sharper dilemmas. US News World Rep. 2000 Apr 3;128(13):58–60. News . [PubMed: 10788256]
72.
Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol. 1999 Dec;23(12):1471–1479. Not eligible exposure . [PubMed: 10584700]
73.
Brown JA, Garlitz C, Gomella LG. et al. Pathologic comparison of laparoscopic versus open radical retropubic prostatectomy specimens. Urology. 2003 Sep;62(3):481–486. Not eligible exposure . [PubMed: 12946751]
74.
Brucker PS, Cella D. Measuring self-reported sexual function in men with prostate cancer. Urology. 2003 Oct;62(4):596–606. Review . [PubMed: 14550425]
75.
Bukkapatnam R, Pow-Sang JM. Radical prostatectomy in the management of clinically localized prostate cancer. Cancer Control. 2001 Nov–Dec;8(6):496–502. Review . [PubMed: 11807419]
76.
Burney TL, Campbell EC Jr, Naslund MJ. et al. Complications of staging laparoscopic pelvic lymphadenectomy. Surg Laparosc Endosc. 1993 Jun;3(3):184–190. No provider characteristics . [PubMed: 8111554]
77.
Bussemakers MJ. Changes in gene expression and targets for therapy. Eur Urol. 1999;35(56):408–412. Review . [PubMed: 10325497]
78.
Cadeddu JA, Kavoussi LR. Laparoscopic radical prostatectomy: is it feasible and reasonable? Urol Clin North Am. 2001 Aug;28(3):655–661. Review . [PubMed: 11590820]
79.
Cagiannos I, Karakiewicz P, Graefen M. et al. Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol. 2004 Feb;171(2 Pt 1):692–696. Not eligible exposure . [PubMed: 14713788]
80.
Cangiano TG, Litwin MS, Naitoh J. et al. Intraoperative frozen section monitoring of nerve sparing radical retropubic prostatectomy. J Urol. 1999 Sep;162(3 Pt 1):655–658. Not eligible exposure . [PubMed: 10458335]
81.
Cantor SB, Spann SJ, Volk RJ. et al. Prostate cancer screening: a decision analysis. J Fam Pract. 1995 Jul;41(1):33–41. Not eligible exposure . [PubMed: 7798064]
82.
Carswell CI, Figgitt DP. Bicalutamide: in early-stage prostate cancer. Drugs. 2002;62(17):2471–2479. discussion 2480–2471. Not eligible exposure. [PubMed: 12421104]
83.
Catton C, Gospodarowicz M, Warde P. et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001 Apr;59(1):51–60. Not eligible exposure . [PubMed: 11295206]
84.
Chang CP, Chang YH, Chiang H, Chen MT, Chang LS. Incidental adenocarcinoma of the prostate: a retrospective analysis. Eur Urol. 1991;20(4):282–286. Not eligible exposure . [PubMed: 1726085]
85.
Chaussy C, Thuroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep. 2003 Jun;4(3):248–252. Not eligible exposure . [PubMed: 12756090]
86.
Chen BT, Wood DP Jr. Salvage prostatectomy in patients who have failed radiation therapy or cryotherapy as primary treatment for prostate cancer. Urology. 2003 Dec 29;62(Suppl 1):69–78. Review . [PubMed: 14747044]
87.
Cheng L, Cheville JC, Bostwick DG. Diagnosis of prostate cancer in needle biopsies after radiation therapy. Am J Surg Pathol. 1999 Oct;23(10):1173–1183. Not eligible exposure . [PubMed: 10524518]
88.
Cheng L, Cheville JC, Pisansky TM. et al. Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. Am J Surg Pathol. 1999 Jul;23(7):803–808. Not eligible exposure . [PubMed: 10403303]
89.
Cheng L, Koch MO, Juliar BE. et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol. 2005 May 1;23(13):2911–2917. Not eligible exposure . [PubMed: 15860849]
90.
Cher ML, Shinohara K, Breslin S. et al. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Br J Urol. 1995 Jun;75(6):771–777. Not eligible exposure . [PubMed: 7542137]
91.
Cherullo EE, Ponsky LE, Goyal KK. et al. Variable definitions influence the reporting of biochemical failure rates. Prostate Cancer Prostatic Dis. 2002;5(1):54–58. Not eligible exposure . [PubMed: 15195131]
92.
Cheung R, Altschuler MD, D'Amico AV. et al. Using the receiver operating characteristic curve to select pretreatment and pathologic predictors for early and late postprostatectomy PSA failure. Urology. 2001 Sep;58(3):400–405. Not eligible exposure . [PubMed: 11549488]
93.
Cheung R, Altschuler MD, D'Amico AV. et al. ROC optimization may improve risk stratification of prostate cancer patients. Urology. 2001 Feb;57(2):286–290. Not eligible exposure . [PubMed: 11182338]
94.
Cheville JC, Tindall D, Boelter C. et al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer. 2002 Sep 1;95(5):1028–1036. Not eligible target population . [PubMed: 12209687]
95.
Chodak G. Conservative management of clinically-localized prostate cancer. Can J Oncol. 1994 Nov;4(Suppl 1):20–21. discussion 22–23. Review. [PubMed: 8853484]
96.
Chodak GW. Prostate cancer. Lancet. 1997 May 24;349(9064):1551. author reply 1551–1552. Comment. [PubMed: 9167480]
97.
Choo R, Morton G, Danjoux C. et al. Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate carcinoma after surgery. Radiother Oncol. 2005 Feb;74(2):163–167. Not eligible exposure . [PubMed: 15734204]
98.
Chow P, Wong M, Foo KT. Clinical profile of stage D carcinoma of the prostate—a ten-year experience. Ann Acad Med Singapore. 1993 Mar;22(2):254–256. Not eligible exposure . [PubMed: 8363343]
99.
Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care. 2001 Oct;39(10):1118–1130. Not eligible exposure . [PubMed: 11567174]
100.
Clark PE, Peereboom DM, Dreicer R. et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 2001 Feb;57(2):281–285. Not eligible exposure . [PubMed: 11182337]
101.
Clegg LX, Feuer EJ, Midthune DN, et al. Impact of Reporting Delay and Reporting Error on Cancer Incidence Rates and Trends. J Natl Cancer Inst. October 16, 2002 2002;94(20):1537–1545. Not eligible exposure. [PubMed: 12381706]
102.
Coetzee LJ, Hars V, Paulson DF. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology. 1996 Feb;47(2):232–235. Not eligible exposure . [PubMed: 8607240]
103.
Cohen YC, Olmer L, Mozes B. Two-dimensional outcome analysis as a guide for quality assurance of prostatectomy. Int J Qual Health Care. 1996 Feb;8(1):67–73. Not eligible target population . [PubMed: 8680819]
104.
Cookson MS, Sogani PC, Russo P. et al. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol. 1997 Mar;79(3):432–438. Not eligible exposure . [PubMed: 9117227]
105.
Copeland B, Clark JM, Sura A. et al. Prostate carcinoma metastatic to the cervical lymph nodes: report of two cases and review of the literature. Am J Otolaryngol. 2001 Nov–Dec;22(6):420–423. Review . [PubMed: 11713729]
106.
Corn BW, Valicenti RK, Mulholland SG. et al. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy. Urology. 1998 May;51(5):782–787. Not eligible exposure . [PubMed: 9610592]
107.
Costello AJ. Contemporary view of prostate cancer diagnosis and treatment. Aust Fam Physician. 2003 Jun;32(6):396–398. Review . [PubMed: 12833761]
108.
Costello AJ. Minimally invasive radical prostatectomy: now safe and efficacious. ANZ J Surg. 2004 Dec;74(12):1038. Comment . [PubMed: 15574141]
109.
Costello AJ, Haxhimolla H, Crowe H. et al. Installation of telerobotic surgery and initial experience with telerobotic radical prostatectomy. BJU Int. 2005 Jul;96(1):34–38. Not eligible exposure . [PubMed: 15963116]
110.
Crawford ED, DeAntoni EP, Hussain M. et al. Prostate cancer clinical trials of the Southwest Oncology Group. Oncology (Williston Park) 1997 Aug;11(8):1154–1163. discussion 1163–1170. Review. [PubMed: 9268978]
111.
Critz FA. Summary of simultaneous irradiation for prostate cancer. Urology. 2004 Oct;64(4):633–636. Not eligible exposure . [PubMed: 15491686]
112.
Cross CK, Shultz D, Malkowicz SB. et al. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol. 2002 Jun 15;20(12):2863–2868. Not eligible exposure . [PubMed: 12065563]
113.
Da Pozzo LF, Francesca F, Colombo R. et al. Pathologic features and clinical outcome after anatomic radical prostatectomy by transcoccygeal approach. Urology. 1997 Mar;49(3):392–399. Not eligible exposure . [PubMed: 9123704]
114.
Dahm P, Vieweg J, Newhall PM. et al. Outcome profiles of locoregional disease after radical prostatectomy and radiotherapy. World J Urol. 2000 Jun;18(3):173–178. Not eligible exposure . [PubMed: 10926080]
115.
Dalkin BL. Endoscopic evaluation and treatment of anastomotic strictures after radical retropubic prostatectomy. J Urol. 1996 Jan;155(1):206–208. Not eligible exposure . [PubMed: 7490836]
116.
Dalkin BL. Re: Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001 Mar 7;93(5):401–402. Comment . [PubMed: 11238710]
117.
Dalkin BL, Ahmann FR, Nagle R. et al. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol. 1996 Apr;155(4):1357–1360. Not eligible exposure . [PubMed: 8632574]
118.
D'Amico A, Altschuler M, Whittington R. et al. The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer. Clin Perform Qual Health Care. 1993 Oct–Dec;1(4):219–222. Not eligible exposure . [PubMed: 10135639]
119.
D'Amico AV, Tempany CM, Schultz D. et al. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology. 2003 Dec;62(6):1063–1067. Not eligible exposure . [PubMed: 14665356]
120.
D'Amico AV. Combined-modality staging for localized adenocarcinoma of the prostate. Oncology (Williston Park) 2001 Aug;15(8):1049–1059. discussion 1060–1042, 1064–1045, 1069–1070,1073–1045. Review. [PubMed: 11548976]
121.
D'Amico AV, Chen MH, Oh-Ung J. et al. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):436–441. Not eligible exposure . [PubMed: 12243819]
122.
D'Amico AV, Chen MH, Roehl KA. et al. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol. 2005 Aug 1;23(22):4975–4979. Not eligible exposure . [PubMed: 16051949]
123.
D'Amico AV, Coleman CN. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. J Clin Oncol. 1996 Jan;14(1):304–315. Review . [PubMed: 8558212]
124.
D'Amico AV, Cote K, Loffredo M. et al. Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma. Cancer. 2003 Jan 1;97(1):56–62. Not eligible exposure . [PubMed: 12491505]
125.
D'Amico AV, Desjardin A, Chung A. et al. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer. 1998 May 15;82(10):1887–1896. Not eligible exposure . [PubMed: 9587121]
126.
D'Amico AV, Moul JW, Carroll PR. et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003 Sep 17;95(18):1376–1383. Not eligible exposure . [PubMed: 13130113]
127.
D'Amico AV, Whittington R, Kaplan I. et al. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4–20 nanograms per milliliter. Cancer. 1998 Jan 15;82(2):334–341. Not eligible exposure . [PubMed: 9445191]
128.
D'Amico AV, Whittington R, Malkowicz B. et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol. 2000 Sep;164(3 Pt 1):759–763. Not eligible exposure . [PubMed: 10953141]
129.
D'Amico AV, Whittington R, Malkowicz SB. et al. Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening. Urology. 2001 Sep;58(3):406–410. Not eligible exposure . [PubMed: 11549489]
130.
D'Amico AV, Whittington R, Malkowicz SB. et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000 Mar;18(6):1164–1172. Not eligible exposure . [PubMed: 10715284]
131.
D'Amico AV, Whittington R, Malkowicz SB. et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol. 1995 Jul;154(1):131–138. Not eligible exposure . [PubMed: 7539857]
132.
D'Amico AV, Whittington R, Malkowicz SB. et al. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. Mol Urol. 2000 Fall;4(3):171–175. discussion 177. Not eligible exposure. [PubMed: 11062371]
133.
D'Amico AV, Whittington R, Malkowicz SB. et al. A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urology. 1998 Oct;52(4):631–636. Not eligible exposure . [PubMed: 9763083]
134.
D'Amico AV, Whittington R, Malkowicz SB. et al. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7. Cancer. 2000 May 1;88(9):2110–2115. Not eligible exposure . [PubMed: 10813723]
135.
Davidson PJ, van den Ouden D, Schroeder FH. Radical prostatectomy: prospective assessment of mortality and morbidity. Eur Urol. 1996;29(2):168–173. Not eligible exposure . [PubMed: 8647142]
136.
Davis BJ, Haddock MG, Wilson TM. et al. Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: is extraprostatic seed placement necessary? Tech Urol. 2000 Jun;6(2):70–77. Not eligible exposure . [PubMed: 10798803]
137.
Davis M, Sofer M, Gomez-Marin O. et al. The use of cell salvage during radical retropubic prostatectomy: does it influence cancer recurrence? BJU Int. 2003 Apr;91(6):474–476. Not eligible exposure . [PubMed: 12656896]
138.
Davis NB, Jani AB, Vogelzang NJ. Selecting a secondary treatment. Urol Clin North Am. 2003 May;30(2):403–414. Review . [PubMed: 12735514]
139.
De La Rosette JJ, Abbou CC, Rassweiler J. et al. Laparoscopic radical prostatectomy: a European virus with global potentials. Arch Esp Urol. 2002 Jul–Aug;55(6):603–609. Review . [PubMed: 12224159]
140.
de la Taille A, Flam TA, Thiounn N. et al. Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy. BJU Int. 2002 Dec;90(9):887–892. Not eligible exposure . [PubMed: 12460351]
141.
de Matteis A, Guidi A, Di Paolo B. et al. Endothelin-1 in human prostatic carcinoma treated with androgen withdrawal: an immunohistochemical study. Cancer. 2001 May 15;91(10):1933–1939. Not eligible exposure . [PubMed: 11346876]
142.
de Vere White R. Present and future management of prostate cancer. Cancer Biother Radiopharm. 2000 Apr;15(2):121–125. Editorial . [PubMed: 10803316]
143.
Dearnaley DP. Radiotherapy of prostate cancer: established results and new developments. Semin Surg Oncol. 1995 Jan–Feb;11(1):50–59. Review . [PubMed: 7754276]
144.
Demanes DJ, Rodriguez RR, Schour L. et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1306–1316. Not eligible exposure . [PubMed: 15817332]
145.
Derweesh IH, Kupelian PA, Zippe C. et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol. 2004 Jul–Aug;22(4):300–306. Not eligible exposure . [PubMed: 15283887]
146.
Desai S, Kulkarni JN. Re: Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol. 1998 Oct;160(4):1442. Comment . [PubMed: 9751387]
147.
deVere White RW, Hackman RM, Soares SE. et al. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology. 2004 Feb;63(2):259–263. Not eligible exposure . [PubMed: 14972467]
148.
Di Blasio CJ, Rhee AC, Cho D. et al. Predicting clinical end points: treatment nomograms in prostate cancer. Semin Oncol. 2003 Oct;30(5):567–586. Review . [PubMed: 14571407]
149.
Di Silverio F, D'Eramo G, Buscarini M. et al. Is there always a role for radical prostatectomy in the treatment of localized prostate cancer? Minerva Urol Nefrol. 1995 Sep;47(3):117–124. Review . [PubMed: 8815548]
150.
Di Silverio F, D'Eramo G, Buscarini M. et al. DNA ploidy, Gleason score, pathological stage and serum PSA levels as predictors of disease-free survival in C-D1 prostatic cancer patients submitted to radical retropubic prostatectomy. Eur Urol. 1996;30(3):316–321. Not eligible exposure . [PubMed: 8931963]
151.
Dillioglugil O, Leibman BD, Kattan MW. et al. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997 Jul;50(1):93–99. Not eligible exposure . [PubMed: 9218025]
152.
DiMarco DS, Zincke H, Sebo TJ. et al. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol. 2005 Apr;173(4):1121–1125. Not eligible exposure . [PubMed: 15758719]
153.
DiPaola RS, Chenven ES, Shih WJ. et al. Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma. Cancer. 2001 Oct 15;92(8):2065–2071. Not eligible exposure . [PubMed: 11596021]
154.
Ditonno P, Battaglia M, Selvaggi FP. Adjuvant hormone therapy after radical prostatectomy: indications and results. Tumori. 1997 Mar–Apr;83(2):567–575. Review . [PubMed: 9226023]
155.
Djavan B, Moul JW, Zlotta A. et al. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol. 2003 Jan;43(1):12–27. Review . [PubMed: 12507539]
156.
Djavan B, Susani M, Shariat S. et al. Transperineal radiofrequency interstitial tumor ablation (RITA) of the prostate. Tech Urol. 1998 Jun;4(2):103–109. Not eligible exposure . [PubMed: 9623628]
157.
Do T, Dave G, Parker R. et al. Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1220–1225. Not eligible exposure . [PubMed: 11483332]
158.
Donovan J, Hamdy F, Neal D. et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7(14):1–88. Review . [PubMed: 12709289]
159.
Downs TM, Kane CJ, Grossfeld GD. et al. Surgery for prostate cancer: rationale, technique and outcomes. Cancer Metastasis Rev. 2002;21(1):29–44. Review . [PubMed: 12400995]
160.
Downs TM, Sadetsky N, Pasta DJ. et al. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer—data from CaPSURE. J Urol. 2003 Nov;170(5):1822–1827. Not eligible exposure . [PubMed: 14532784]
161.
Dreicer R. Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomy. Cancer Treat Rev. 2002 Aug;28(4):189–194. Review . [PubMed: 12363459]
162.
Dreicer R, Magi-Galluzzi C, Zhou M. et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004 Jun;63(6):1138–1142. Not eligible exposure . [PubMed: 15183967]
163.
Duchesne GM, Dowling C, Frydenberg M. et al. Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study. Urology. 2003 Jan;61(1):179–183. Not eligible exposure . [PubMed: 12559292]
164.
Dunsmuir WD, McFarlane JP, Tan A. et al. Gyrus bipolar electrovaporization vs transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y follow-up. Prostate Cancer Prostatic Dis. 2003;6(2):182–186. Not eligible exposure . [PubMed: 12806380]
165.
Eastham JA, Kelly WK, Grossfeld GD. et al. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003 Dec 29;62(Suppl 1):55–62. Not eligible exposure . [PubMed: 14747042]
166.
Eden CG, Cahill D, Vass JA. et al. Laparoscopic radical prostatectomy: the initial UK series. BJU Int. 2002 Dec;90(9):876–882. Not eligible exposure . [PubMed: 12460349]
167.
Egawa S, Arai Y, Kawakita M. et al. Surgical outcome of laparoscopic radical prostatectomy: summary of early multiinstitutional experience in Japan. Int J Clin Oncol. 2003 Apr;8(2):97–103. No provider characteristics . [PubMed: 12720102]
168.
Egawa S, Matsui Y, Matsumoto K. et al. Impact of biochemical failure on long-term clinical outcome after radical prostatectomy for prostate cancer in Japan. Prostate Cancer Prostatic Dis. 2004;7(2):152–157. Not eligible exposure . [PubMed: 15175664]
169.
Egawa S, Matsumoto K, Iwamura M. et al. Impact of life expectancy and tumor doubling time on the clinical significance of prostate cancer in Japan. Jpn J Clin Oncol. 1997 Dec;27(6):394–400. Not eligible exposure . [PubMed: 9438001]
170.
Egawa S, Ohori M, Iwamura M. et al. Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy. BJU Int. 1999 Nov;84(7):815–820. Not eligible exposure . [PubMed: 10532978]
171.
Egawa S, Suyama K, Arai Y. et al. A study of pretreatment nomograms to predict pathological stage and biochemical recurrence after radical prostatectomy for clinically resectable prostate cancer in Japanese men. Jpn J Clin Oncol. 2001 Feb;31(2):74–81. Not eligible exposure . [PubMed: 11302346]
172.
Egawa S, Suyama K, Arai Y. et al. Treatment outcome by risk group after radical prostatectomy in Japanese men. Int J Urol. 2001 Jun;8(6):295–300. Not eligible exposure . [PubMed: 11389745]
173.
Egevad L, Granfors T, Karlberg L. et al. Prognostic value of the Gleason score in prostate cancer. BJU Int. 2002 Apr;89(6):538–542. Not eligible exposure . [PubMed: 11942960]
174.
Elkin EB, Cowen ME, Cahill D. et al. Preference assessment method affects decision-analytic recommendations: a prostate cancer treatment example. Med Decis Making. 2004 Sep–Oct;24(5):504–510. Not eligible exposure . [PubMed: 15358999]
175.
Elliott K, Wallner K, Merrick G. et al. Medical malpractice of prostate brachytherapy. Brachytherapy. 2004;3(4):231–236. Not eligible exposure . [PubMed: 15607155]
176.
Eng TY, Thomas CR, Herman TS. Primary radiation therapy for localized prostate cancer. Urol Oncol. 2002 Nov–Dec;7(6):239–257. Review . [PubMed: 12504845]
177.
Epperson WJ. Radical prostatectomy in the treatment of prostate cancer. Am Fam Physician. Dec 1998;58(9):1972, 1977–1978. Comment. [PubMed: 9861875]
178.
Epstein JI, Partin AW, Potter SR. et al. Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology. 2000 Aug 1;56(2):283–288. Not eligible exposure . [PubMed: 10925095]
179.
Erdogru T, Teber D, Frede T. et al. Comparison of transperitoneal and extraperitoneal laparoscopic radical prostatectomy using match-pair analysis. Eur Urol. 2004 Sep;46(3):312–319. discussion 320. Not eligible exposure. [PubMed: 15306100]
180.
Escandon AS, Garcia OG. Use of a laparoscopic instrument to improve urethrovesical anastomosis quality during retropubic radical prostatectomy. Tech Urol. 2000 Mar;6(1):39–41. Not eligible exposure . [PubMed: 10708148]
181.
Evans RA. Re: Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol. 1995 Aug;154(2 Pt 1):537–538. Comment . [PubMed: 7541867]
182.
Fair WR, Scher HI. Neoadjuvant hormonal therapy plus surgery for prostate cancer. The MSKCC experience. Surg Oncol Clin N Am. 1997 Oct;6(4):831–846. Review . [PubMed: 9309096]
183.
Farhat WA, Habbal AA, Khauli RB. A guideline to clinical utility of prostate specific antigen. Saudi Med J. 2000 Mar;21(3):223–227. Review . [PubMed: 11533789]
184.
Febbo PG, Sellers WR. Use of expression analysis to predict outcome after radical prostatectomy. J Urol. 2003 Dec;170(6 Pt 2):S11–19. discussion S19–20. Not eligible exposure. [PubMed: 14610405]
185.
Feleppa EJ, Fair WR, Liu T. et al. Three-dimensional ultrasound analyses of the prostate. Mol Urol. 2000 Fall;4(3):133–139. discussion 141. No provider characteristics. [PubMed: 11062367]
186.
Feneley MR, Gillatt DA, Hehir M. et al. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome. Br J Urol. 1996 Dec;78(6):911–918. discussion 919–920. Not eligible exposure. [PubMed: 9014719]
187.
Fergany A, Kupelian PA, Levin HS. et al. No difference in biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients. Urology. 2000 Jul;56(1):92–95. Not eligible exposure . [PubMed: 10869632]
188.
Fichtner J. The management of prostate cancer in patients with a rising prostate-specific antigen level. BJU Int. 2000 Jul;86(2):181–190. quiz ii–iii. Review. [PubMed: 10886105]
189.
Filipas D, Fisch M, Stein R. et al. Rhabdomyosarcoma of the bladder, prostate or vagina: the role of surgery. BJU Int. 2004 Jan;93(1):125–129. Not eligible target population . [PubMed: 14678383]
190.
Fleming C, Wasson JH, Albertsen PC. et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. Jama. 1993 May 26;269(20):2650–2658. Not eligible exposure . [PubMed: 8487449]
191.
Fletcher SG, Theodorescu D. Surgery or radiation: what is the optimal management for locally advanced prostate cancer? Can J Urol. 2005 Feb;12(Suppl 1):58–61. discussion 101–102. Review. [PubMed: 15780168]
192.
Flood AB, Scott WR, Ewy W. Does practice make perfect? Part I: The relation between hospital volume and outcomes for selected diagnostic categories. Med Care. 1984 Feb;22(2):98–114. Not eligible target population . [PubMed: 6700280]
193.
Foley CL, Bott SR, Thomas K. et al. A large prostate at radical retropubic prostatectomy does not adversely affect cancer control, continence or potency rates. BJU Int. 2003 Sep;92(4):370–374. Not eligible exposure . [PubMed: 12930421]
194.
Forman JD. The metamorphosis of a postprostatectomy patient: from curable to palliative. Urol Oncol. 2004 Jan–Feb;22(1):48–49. Not eligible exposure . [PubMed: 14969804]
195.
Forman JD, Velasco J. Therapeutic radiation in patients with a rising post-prostatectomy PSA level. Oncology (Williston Park) 1998 Jan;12(1):33–39. discussion 39, 43–34, 47. Review. [PubMed: 9474586]
196.
Forster TH, Stoffel F, Gasser TC. Hormone therapy in advanced prostate cancer. Front Radiat Ther Oncol. 2002;36:49–65. Review . [PubMed: 11842755]
197.
Fourcade RO. Adjuvant treatment for failure of local radical therapy. Eur Urol. 1997;31(Suppl 2):11–13. discussion 24–17. Not eligible exposure. [PubMed: 9074905]
198.
Fowler JE Jr, Braswell NT, Pandey P. et al. Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center. J Urol. 1995 Mar;153(3 Pt 2):1026–1031. Not eligible exposure . [PubMed: 7853550]
199.
Frauscher F, Gradl J, Pallwein L. Prostate ultrasound—for urologists only. Cancer Imaging. 2005;5(Spec No A):S76–82. Review . [PMC free article: PMC1665315] [PubMed: 16361140]
200.
Frazier HA, Robertson JE, Dodge RK. et al. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer. 1993 Jun 15;71(12):3993–4001. Not eligible exposure . [PubMed: 8508365]
201.
Frazier HA, Robertson JE, Humphrey PA. et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol. 1993 Mar;149(3):516–518. Not eligible exposure . [PubMed: 7679755]
202.
Freedland SJ, Amling CL, Terris MK. et al. Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? Results from the SEARCH database. Prostate Cancer Prostatic Dis. 2003;6(3):261–265. Not eligible exposure . [PubMed: 12970733]
203.
Freedland SJ, Aronson WJ, Kane CJ. et al. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer. 2004 Aug 15;101(4):748–753. Not eligible exposure . [PubMed: 15305405]
204.
Freedland SJ, Aronson WJ, Terris MK. et al. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol. 2003 Jun;169(6):2136–2141. Not eligible exposure . [PubMed: 12771735]
205.
Freedland SJ, deGregorio F, Sacoolidge JC. et al. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol. 2003 Apr;169(4):1325–1330. Not eligible exposure . [PubMed: 12629353]
206.
Freedland SJ, Presti JC Jr, Kane CJ. et al. Do younger men have better biochemical outcomes after radical prostatectomy? Urology. 2004 Mar;63(3):518–522. Not eligible exposure . [PubMed: 15028449]
207.
Froehner M, Koch R, Litz R. et al. Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology. 2003 Oct;62(4):698–701. Not eligible exposure . [PubMed: 14550446]
208.
Froehner M, Koch R, Litz R. et al. Preoperative cardiopulmonary risk assessment as predictor of early noncancer and overall mortality after radical prostatectomy. Urology. 2003 Mar;61(3):596–600. Not eligible exposure . [PubMed: 12639654]
209.
Fromme EK, Eilers KM, Mori M. et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004 Sep 1;22(17):3485–3490. Not eligible target population . [PubMed: 15337796]
210.
Fromont G, Guillonneau B, Validire P. et al. Laparoscopic radical prostatectomy. preliminary pathologic evaluation. Urology. 2002 Oct;60(4):661–665. Not eligible exposure . [PubMed: 12385929]
211.
Fujikawa K, Itoh T, Nishio Y. et al. The role of volume-weighted mean nuclear volume in predicting disease outcome in patients with prostate cancer treated with radical prostatectomy. Apmis. 1999 Aug;107(8):773–778. Not eligible exposure . [PubMed: 10515128]
212.
Fukawa T, Numata K, Yamanaka M. et al. Prostatic carcinosarcoma: a case report and review of literature. Int J Urol. 2003 Feb;10(2):108–113. Review . [PubMed: 12588610]
213.
Galalae RM, Kovacs G, Schultze J. et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):81–90. Not eligible exposure . [PubMed: 11777625]
214.
Gallucci M, Puppo P, Perachino M. et al. Transurethral electrovaporization of the prostate vs transurethral resection. Results of a multicentric, randomized clinical study on 150 patients. Eur Urol. 1998;33(4):359–364. Not eligible target population . [PubMed: 9612677]
215.
Gancarczyk KJ, Wu H, McLeod DG. et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology. 2003 Mar;61(3):589–595. Not eligible exposure . [PubMed: 12639653]
216.
Gao X, Qiu JG, Cai YB. et al. Laparoscopic radical prostatectomy. Chin Med J (Engl) 2004 Jan;117(1):148–149. Case reports . [PubMed: 14733793]
217.
Gardner TA, Bissonette EA, Petroni GR. et al. Surgical and postoperative factors affecting length of hospital stay after radical prostatectomy. Cancer. 2000 Jul 15;89(2):424–430. Not eligible exposure . [PubMed: 10918175]
218.
Garg MK, Tekyi-Mensah S, Bolton S. et al. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology. 1998 Jun;51(6):998–1002. Not eligible exposure . [PubMed: 9609639]
219.
Garnick MB, Fair WR. Prostate cancer: emerging concepts. Part I. Ann Intern Med. 1996 Jul 15;125(2):118–125. Review . [PubMed: 8678366]
220.
Garrett KL, McNeal JE, Cohen RJ. Intraoperative lymph node staging of prostate cancer: the case against. ANZ J Surg. 2003 May;73(5):263–266. Not eligible exposure . [PubMed: 12752279]
221.
Garzotto M, Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol. 1998 Mar;159(3):950–954. discussion 954–955. Not eligible exposure. [PubMed: 9474190]
222.
George DJ. Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology. 2002 Sep;60(3 Suppl 1):115–121. discussion 122. Review. [PubMed: 12231066]
223.
Gerber GS. Conservative approach to the management of prostate cancer. A critical review. Eur Urol. 1994;26(4):271–275. Review . [PubMed: 7713123]
224.
Gheiler EL, Tefilli MV, Tiguert R. et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology. 1998 May;51(5):789–795. Not eligible exposure . [PubMed: 9610593]
225.
Gill IS. Laparoscopic pelvic lymphadenectomy: transperitoneal approach. Semin Surg Oncol. 1996 Mar–Apr;12(2):126–133. Review . [PubMed: 8685578]
226.
Gilling PJ, Kennett K, Das AK. et al. Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation: an update on the early clinical experience. J Endourol. 1998 Oct;12(5):457–459. Not eligible exposure . [PubMed: 9847070]
227.
Gilling PJ, Kennett KM, Fraundorfer MR. Holmium laser enucleation of the prostate for glands larger than 100 g: an endourologic alternative to open prostatectomy. J Endourol. 2000 Aug;14(6):529–531. Not eligible exposure . [PubMed: 10954311]
228.
Gleave ME, Bruchovsky N, Moore MJ. et al. Prostate cancer: 9. Treatment of advanced disease. Cmaj. 1999 Jan 26;160(2):225–232. Review . [PMC free article: PMC1229995] [PubMed: 9951446]
229.
Gleave ME, Goldenberg SL, Jones EC. et al. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Semin Urol Oncol. 1996 May;14(2 Suppl 2):39–45. discussion 46–37. Review. [PubMed: 8725890]
230.
Gleave ME, La Bianca SE, Goldenberg SL. et al. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology. 2000 Aug 1;56(2):289–294. Not eligible exposure . [PubMed: 10925096]
231.
Glode LM. Early prostate cancer diagnosis and therapy. Adv Intern Med. 2000;45:41–64. Review . [PubMed: 10635045]
232.
Goharderakhshan RZ, Grossfeld GD, Kassis A. et al. Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy. Urology. 2000 Oct 1;56(4):622–626. Not eligible exposure . [PubMed: 11018618]
233.
Goluboff ET, Benson MC. External beam radiation therapy does not offer long-term control of prostate cancer. Urol Clin North Am. 1996 Nov;23(4):617–621. Review . [PubMed: 8948415]
234.
Gomella LG, Zeltser I, Valicenti RK. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer. Urology. 2003 Dec 29;62(Suppl 1):46–54. Review . [PubMed: 14747041]
235.
Gomez P, Manoharan M, Sved P. et al. Radical retropubic prostatectomy in Hispanic patients. Cancer. 2004 Apr 15;100(8):1628–1632. Not eligible exposure . [PubMed: 15073849]
236.
Gomha MA, Boone TB. Artificial urinary sphincter for post-prostatectomy incontinence in men who had prior radiotherapy: a risk and outcome analysis. J Urol. 2002 Feb;167(2 Pt 1):591–596. Not eligible exposure . [PubMed: 11792924]
237.
Gontero P, Fontana F, Zitella A. et al. A prospective evaluation of efficacy and compliance with a multistep treatment approach for erectile dysfunction in patients after non-nerve sparing radical prostatectomy. BJU Int. 2005 Feb;95(3):359–365. Not eligible exposure . [PubMed: 15679794]
238.
Gontero P, Kirby RS. Nerve-sparing radical retropubic prostatectomy: techniques and clinical considerations. Prostate Cancer Prostatic Dis. 2005;8(2):133–139. Review . [PubMed: 15711608]
239.
Gorey K, Holowaty E, Fehringer G, et al. Gorey K, Holowaty E, Fehringer G, et al. An international comparison of cancer survival: metropolitan Toronto, Ontario, and Honolulu, Hawaii. Am J Public Health. December 1, 2000 2000;90(12):1866–1872. Not eligible target population. [PMC free article: PMC1446420] [PubMed: 11111258]
240.
Gould RS. Total cryosurgery of the prostate versus standard cryosurgery versus radical prostatectomy: comparison of early results and the role of transurethral resection in cryosurgery. J Urol. 1999 Nov;162(5):1653–1657. Not eligible exposure . [PubMed: 10524891]
241.
Graefen M, Karakiewicz PI, Cagiannos I. et al. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2002 Mar;167(3):1306–1309. Not eligible exposure . [PubMed: 11832719]
242.
Graefen M, Noldus J, Pichlmeier U. et al. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol. 1999;36(1):21–30. Not eligible exposure . [PubMed: 10364651]
243.
Grampsas SA, Miller GJ, Crawford ED. Salvage radical prostatectomy after failed transperineal cryotherapy: histologic findings from prostate whole-mount specimens correlated with intraoperative transrectal ultrasound images. Urology. 1995 Jun;45(6):936–941. Not eligible exposure . [PubMed: 7771026]
244.
Gregorio DI, Kulldorff M, Sheehan TJ, et al. Geographic distribution of prostate cancer incidence in the era of PSA testing, Connecticut, 1984 to 1998. Urology. 2004/1 2004;63(1):78–82. Not eligible outcomes. [PubMed: 14751353]
245.
Grein U, Meyer WW. Local recurrent cancer after radical prostatectomy and incontinence. Is the artificial urinary sphincter a useful therapeutic option? Urol Int. 2001;66(1):9–12. Not eligible exposure . [PubMed: 11150943]
246.
Gretzer MB, Trock BJ, Han M. et al. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol. 2002 Oct;168(4 Pt 1):1419–1422. Not eligible exposure . [PubMed: 12352408]
247.
Grignon DJ, Sakr WA. Pathologic staging of prostate carcinoma. What are the issues? Cancer. 1996 Jul 15;78(2):337–340. Review . [PubMed: 8674013]
248.
Grimm MO, Kamphausen S, Hugenschmidt H. et al. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol. 2002 Jun;41(6):628–634. discussion 634. Not eligible exposure. [PubMed: 12074780]
249.
Grimm PD, Blasko JC, Sylvester JE. et al. Technical improvement in permanent seed implantation: a two-stage brachytherapy system. Description and comparison with current technique. Brachytherapy. 2004;3(1):34–40. No provider characteristics . [PubMed: 15110312]
250.
Grise P, Thurman S. Urinary incontinence following treatment of localized prostate cancer. Cancer Control. 2001 Nov–Dec;8(6):532–539. Review . [PubMed: 11807423]
251.
Gross C, Stamey T, Hancock S. et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) J Urol. 1998 Jun;159(6):2035–2039. discussion 2039–2040. Not eligible exposure. [PubMed: 9598513]
252.
Grossfeld GD, Li YP, Lubeck DP. et al. Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy. Urology. 2002 Sep;60(3 Suppl 1):57–62. discussion 62–53. Review. [PubMed: 12231051]
253.
Grossfeld GD, Small EJ, Lubeck DP. et al. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology. 2001 Aug;58(2 Suppl 1):56–64. Review . [PubMed: 11502450]
254.
Guazzoni G, Montorsi F, Bergamaschi F. et al. Open surgical revision of laparoscopic pelvic lymphadenectomy for staging of prostate cancer: the impact of laparoscopic learning curve. J Urol. 1994 Apr;151(4):930–933. No provider characteristics . [PubMed: 8126828]
255.
Guillonneau B, Cathelineau X, Barret E. et al. Laparoscopic radical prostatectomy: technical and early oncological assessment of 40 operations. Eur Urol. 1999;36(1):14–20. Not eligible exposure . [PubMed: 10364650]
256.
Guillonneau B, Cathelineau X, Doublet JD. et al. Laparoscopic radical prostatectomy: the lessons learned. J Endourol. 2001 May;15(4):441–445. discussion 447–448. Not eligible exposure. [PubMed: 11394459]
257.
Guillonneau B, Vallancien G. Laparoscopic radical prostatectomy: the Montsouris technique. J Urol. 2000 Jun;163(6):1643–1649. Not eligible exposure . [PubMed: 10799152]
258.
Gurdal M, Tekin A, Yucebas E. et al. Nd:YAG laser ablation plus transurethral resection for large prostates in high-risk patients. Urology. 2003 Nov;62(5):914–917. Not eligible target population . [PubMed: 14624919]
259.
Hachiya T, Akakura K, Saito S. et al. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan. BJU Int. 2005 Mar;95(4):534–540. Not eligible exposure . [PubMed: 15705075]
260.
Hachiya T, Endo M, Nogaki J. et al. Significance of prostate-specific antigen after radical prostatectomy. Int J Urol. 1997 Sep;4(5):461–466. Not eligible exposure . [PubMed: 9354947]
261.
Haese A, Huland E, Graefen M. et al. Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure. Anticancer Res. 1999 Jul–Aug;19(4A):2641–2644. Not eligible exposure . [PubMed: 10470210]
262.
Haggman M, Brandstedt S, Norlen BJ. Rectal perforation after retropubic radical prostatectomy: occurrence and management. Eur Urol. 1996;29(3):337–340. Not eligible exposure . [PubMed: 8740020]
263.
Hammadeh MY, Madaan S, Hines J. et al. 5-year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. Urology. 2003 Jun;61(6):1166–1171. Not eligible target population . [PubMed: 12809891]
264.
Hammadeh MY, Philp T. Transurethral electrovaporization of the prostate (TUVP) is effective, safe and durable. Prostate Cancer Prostatic Dis. 2003;6(2):121–126. Review . [PubMed: 12806369]
265.
Han KR, Cohen JK, Miller RJ. et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol. 2003 Oct;170(4 Pt 1):1126–1130. No provider characteristics . [PubMed: 14501706]
266.
Han M, Snow PB, Epstein JI. et al. A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology. 2000 Dec 20;56(6):994–999. Not eligible exposure . [PubMed: 11113746]
267.
Handler S. How valuable is prostate-specific antigen screening? Minn Med. 1996 Jun;79(6):2. Comment . [PubMed: 8692130]
268.
Hanks GE. External beam radiation treatment for prostate cancer: still the gold standard. Oncology (Williston Park). Mar 1992;6(3):79–86, 89; discussion 90–74. Not eligible exposure. [PubMed: 1533146]
269.
Hara I, Kawabata G, Miyake H. et al. Feasibility and usefulness of laparoscopic radical prostatectomy: Kobe University experience. Int J Urol. 2002 Nov;9(11):635–640. Not eligible exposure . [PubMed: 12534908]
270.
Harris MJ. Radical perineal prostatectomy: cost efficient, outcome effective, minimally invasive prostate cancer management. Eur Urol. 2003 Sep;44(3):303–308. discussion 308. Not eligible exposure. [PubMed: 12932927]
271.
Harris RD, Schned AR, Heaney JA. Staging of prostate cancer with endorectal MR imaging: lessons from a learning curve. Radiographics. 1995 Jul;15(4):813–829. discussion 829–832. No provider characteristics. [PubMed: 7569131]
272.
Hasan WA, Gill IS. Laparoscopic radical prostatectomy: current status. BJU Int. 2004 Jul;94(1):7–11. Review . [PubMed: 15217422]
273.
Hassan Y, Tazaki E, Egawa S. et al. Decision making using hybrid rough sets and neural networks. Int J Neural Syst. 2002 Dec;12(6):435–446. Not eligible exposure . [PubMed: 12528195]
274.
Hautmann RE, Stein JP. Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin North Am. 2005 May;32(2):177–185. Review . [PubMed: 15862615]
275.
Hawatmeh AS, Walters FP, Wooster CA. Early clinical experience with percutaneous cryosurgical ablation of the prostate. Mo Med. 1995 Nov;92(11):705–709. No provider characteristics . [PubMed: 8569673]
276.
Held-Warmkessel J. What your patient needs to know about prostate cancer. Nursing. 2002 Dec;32(12):36–42. quiz N232. Review. [PubMed: 12468938]
277.
Hellerstedt B. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer. Urology. 2003 Dec 29;62(Suppl 1):79–86. Review . [PubMed: 14747045]
278.
Henry AM, Wilkinson C, Wylie JP. et al. Trans-perineal implantation of radio-opaque treatment verification markers into the prostate: an assessment of procedure related morbidity, patient acceptability and accuracy. Radiother Oncol. 2004 Oct;73(1):57–59. No provider characteristics . [PubMed: 15465146]
279.
Herrell SD, Trachtenberg J, Theodorescu D. Staging pelvic lymphadenectomy for localized carcinoma of the prostate: a comparison of 3 surgical techniques. J Urol. 1997 Apr;157(4):1337–1339. No provider characteristics . [PubMed: 9120934]
280.
Hindley RG, Mostafid AH, Brierly RD. et al. The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate. BJU Int. 2001 Aug;88(3):217–220. Not eligible target population . [PubMed: 11488732]
281.
Hoffman RM, Stone SN, Hunt WC, et al. Effects of Misattribution in Assigning Cause of Death on Prostate Cancer Mortality Rates. Annals of Epidemiology. 2003/7 2003;13(6):450–454. Not eligible exposure. [PubMed: 12875804]
282.
Hoinkis C, Hakenberg OW, Lehmann D. et al. Evaluation of dose-volume histograms after prostate seed implantation. 4-year experience. Strahlenther Onkol. 2004 Sep;180(9):550–556. No provider characteristics . [PubMed: 15378185]
283.
Hollenbeck BK, Rubin MA. Prostate sampling to predict radical prostatectomy outcome. Urology. 2001 Feb;57(2):394–395. Comment . [PubMed: 11246646]
284.
Holzman D. Surgery's role in prostate cancer spurs ongoing debate. J Natl Cancer Inst. 1997 Feb 19;89(4):282–283. News . [PubMed: 9048830]
285.
Homma Y, Akaza H, Okada K. et al. Preoperative endocrine therapy for clinical stage A2, B, and C prostate cancer: an interim report on short-term effects. Prostate Cancer Study Group. Int J Urol. 1997 Mar;4(2):144–151. Not eligible exposure . [PubMed: 9179687]
286.
Homma Y, Akaza H, Okada K. et al. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group. Int J Urol. 1999 May;6(5):229–237. discussion 238–229. Not eligible exposure. [PubMed: 10375185]
287.
Homma Y, Akaza H, Okada K. et al. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results. Int J Urol. 2004 May;11(5):295–303. Not eligible exposure . [PubMed: 15147545]
288.
Homma Y, Kawabe K, Hayashi K. Urologic morbidity and its influence on global satisfaction with treatment outcome after radical prostatectomy for prostate cancer. Int J Urol. 1998 Nov;5(6):556–561. Not eligible exposure . [PubMed: 9855124]
289.
Horwich A, Parker CC, Huddart RA. et al. Management of early prostate cancer. Ann Oncol. 2002;13(Suppl 4):83–87. Review . [PubMed: 12401671]
290.
Horwitz EM, Hanlon AL, Pinover WH. et al. The cost effectiveness of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1219–1225. Not eligible exposure . [PubMed: 10613316]
291.
Hoznek A, Antiphon P, Borkowski T. et al. Assessment of surgical technique and perioperative morbidity associated with extraperitoneal versus transperitoneal laparoscopic radical prostatectomy. Urology. 2003 Mar;61(3):617–622. Not eligible exposure . [PubMed: 12639658]
292.
Hoznek A, Menard Y, Salomon L. et al. Update on laparoscopic and robotic radical prostatectomy. Curr Opin Urol. 2005 May;15(3):173–180. Review . [PubMed: 15815194]
293.
Hsu EI, Hong EK, Lepor H. Influence of body weight and prostate volume on intraoperative, perioperative, and postoperative outcomes after radical retropubic prostatectomy. Urology. 2003 Mar;61(3):601–606. Not eligible exposure . [PubMed: 12639655]
294.
Hughes PD. Prostate cancer in Victoria in 1993: patterns of reported management. Med J Aust. 2000 Jun 5;172(11):565–566. Comment . [PubMed: 10920760]
295.
Hugosson J, Bergdahl S, Norlen L. et al. Outpatient transurethral incision of the prostate under local anesthesia: operative results, patient security and cost effectiveness. Scand J Urol Nephrol. 1993;27(3):381–385. Not eligible target population . [PubMed: 7507261]
296.
Huland H. The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument against. Eur Urol. 1996;29(Suppl 2):31–33. Review . [PubMed: 8717459]
297.
Hussain A, Dawson N, Amin P. et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol. 2005 Apr 20;23(12):2789–2796. Not eligible exposure . [PubMed: 15837994]
298.
Ilkjaer LB, Lund L, Nielsen KT. Outcome of transurethral prostatectomy in men over 80 years. Scand J Urol Nephrol. 1998 Jul;32(4):270–272. Not eligible exposure . [PubMed: 9764454]
299.
Imperato PJ, Nenner RP, Will TO. Trends in radical prostatectomy in New York State. Am J Med Qual. 1996 Winter;11(4):205–213. Not eligible exposure . [PubMed: 8972938]
300.
Iselin CE, Box JW, Vollmer RT. et al. Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer. 1998 Dec 1;83(11):2353–2360. Not eligible exposure . [PubMed: 9840535]
301.
Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy: oncological outcome during a 20-year period. J Urol. 1999 Jan;161(1):163–168. Not eligible exposure . [PubMed: 10037390]
302.
Isom-Batz G, Bianco FJ Jr, Kattan MW. et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005 Jun;173(6):1935–1937. Not eligible exposure . [PMC free article: PMC1855287] [PubMed: 15879785]
303.
Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl. 1995;172:65–72. Not eligible exposure . [PubMed: 8578259]
304.
Jackson CL. Urologic laparoscopy. Surg Oncol Clin N Am. 2001 Jul;10(3):571–578. Review . [PubMed: 11685928]
305.
Jani AB, Kao J. Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis. Cancer. 2005 May 1;103(9):1833–1842. Review . [PubMed: 15756656]
306.
Janoff DM, Parra RO. Contemporary appraisal of radical perineal prostatectomy. J Urol. 2005 Jun;173(6):1863–1870. Review . [PubMed: 15879765]
307.
Jarred RA, Keikha M, Dowling C. et al. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1689–1696. Not eligible exposure . [PubMed: 12496063]
308.
Jayadevappa R, Chhatre S, Weiner M. et al. Medical care cost of patients with prostate cancer. Urol Oncol. 2005 May–Jun;23(3):155–162. Not eligible exposure . [PubMed: 15907714]
309.
Jhaveri FM, Zippe CD, Klein EA. et al. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999 Nov;54(5):884–890. Not eligible exposure . [PubMed: 10565752]
310.
Jo Y, Junichi H, Tomohiro F. et al. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life. BJU Int. 2005 Jul;96(1):43–47. Not eligible exposure . [PubMed: 15963118]
311.
Johnson CW, Anastasiadis AG, McKiernan JM. et al. Prognostic indicators for long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles. Urol Oncol. 2004 Mar–Apr;22(2):107–111. Not eligible exposure . [PubMed: 15082006]
312.
Kabalin JN, Bite G, Doll S. Neodymium:YAG laser coagulation prostatectomy: 3 years of experience with 227 patients. J Urol. 1996 Jan;155(1):181–185. Not eligible exposure . [PubMed: 7490827]
313.
Kahn D, Austin JC, Maguire RT. et al. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother Radiopharm. 1999 Apr;14(2):99–111. Not eligible exposure . [PubMed: 10850293]
314.
Kahn D, Williams RD, Haseman MK. et al. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol. 1998 Jan;16(1):284–289. Not eligible exposure . [PubMed: 9440754]
315.
Kaisary AV. Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. Prostate Cancer Prostatic Dis. 2005;8(2):140–151. Review . [PubMed: 15852051]
316.
Kanto S, Ohyama C, Okada Y. et al. Clinical features of prostate cancer patients younger than 50 years: report of seven cases. Int J Urol. 2002 Feb;9(2):91–94. Not eligible exposure . [PubMed: 12028298]
317.
Kantoff PW, Talcott JA. The prostate specific antigen. Its use as a tumor marker for prostate cancer. Hematol Oncol Clin North Am. 1994 Jun;8(3):555–572. Review . [PubMed: 8707772]
318.
Kattan MW. Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol. 2003 Dec;170(6 Pt 2):S6–9. discussion S10. No provider characteristics. [PubMed: 14610404]
319.
Kattan MW, Eastham JA, Stapleton AM. et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998 May 20;90(10):766–771. Not eligible exposure . [PubMed: 9605647]
320.
Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999 May;17(5):1499–1507. Not eligible exposure . [PubMed: 10334537]
321.
Kaufman JM. Re: Factors predicting recovery of erections after radical prostatectomy. J Urol. 2001 Aug;166(2):634. Comment . [PubMed: 11458107]
322.
Kavoussi LR, Sosa E, Chandhoke P. et al. Complications of laparoscopic pelvic lymph node dissection. J Urol. 1993 Feb;149(2):322–325. No provider characteristics . [PubMed: 8426411]
323.
Kaye KW, Creed KE, Wilson GJ. et al. Urinary continence after radical retropubic prostatectomy. Analysis and synthesis of contributing factors: a unified concept. Br J Urol. 1997 Sep;80(3):444–501. Not eligible exposure . [PubMed: 9313665]
324.
Kendirci M, Hellstrom WJ. Current concepts in the management of erectile dysfunction in men with prostate cancer. Clin Prostate Cancer. 2004 Sep;3(2):87–92. Review . [PubMed: 15479491]
325.
Kerbl K, Clayman RV, Petros JA. et al. Staging pelvic lymphadenectomy for prostate cancer: a comparison of laparoscopic and open techniques. J Urol. 1993 Aug;150(2 Pt 1):396–398. discussion 399. No provider characteristics. [PubMed: 8326562]
326.
Keyser D, Kupelian PA, Zippe CD. et al. Stage T1–2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery? Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):723–729. Not eligible exposure . [PubMed: 9240638]
327.
Khan FA, Kaisary AV, Boustead GB. et al. PSA recurrence following radical prostatectomy is comparable for all age groups in the UK. Prostate Cancer Prostatic Dis. 2005;8(2):158–162. Not eligible exposure . [PubMed: 15768048]
328.
Khan MA, Han M, Partin AW. et al. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology. 2003 Jul;62(1):86–91. discussion 91–82. Not eligible exposure. [PubMed: 12837428]
329.
Khatami A, Damber JE, Lodding P. et al. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?—A case control study. Scand J Urol Nephrol. 2003;37(3):213–217. Not eligible exposure . [PubMed: 12775279]
330.
Khil MS, Kim JH. Therapeutic options for localized carcinoma of the prostate: the role of external beam radiation therapy. Henry Ford Hosp Med J. 1992;40(12):103–107. Review . [PubMed: 1428958]
331.
Kiel HJ, Wieland WF, Rossler W. Local control of prostate cancer by transrectal HIFU-therapy. Arch Ital Urol Androl. 2000 Dec;72(4):313–319. No provider characteristics . [PubMed: 11221062]
332.
Kim BS, Lashkari A, Vongtama R. et al. Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Prostate Cancer. 2004 Sep;3(2):93–97. Not eligible exposure . [PubMed: 15479492]
333.
Kim JC, Gerber GS. Should laparoscopy be the standard approach used for pelvic lymph node dissection? Curr Urol Rep. 2001 Apr;2(2):171–179. Review . [PubMed: 12084287]
334.
King CR, Presti JC Jr, Gill H. et al. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):341–347. Not eligible exposure . [PubMed: 15145146]
335.
Kiriyama I, Ohgaki K, Ohba S. et al. Prostate cancer in patients with Hansen's disease. Int J Urol. 2003 Mar;10(3):177–179. Not eligible target population . [PubMed: 12622716]
336.
Kish JA. Neoadjuvant androgen ablation in localized carcinoma of the prostate. Cancer Control. 2001 Mar–Apr;8(2):155–162. Review . [PubMed: 11326170]
337.
Kiyokawa H, Kato H. Radical retropubic prostatectomy through a minimal incision with portless endoscopy: our initial experience. Int J Urol. 2006 Jan;13(1):7–9. No provider characteristics . [PubMed: 16448424]
338.
Klabunde CN, Potosky AL, Harlan LC. et al. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998 Sep;36(9):1337–1348. Not eligible outcomes . [PubMed: 9749657]
339.
Klassen AC, Curriero FC, Hong JH, et al. The role of area-level influences on prostate cancer grade and stage at diagnosis. Preventive Medicine. 2004/9 2004;39(3):441–448. Not eligible outcomes. [PubMed: 15313082]
340.
Klee LW, Grmoljez P. Combined radical retropubic prostatectomy and rectal resection. Urology. 1999 Oct;54(4):679–681. Not eligible exposure . [PubMed: 10510927]
341.
Klein EA. Prostate cancer. J Urol. 1995 Jul;154(1):143–144. Comment . [PubMed: 7539858]
342.
Klein EA. Radiation therapy versus radical prostatectomy in the PSA era: a urologist's view. Semin Radiat Oncol. 1998 Apr;8(2):87–94. Review . [PubMed: 9516589]
343.
Klein EA, Kupelian PA, Dreicer R. et al. Locally advanced prostate cancer. Curr Treat Options Oncol. 2001 Oct;2(5):403–411. Review . [PubMed: 12057103]
344.
Klein EA, Kupelian PA, Tuason L. et al. Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy. Urology. 1998 May;51(5):766–773. Not eligible exposure . [PubMed: 9610590]
345.
Klutke CG, Tiemann DD, Nadler RB. et al. Antegrade collagen injection for stress incontinence after radical prostatectomy: technique and early results. J Endourol. 1996 Jun;10(3):279–282. Not eligible exposure . [PubMed: 8740392]
346.
Knight SJ, Nathan DP, Siston AK. et al. Pilot study of a utilities-based treatment decision intervention for prostate cancer patients. Clin Prostate Cancer. 2002 Sep;1(2):105–114. Not eligible exposure . [PubMed: 15046701]
347.
Koch MO. Predicting outcomes after radical prostatectomy. J Urol. 2000 Nov;164(5):1601. Comment . [PubMed: 11025713]
348.
Koch MO, Foster RS, Bell B. et al. Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. J Urol. 2000 Sep;164(3 Pt 1):749–753. Not eligible exposure . [PubMed: 10953139]
349.
Koch MO, Smith JA Jr. Influence of patient age and co-morbidity on outcome of a collaborative care pathway after radical prostatectomy and cystoprostatectomy. J Urol. 1996 May;155(5):1681–1684. Not eligible exposure . [PubMed: 8627853]
350.
Kochakarn W, Ratana-Olarn K, Viseshsindh V. Vesicourethral strictures after radical prostatectomy: review of treatment and outcome. J Med Assoc Thai. 2002 Jan;85(1):63–66. Not eligible exposure . [PubMed: 12075722]
351.
Kollermann J, Caprano J, Budde A. et al. Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy. Urology. 2003 Sep;62(3):476–480. Not eligible exposure . [PubMed: 12946750]
352.
Kollermann MW, Pantel K, Enzmann T. et al. Supersensitive PSA-monitored neoadjuvant hormone treatment of clinically localized prostate cancer: effects on positive margins, tumor detection and epithelial cells in bone marrow. Eur Urol. 1998 Oct;34(4):318–324. Not eligible exposure . [PubMed: 9748679]
353.
Koppie TM, Grossfeld GD, Nudell DM. et al. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol. 2001 Jul;166(1):111–115. Not eligible exposure . [PubMed: 11435834]
354.
Korman HJ, Mulholland TL, Huang R. Preservation of fecal continence and bowel function after radical perineal and retropubic prostatectomy: a questionnaire-based outcomes study. Prostate Cancer Prostatic Dis. 2004;7(3):249–252. Not eligible exposure . [PubMed: 15249929]
355.
Koyanagi T. Assessing a new surgical procedure: an initial step to randomized trial. Int J Clin Oncol. 2003 Apr;8(2):124–125. Comment . [PubMed: 12720108]
356.
Krahn M, Ritvo P, Irvine J. et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003 Jan;41(1):153–164. Not eligible exposure . [PubMed: 12544552]
357.
Krogh J, Jensen JS, Iversen HG. et al. Age as a prognostic variable in patients undergoing transurethral prostatectomy. Scand J Urol Nephrol. 1993;27(2):225–229. Not eligible target population . [PubMed: 8351477]
358.
Kuefer R, Hofer MD, Zorn CS. et al. Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer. 2005 Jun 6;92(11):2018–2023. Not eligible exposure . [PMC free article: PMC2361796] [PubMed: 15870707]
359.
Kumar V, Toussi H, Marr C. et al. The benefits of radical prostatectomy beyond cancer control in symptomatic men with prostate cancer. BJU Int. 2004 Mar;93(4):507–509. Not eligible exposure . [PubMed: 15008719]
360.
Kundel Y, Pfeffer R, Lauffer M. et al. Salvage prostatic fossa radiation therapy for biochemical failure after radical prostatectomy: the Sheba experience. Isr Med Assoc J. 2004 Jun;6(6):329–331. Not eligible exposure . [PubMed: 15214457]
361.
Kuyu H, Lee WR, Bare R. et al. Recent advances in the treatment of prostate cancer. Ann Oncol. 1999 Aug;10(8):891–898. Review . [PubMed: 10509148]
362.
Kylmala T, Kaipia A, Matikainen M. Management of prolonged urinary leakage at the urethro-vesical anastomosis. Urol Int. 2005;74(4):298–300. Case reports . [PubMed: 15897692]
363.
Lacombe L, Maillette A, Meyer F. et al. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int J Cancer. 2001 May 20;95(3):135–139. Not eligible exposure . [PubMed: 11307144]
364.
LaFontaine P, Chan D, Partin AW. et al. Minilaparotomy radical retropubic prostatectomy: updated technique and results. Semin Urol Oncol. 2000 Feb;18(1):19–27. Not eligible exposure . [PubMed: 10719926]
365.
Lam JS, Sclar JD, Desai M. et al. Is Hispanic race an important predictor of treatment failure following radical prostatectomy for prostate cancer? J Urol. 2004 Nov;172(5 Pt 1):1856–1859. Not eligible exposure . [PubMed: 15540738]
366.
Lance RS, Freidrichs PA, Kane C. et al. A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. BJU Int. 2001 Jan;87(1):61–65. Not eligible exposure . [PubMed: 11121994]
367.
Landmann C. Radiation therapy of localized prostate cancer. Ann Urol (Paris) 1994;28(4):207–220. Not eligible exposure . [PubMed: 7979211]
368.
Lang GS, Ruckle HC, Hadley HR. et al. One hundred consecutive laparoscopic pelvic lymph node dissections: comparing complications of the first 50 cases to the second 50 cases. Urology. 1994 Aug;44(2):221–225. Review . [PubMed: 8048197]
369.
Larson TR, Rrobertson DW, Corica A. et al. In vivo interstitial temperature mapping of the human prostate during cryosurgery with correlation to histopathologic outcomes. Urology. 2000 Apr;55(4):547–552. Not eligible exposure . [PubMed: 10736499]
370.
Lassiter LK, Eisenberger MA. The dilemma of patients with a rising PSA level after definitive local therapy for prostate cancer. Semin Urol Oncol. 2002 May;20(2):146–154. Not eligible exposure . [PubMed: 12012301]
371.
Laven BA, Alsikafi NF, Yang XJ. et al. Minor modifications in apical dissection of radical retropubic prostatectomy in patients with clinical stage T2 prostate cancer reduce positive surgical margin incidence. Urology. 2004 Jan;63(1):95–98. Not eligible exposure . [PubMed: 14751357]
372.
Lawrence G, Crawford J. Systemic benefit of local radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1510–1511. author reply 1511. Comment. [PubMed: 14630294]
373.
Lawton CA, Winter K, Murray K. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):937–946. Not eligible exposure . [PubMed: 11240234]
374.
Lee CT. Re: Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2004 May 5;96(9):718–719. Comment . [PubMed: 15126615]
375.
Lee CT, Capodieci P, Osman I. et al. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res. 1999 May;5(5):977–983. Not eligible exposure . [PubMed: 10353729]
376.
Lee D. Radical prostatectomy improves cancer-specific survival but not overall survival in early-stage prostate cancer. Clin Prostate Cancer. 2003 Jun;2(1):15–17. Not eligible exposure . [PubMed: 15046677]
377.
Lee LW, McBain CA, Swindell R. et al. Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy. Clin Oncol (R Coll Radiol) 2004 Dec;16(8):517–522. Not eligible exposure . [PubMed: 15630843]
378.
Lee R, Penson DF. Treatment outcomes in localized prostate cancer: a patient-oriented approach. Semin Urol Oncol. 2002 Feb;20(1):63–73. Review . [PubMed: 11828359]
379.
Lee WR, deGuzman AF, Bare RL. et al. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):83–88. No provider characteristics . [PubMed: 10656377]
380.
Leibovich BC, Blute ML, Bostwick DG. et al. Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology. 2000 Nov 1;56(5):726–729. Not eligible exposure . [PubMed: 11068288]
381.
Leibowitz R, Tucker SJ. PSA response to thalidomide in patients with advanced prostate cancer. Oncology (Williston Park) 2002 Sep;16(9):1146–1148. Not eligible target population . [PubMed: 12380944]
382.
Lepor H. Radical prostatectomy: status and opportunities for improving outcomes. Cancer Invest. 2004;22(3):435–444. Review . [PubMed: 15493364]
383.
Lepor H, Kaci L. Contemporary evaluation of operative parameters and complications related to open radical retropubic prostatectomy. Urology. 2003 Oct;62(4):702–706. Not eligible exposure . [PubMed: 14550447]
384.
Lepor H, Kaci L. Role of intraoperative biopsies during radical retropubic prostatectomy. Urology. 2004 Mar;63(3):499–502. Not eligible exposure . [PubMed: 15028445]
385.
Lepor H, Kaci L. The impact of open radical retropubic prostatectomy on continence and lower urinary tract symptoms: a prospective assessment using validated self-administered outcome instruments. J Urol. 2004 Mar;171(3):1216–1219. Not eligible exposure . [PubMed: 14767305]
386.
Lerner SE, Blute ML, Bergstralh EJ. et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol. 1996 Jul;156(1):137–143. Not eligible exposure . [PubMed: 8648775]
387.
Lerner SE, Blute ML, Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol. 1995 Oct;154(4):1447–1452. Not eligible exposure . [PubMed: 7658555]
388.
Lerner SE, Blute ML, Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol. 1995 Sep;154(3):1103–1109. Not eligible exposure . [PubMed: 7543608]
389.
Lerner SE, Blute ML, Zincke H. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol. 1996 May;14(2 Suppl 2):12–20. discussion 21. Review. [PubMed: 8725887]
390.
Lertakyamanee J, Ruksamanee EO, Tantiwong A. et al. The risk and effectiveness of transurethral resection of prostate. J Med Assoc Thai. 2002 Dec;85(12):1288–1295. Not eligible target population . [PubMed: 12678166]
391.
Leventis AK, Shariat SF, Kattan MW. et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001 Feb 15;19(4):1030–1039. Not eligible exposure . [PubMed: 11181666]
392.
Li H, Sugimura K, Boku M. et al. MR findings of prostatic urethral polyp in an adult. Eur Radiol. 2003 Dec;13(Suppl 4):L105–108. Not eligible target population . [PubMed: 15018173]
393.
Liauw SL, Webster WS, Pistenmaa DA. et al. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology. 2003 Jun;61(6):1204–1210. Not eligible exposure . [PubMed: 12809898]
394.
Lillis P, Thompson IM Jr. Should asymptomatic progression following definitive local treatment for prostate cancer be treated? Hematol Oncol Clin North Am. 1996 Jun;10(3):703–712. Review . [PubMed: 8773506]
395.
Lobe TE, Wiener E, Andrassy RJ. et al. The argument for conservative, delayed surgery in the management of prostatic rhabdomyosarcoma. J Pediatr Surg. 1996 Aug;31(8):1084–1087. Not eligible target population . [PubMed: 8863239]
396.
Long JP. Cryosurgical ablation of the prostate: current technique and clinical outcomes. Surg Technol Int. 2003;11:213–219. Review . [PubMed: 12931304]
397.
Loren AW, Bennett I, Cronholm P. et al. Re: Life after radical prostatectomy: a longitudinal study. J Urol. 2002 Jul;168(1):203–204. author reply 204. Comment. [PubMed: 12050540]
398.
Lorente JA, Arango O, Bielsa O. et al. A longer duration of neo-adjuvant combined androgen blockade prior to radical prostatectomy may lead to lower tumour volume of localised prostate cancer. Eur Urol. 2003 Feb;43(2):119–123. Not eligible exposure . [PubMed: 12565768]
399.
Losa A, Nava LD, Di Muzio N. et al. Salvage brachytherapy for local recurrence after radical prostatectomy and subsequent external beam radiotherapy. Urology. 2003 Dec;62(6):1068–1072. Not eligible exposure . [PubMed: 14665357]
400.
Lubeck DP, Grossfeld GD, Carroll PR. A review of measurement of patient preferences for treatment outcomes after prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):72–77. discussion 77–78. Review. [PubMed: 12231054]
401.
Lu-Yao GL, Barry MJ, Chang CH. et al. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT) Urology. 1994 Nov;44(5):692–698. discussion 698–699. Not eligible target population. [PubMed: 7526526]
402.
Madalinska JB, Essink-Bot ML, de Koning HJ. et al. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 2001 Mar 15;19(6):1619–1628. Not eligible exposure . [PubMed: 11250990]
403.
Maier J, Forman J, Tekyi-Mensah S. et al. Salvage radiation for a rising PSA following radical prostatectomy. Urol Oncol. 2004 Jan–Feb;22(1):50–56. Not eligible exposure . [PubMed: 14969805]
404.
Makhlouf AA, Boyd JC, Chapman TN. et al. Perioperative costs and charges of prostate brachytherapy and prostatectomy. Urology. 2002 Oct;60(4):656–660. Not eligible exposure . [PubMed: 12385928]
405.
Malkowicz SB. Serum prostate-specific antigen elevation in the post-radical prostatectomy patient. Urol Clin North Am. 1996 Nov;23(4):665–675. Review . [PubMed: 8948419]
406.
Mameghan H, Fisher R, Mameghan J. et al. Results of external beam radiotherapy in 448 patients with clinically localized adenocarcinoma of the prostate. Aust N Z J Surg. 1994 Jun;64(6):389–394. Not eligible exposure . [PubMed: 8010899]
407.
Manoharan M, Bird VG, Kim SS. et al. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8. BJU Int. 2003 Oct;92(6):539–544. Not eligible exposure . [PubMed: 14511029]
408.
Manseck A, Wirth M, Theiss M. et al. Radical prostatectomy in patients with incidental prostate carcinoma. Urol Int. 1994;53(4):196–208. Not eligible exposure . [PubMed: 7531896]
409.
Marcovich R, Wojno KJ, Wei JT. et al. Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. Urology. 2000 Jun;55(6):904–908. Not eligible exposure . [PubMed: 10840106]
410.
Mark DH. Mortality of patients after radical prostatectomy: analysis of recent Medicare claims. J Urol. 1994 Sep;152(3):896–898. Not eligible exposure . [PubMed: 8051747]
411.
Maroni PD, Crawford ED. Surgical management of prostate cancer: optimizing patient selections and clinical outcome. Surg Oncol Clin N Am. 2005 Apr;14(2):301–319. Not eligible exposure . [PubMed: 15817241]
412.
Maroun L, Jakobsen H, Kromann-Andersen B. et al. Amyloidosis of the seminal vesicle—a case report and review of the literature. Scand J Urol Nephrol. 2003;37(6):519–521. Review . [PubMed: 14675929]
413.
Marshall CL, Chapin CA, Shapiro L. et al. Radical prostatectomy for localized prostate cancer: trying to define quality care. Clin Perform Qual Health Care. 1993 Oct–Dec;1(4):243–250. Review . [PubMed: 10135643]
414.
Martorana G, Manferrari F, Bertaccini A. et al. Laparoscopic radical prostatectomy: oncological evaluation in the early phase of the learning curve comparing to retropubic approach. Arch Ital Urol Androl. 2004 Mar;76(1):1–5. No provider characteristics . [PubMed: 15185814]
415.
Masters JG, Rice ML. Improvement in urinary symptoms after radical prostatectomy: a prospective evaluation of flow rates and symptom scores. BJU Int. 2003 Jun;91(9):795–797. Not eligible exposure . [PubMed: 12780834]
416.
Masuda M, Iki M, Noguchi S. et al. The worst histologic elements predict prognosis in moderately-differentiated prostate cancer patients with androgen-withdrawal endocrine therapy. Eur Urol. 1999 Sep;36(3):197–202. Not eligible exposure . [PubMed: 10450002]
417.
Matsushima H, Goto T, Hosaka Y. et al. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer. 1999 Apr 15;85(8):1822–1827. Not eligible exposure . [PubMed: 10223578]
418.
Matuszewski M, Stanek A, Maruszak H. et al. Laparoscopic treatment of parapubic postprostatectomy hernia. Eur Urol. 1999 Nov;36(5):418–420. Not eligible exposure . [PubMed: 10516453]
419.
May F, Hartung R, Breul J. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy. BJU Int. 2001 Nov;88(7):702–707. Not eligible exposure . [PubMed: 11890240]
420.
May J, McGovern F. Hemostatic hydrodissection: a new technique to promote nerve-sparing during radical retropubic prostatectomy. Curr Urol Rep. 2005 Feb;6(1):1. Case-reports . [PubMed: 15610691]
421.
McAllister WJ, Absalom MJ, Mir K. et al. Does endoscopic laser ablation of the prostate stand the test of time? Five-year results from a multicentre randomized controlled trial of endoscopic laser ablation against transurethral resection of the prostate. BJU Int. 2000 Mar;85(4):437–439. Not eligible target population . [PubMed: 10691822]
422.
McCarthy JF, Catalona WJ, Hudson MA. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J Urol. 1994 Jun;151(6):1575–1578. Not eligible exposure . [PubMed: 7514691]
423.
McWilliams JM, Zaslavsky AM, Meara E, et al. Impact of Medicare Coverage on Basic Clinical Services for Previously Uninsured Adults. JAMA. August 13, 2003 2003;290(6):757–764. Not eligible exposure. [PubMed: 12915428]
424.
Mehta SS, Lubeck DP, Sadetsky N. et al. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol. 2004 Jan;171(1):215–219. Not eligible exposure . [PubMed: 14665879]
425.
Meier DE, Tarpley JL, Imediegwu OO. et al. The outcome of suprapubic prostatectomy: a contemporary series in the developing world. Urology. 1995 Jul;46(1):40–44. Not eligible exposure . [PubMed: 7541584]
426.
Meininger D, Byhahn C, Bueck M. et al. Effects of prolonged pneumoperitoneum on hemodynamics and acid-base balance during totally endoscopic robot-assisted radical prostatectomies. World J Surg. 2002 Dec;26(12):1423–1427. Not eligible exposure . [PubMed: 12297911]
427.
Meng MV, Grossfeld GD, Williams GH. et al. Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res. 2001 Sep;7(9):2712–2718. Not eligible exposure . [PubMed: 11555583]
428.
Menon M, Shrivastava A, Tewari A. et al. Laparoscopic and robot assisted radical prostatectomy: establishment of a structured program and preliminary analysis of outcomes. J Urol. 2002 Sep;168(3):945–949. No provider characteristics . [PubMed: 12187196]
429.
Menon M, Tewari A. Robotic radical prostatectomy and the Vattikuti Urology Institute technique: an interim analysis of results and technical points. Urology. 2003 Apr;61(4 Suppl 1):15–20. Not eligible exposure . [PubMed: 12657356]
430.
Meraj S, Nagler HM, Homel P. et al. Radical prostatectomy: size of the prostate gland and its relationship with acute perioperative complications. Can J Urol. 2003 Feb;10(1):1743–1748. Not eligible exposure . [PubMed: 12625852]
431.
Mettlin C. Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies, 1974-1993. Prostate. 1997 Aug 1;32(3):221–226. Review . [PubMed: 9254902]
432.
Mettlin CJ, Murphy GP, Sylvester J. et al. Results of hospital cancer registry surveys by the American College of Surgeons: outcomes of prostate cancer treatment by radical prostatectomy. Cancer. 1997 Nov 1;80(9):1875–1881. Not eligible exposure . [PubMed: 9351563]
433.
Meyer F, Bairati I, Bedard C. et al. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer. Urology. 2001 Aug;58(2 Suppl 1):71–77. Not eligible exposure . [PubMed: 11502453]
434.
Meyer F, Moore L, Bairati I. et al. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol. 1999 Dec;162(6):2024–2028. Not eligible exposure . [PubMed: 10569561]
435.
Mian BM, Troncoso P, Okihara K. et al. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol. 2002 Apr;167(4):1675–1680. Not eligible exposure . [PubMed: 11912386]
436.
Migliari R, Pistolesi D, De Angelis M. Polypropilene sling of the bulbar urethra for post-radical prostatectomy incontinence. Eur Urol. 2003 Feb;43(2):152–157. Not eligible exposure . [PubMed: 12565773]
437.
Milbank AJ, Dreicer R, Klein EA. Hormonal therapy for prostate cancer: primum non nocere. Urology. 2002 Nov;60(5):738–741. Editorial . [PubMed: 12429287]
438.
Miller DC, Sanda MG, Dunn RL. et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005 Apr 20;23(12):2772–2780. Not eligible exposure . [PubMed: 15837992]
439.
Minardi D, Galosi AB, Giannulis I. et al. Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy. Scand J Urol Nephrol. 2004;38(1):19–25. Not eligible exposure . [PubMed: 15204422]
440.
Mireku-Boateng AO, Oben F. Surgical outcome of radical retropubic prostatectomy is not adversely affected by preexisting three-piece inflatable penile implant. Urol Int. 2005;74(3):221–223. Not eligible exposure . [PubMed: 15812207]
441.
Mitchell JA, Cooperberg MR, Elkin EP. et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005 Apr;173(4):1126–1131. Not eligible exposure . [PubMed: 15758720]
442.
Mitsiades CS, Lembessis P, Sourla A. et al. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis. 2004;21(6):495–505. Not eligible exposure . [PubMed: 15679047]
443.
Miyake H, Sakal I, Harada K. et al. Clinicopathological outcome of radical retropubic prostatectomy for 200 men with prostate cancer in a single institution in Japan. Hinyokika Kiyo. 2004 Mar;50(3):151–156. Not eligible exposure . [PubMed: 15148765]
444.
Mohler JL. Outpatient pelvic lymph node dissection. J Urol. 1995 Oct;154(4):1439–1442. No provider characteristics . [PubMed: 7658553]
445.
Mohler JL, Figlesthaler WM, Zhang XZ. et al. Nuclear shape analysis for the assessment of local invasion and metastases in clinically localized prostate carcinoma. Cancer. 1994 Dec 1;74(11):2996–3001. Not eligible exposure . [PubMed: 7954263]
446.
Montironi R, Diamanti L, Santinelli A. et al. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study. Pathol Res Pract. 1999;195(4):201–208. Not eligible exposure . [PubMed: 10337657]
447.
Moore KN, Gray M. Urinary incontinence in men: current status and future directions. Nurs Res. 2004 Nov–Dec;53(6 Suppl):S36–41. Review . [PubMed: 15586146]
448.
Moreno JG, Shenot PJ, Shupp-Byrne D. et al. Analysis of tumor spillage during radical prostatectomy using RT-PCR of prostate specific antigen. Tech Urol. 1996 Spring;2(1):54–57. Not eligible exposure . [PubMed: 9118404]
449.
Morgan WR, Bergstralh EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology. 1993 Feb;41(2):113–120. Not eligible exposure . [PubMed: 7684543]
450.
Morton GC. Early prostate cancer. Curr Probl Cancer. 2000 Jan–Feb;24(1):5–51. Review . [PubMed: 10749454]
451.
Mosbacher MR, Schiff PB, Otoole KM. et al. Postprostatectomy salvage radiation therapy for prostate cancer: impact of pathological and biochemical variables and prostate fossa biopsy. Cancer J. 2002 May–Jun;8(3):242–246. Not eligible exposure . [PubMed: 12074323]
452.
Mottet N, Boyer C, Chartier-Kastler E. et al. Artificial urinary sphincter AMS 800 for urinary incontinence after radical prostatectomy: the French experience. Urol Int. 1998;60(Suppl 2):25–29. discussion 35. Not eligible exposure. [PubMed: 9607555]
453.
Moul JW. Outcome research: prostate cancer databases. Urol Oncol. 2002 Jan–Feb;7(1):39–42. Not eligible exposure . [PubMed: 12474540]
454.
Moul JW, Anderson J, Penson DF. et al. Early prostate cancer: prevention, treatment modalities, and quality of life issues. Eur Urol. 2003 Sep;44(3):283–293. Review . [PubMed: 12932925]
455.
Moul JW, Douglas TH, McCarthy WF. et al. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 1996 May;155(5):1667–1673. Not eligible exposure . [PubMed: 8627850]
456.
Moul JW, Wu H, Sun L. et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004 Mar;171(3):1141–1147. Not eligible exposure . [PubMed: 14767288]
457.
Murphy GP, Mettlin C, Menck H. et al. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol. 1994 Nov;152(5 Pt 2):1817–1819. Not eligible exposure . [PubMed: 7523727]
458.
Nadler RB, Andriole GL. Who is best benefited by radical prostatectomy? Hematol Oncol Clin North Am. 1996 Jun;10(3):581–593. Review . [PubMed: 8773498]
459.
Nam RK, Jewett MA, Krahn MD. et al. Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol. 2003 Jun;10(3):1891–1898. Not eligible exposure . [PubMed: 12892576]
460.
Namiki S, Kuwahara M, Ioritani N. et al. An evaluation of urinary function after radical prostatectomy in Japanese men: concordance with definitions of urinary continence. BJU Int. 2005 Mar;95(4):530–533. Not eligible exposure . [PubMed: 15705074]
461.
Namiki S, Tochigi T, Kuwahara M. et al. Health related quality of life in Japanese men after radical prostatectomy or radiation therapy for localized prostate cancer. Int J Urol. 2004 Aug;11(8):619–627. Not eligible exposure . [PubMed: 15285752]
462.
Narayan P, Jajodia P, Stein R. et al. A comparison of fine needle aspiration and core biopsy in diagnosis and preoperative grading of prostate cancer. J Urol. 1989 Mar;141(3):560–563. No provider characteristics . [PubMed: 2918592]
463.
Nasr R, Goldenberg SL. Rising prostate specific antigen after radical prostatectomy: a case based review. Can J Urol. 2001 Aug;8(4):1306–1313. Not eligible exposure . [PubMed: 11564273]
464.
Neal DE. The National Prostatectomy Audit. Br J Urol. 1997 Apr;79(Suppl 2):69–75. Review . [PubMed: 9126073]
465.
Nelson CP, Dunn RL, Wei JT. et al. Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. Urol Oncol. 2003 May–Jun;21(3):213–218. Not eligible exposure . [PubMed: 12810209]
466.
Nelson JB, Lepor H. Prostate cancer: radical prostatectomy. Urol Clin North Am. Nov 2003;30(4):703–723, viii. Review. [PubMed: 14680309]
467.
Neulander EZ. Re: Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol. 2004 Feb;171(2 Pt 1):809. author reply 809–810. Comment. [PubMed: 14713828]
468.
Neulander EZ, Soloway MS. Failure after radical prostatectomy. Urology. 2003 Jan;61(1):30–36. Review . [PubMed: 12559261]
469.
Neulander EZ, Wajsman Z, Greene GF. Radical prostatectomy and postoperative radiation in patients with adenocarcinoma of prostate of intermediate and high risk for recurrence. J Ark Med Soc. 2005 Mar;101(9):276–280. Not eligible exposure . [PubMed: 15787077]
470.
Newling DW. The management of hormone refractory prostate cancer. Eur Urol. 1996;29(Suppl 2):69–74. Review . [PubMed: 8717467]
471.
Nickers P, Lenaerts E, Thissen B. et al. Does inverse planning applied to Iridium192 high dose rate prostate brachytherapy improve the optimization of the dose afforded by the Paris system? Radiother Oncol. 2005 Feb;74(2):131–136. No provider characteristics . [PubMed: 15734200]
472.
Niehoff P, Loch T, Nurnberg N. et al. Feasibility and preliminary outcome of salvage combined HDR brachytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy. Brachytherapy. 2005;4(2):141–145. Not eligible exposure . [PubMed: 15893268]
473.
Noguchi M, Shimada A, Yahara J. et al. Early catheter removal 3 days after radical retropubic prostatectomy. Int J Urol. 2004 Nov;11(11):983–988. Not eligible exposure . [PubMed: 15509202]
474.
Noh C, Kshirsagar A, Mohler JL. Outcomes after radical retropubic prostatectomy. Urology. 2003 Feb;61(2):412–416. Not eligible exposure . [PubMed: 12597958]
475.
Noldus J, Michl U, Graefen M. et al. Patient-reported sexual function after nerve-sparing radical retropubic prostatectomy. Eur Urol. 2002 Aug;42(2):118–124. Not eligible exposure . [PubMed: 12160581]
476.
Norberg M, Holmberg L, Wheeler T. et al. Five year follow-up after radical prostatectomy for localized prostate cancer—a study of the impact of different tumor variables on progression. Scand J Urol Nephrol. 1994 Dec;28(4):391–399. Not eligible exposure . [PubMed: 7533926]
477.
Norderhaug I, Dahl O, Hoisaeter PA. et al. Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness. Eur Urol. 2003 Jul;44(1):40–46. Review . [PubMed: 12814673]
478.
Nudell DM, Grossfeld GD, Weinberg VK. et al. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology. 1999 Dec;54(6):1049–1057. Not eligible exposure . [PubMed: 10604707]
479.
Nuttall MC, van der Meulen J, McIntosh G. et al. Threshold volumes for urological cancer surgery: a survey of UK urologists. BJU Int. 2004 Nov;94(7):1010–1013. Not eligible outcomes . [PubMed: 15541118]
480.
O'Brien MF, Connolly SS, Kelly DG. et al. Should patients with a pre-operative prostate-specific antigen greater than 15 ng/ml be offered radical prostatectomy? Ir J Med Sci. 2004 Jan–Mar;173(1):23–26. Not eligible exposure . [PubMed: 15732232]
481.
Oefelein MG, Grayhack JT, McVary KT. Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate. Cancer. 1995 Dec 15;76(12):2535–2542. Not eligible exposure . [PubMed: 8625082]
482.
Oesterling JE. Long-term follow-up of patients treated by radical prostatectomy for clinically-localized prostate cancer. Can J Oncol. 1994 Nov;4(Suppl 1):24–28. discussion 29–30. Not eligible exposure. [PubMed: 8853485]
483.
Oesterling JE. Radical prostatectomy: the retropubic approach. Urology. 1996 Apr;47(4):460–462. Editorial . [PubMed: 8638350]
484.
Ohori M, Goad JR, Wheeler TM. et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994 Nov;152(5 Pt 2):1843–1849. Not eligible exposure . [PubMed: 7523732]
485.
Ohori M, Scardino PT. Localized prostate cancer. Curr Probl Surg. 2002 Sep;39(9):833–957. Review . [PubMed: 12376729]
486.
Ohyama C, Tsuchiya N, Habuchi T. et al. Rectosigmoidal bladder utilizing intussuscepted ileal segment: a surgical technique for urinary diversion and experiences in 30 patients. Int J Urol. 2004 Jun;11(6):379–385. Not eligible target population . [PubMed: 15157206]
487.
Okotie OT, Aronson WJ, Wieder JA. et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004 Jun;171(6 Pt 1):2260–2264. Not eligible exposure . [PubMed: 15126798]
488.
Oliver SE, Donovan JL, Peters TJ. et al. Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. BJU Int. 2003 Mar;91(4):331–336. discussion 336. Not eligible exposure. [PubMed: 12603408]
489.
Olsson CA, De Vries GM, Benson MC. et al. The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. Br J Urol. 1996 Mar;77(3):411–417. Not eligible exposure . [PubMed: 8814848]
490.
Olsson CA, de Vries GM, Raffo AJ. et al. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol. 1996 May;155(5):1557–1562. Not eligible exposure . [PubMed: 8627821]
491.
Olumi AF, Richie JP, Schultz DJ. et al. Calculated volume of prostate cancer identifies patients with clinical stage T1C disease at high risk of biochemical recurrence after radical prostatectomy: a preliminary study. Urology. 2000 Aug 1;56(2):273–277. Not eligible exposure . [PubMed: 10925093]
492.
Onik G, Narayan P, Vaughan D. et al. Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology. 2002 Jul;60(1):109–114. Not eligible exposure . [PubMed: 12100934]
493.
Ornstein DK, Oh J, Herschman JD. et al. Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am. 1998 Nov;25(4):591–601. Review . [PubMed: 10026768]
494.
Ou YC, Chen JT, Cheng CL. et al. Radical prostatectomy for prostate cancer patients with prostate-specific antigen >20 ng/ml. Jpn J Clin Oncol. 2003 Nov;33(11):574–579. Not eligible exposure . [PubMed: 14711982]
495.
Ozcan F. Correlation of perineural invasion on radical prostatectomy specimens with other pathologic prognostic factors and PSA failure. Eur Urol. 2001 Sep;40(3):308–312. Not eligible exposure . [PubMed: 11684847]
496.
Pagano F, Prayer-Galetti T, d'Arrigo L. et al. Radical surgery for clinically confined prostate cancer. Ann N Y Acad Sci. 1996 Apr 30;784:85–92. Not eligible exposure . [PubMed: 8651620]
497.
Palisaar RJ, Graefen M, Karakiewicz PI. et al. Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer. Eur Urol. 2002 Feb;41(2):155–161. Not eligible exposure . [PubMed: 12074402]
498.
Palisaar RJ, Noldus J, Graefen M. et al. Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical failure. Eur Urol. 2005 Feb;47(2):176–184. Not eligible exposure . [PubMed: 15661411]
499.
Pantel K, Enzmann T, Kollermann J. et al. Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Int J Cancer. 1997 May 16;71(4):521–525. Not eligible exposure . [PubMed: 9178803]
500.
Paquette EL, Connelly RR, Sesterhenn IA. et al. Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma. Cancer. 2001 Nov 15;92(10):2673–2679. Not eligible exposure . [PubMed: 11745203]
501.
Park EL, Dalkin B, Escobar C. et al. Site-specific positive margins at radical prostatectomy: assessing cancer-control benefits of wide excision of the neurovascular bundle on a side with cancer on biopsy. BJU Int. 2003 Feb;91(3):219–222. Not eligible exposure . [PubMed: 12581008]
502.
Parker CC, Dearnaley DP. The management of PSA failure after radical radiotherapy for localized prostate cancer. Radiother Oncol. 1998 Nov;49(2):103–110. Review . [PubMed: 10052875]
503.
Partin AW, Lee BR, Carmichael M. et al. Radical prostatectomy for high grade disease: a reevaluation 1994. J Urol. 1994 Jun;151(6):1583–1586. Not eligible exposure . [PubMed: 8189569]
504.
Patel A, Adshead JM. First clinical experience with new transurethral bipolar prostate electrosurgery resection system: controlled tissue ablation (coblation technology) J Endourol. 2004 Dec;18(10):959–964. Not eligible treatment . [PubMed: 15801362]
505.
Patel VR, Tully AS, Holmes R. et al. Robotic radical prostatectomy in the community setting—the learning curve and beyond: initial 200 cases. J Urol. 2005 Jul;174(1):269–272. No provider characteristics . [PubMed: 15947662]
506.
Patriarca C, Petrella D, Campo B. et al. Elevated E-cadherin and alpha/beta-catenin expression after androgen deprivation therapy in prostate adenocarcinoma. Pathol Res Pract. 2003;199(10):659–665. Not eligible exposure . [PubMed: 14666968]
507.
Paul R, Hoppmann M, van Randenborgh H. et al. Residual benign prostatic glands at the urethrovesical anastomosis after radical retropubic prostatectomy: prediction and impact on disease outcome. Eur Urol. 2004 Sep;46(3):321–326. Not eligible exposure . [PubMed: 15306101]
508.
Paulson DF. Clinically localized prostatic carcinoma. Cancer. 1993 Jun 15;71(12):3797. Comment . [PubMed: 8508346]
509.
Paulson DF, Vieweg JW. Radical perineal prostatectomy: a model for evaluating local response of prostate therapy. Crit Rev Oncol Hematol. 2002 Aug;43(2):135–139. Not eligible exposure . [PubMed: 12191735]
510.
Penedo FJ, Dahn JR, Molton I. et al. Cognitive-behavioral stress management improves stress-management skills and quality of life in men recovering from treatment of prostate carcinoma. Cancer. 2004 Jan 1;100(1):192–200. Not eligible exposure . [PubMed: 14692040]
511.
Perez CA, Beyer DC, Blasko JC. et al. Postradical prostatectomy irradiation in carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun;215(Suppl):1419–1439. Review . [PubMed: 11037557]
512.
Perez CA, Michalski JM, Baglan K. et al. Radiation therapy for increasing prostate-specific antigen levels after radical prostatectomy. Clin Prostate Cancer. 2003 Mar;1(4):235–241. Not eligible exposure . [PubMed: 15040882]
513.
Perez LM, Webster GD. Successful outcome of artificial urinary sphincters in men with post-prostatectomy urinary incontinence despite adverse implantation features. J Urol. 1992 Oct;148(4):1166–1170. Not eligible exposure . [PubMed: 1404630]
514.
Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol. 2003 Apr;4(4):233–241. Review . [PubMed: 12681267]
515.
Peters N, Armstrong K. Racial differences in prostate cancer treatment outcomes: a systematic review. Cancer Nurs. 2005 Mar–Apr;28(2):108–118. Review . [PubMed: 15815180]
516.
Petrovich Z, Lieskovsky G, Langholz B. et al. Comparison of outcomes of radical prostatectomy with and without adjuvant pelvic irradiation in patients with pathologic stage C (T3N0) adenocarcinoma of the prostate. Am J Clin Oncol. 1999 Aug;22(4):323–331. Not eligible exposure . [PubMed: 10440184]
517.
Petrovich Z, Lieskovsky G, Langholz B. et al. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):600–609. Not eligible exposure . [PubMed: 12062603]
518.
Philip J, Dutta Roy S, Scally J. et al. Importance of TURP in diagnosing prostate cancer in men with multiple negative biopsies. Prostate. 2005 Jul 1;64(2):200–202. Not eligible exposure . [PubMed: 15712218]
519.
Pisansky TM. External beam radiotherapy as curative treatment of prostate cancer. Mayo Clin Proc. 2005 Jul;80(7):883–898. Review . [PubMed: 16007894]
520.
Pisansky TM, Blute ML, Hillman DW. et al. The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer. 2002 Aug 1;95(3):513–519. Not eligible exposure . [PubMed: 12209743]
521.
Pisansky TM, Kozelsky TF, Myers RP. et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000 Mar;163(3):845–850. Not eligible exposure . [PubMed: 10687990]
522.
Pisters LL. Salvage radical prostatectomy: refinement of an effective procedure. Semin Radiat Oncol. 2003 Apr;13(2):166–174. Review . [PubMed: 12728446]
523.
Pisters LL, English SF, Scott SM. et al. Salvage prostatectomy with continent catheterizable urinary reconstruction: a novel approach to recurrent prostate cancer after radiation therapy. J Urol. 2000 Jun;163(6):1771–1774. Not eligible exposure . [PubMed: 10799179]
524.
Pitts WR Jr. Outcome research after radical retropubic prostatectomy for prostate cancer. J Natl Cancer Inst. 1998 Jul 15;90(14):1107. Comment . [PubMed: 9672264]
525.
Pollack A, Zagars GK, Rosen II. Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity. Semin Oncol. 1999 Apr;26(2):150–161. Review . [PubMed: 10597726]
526.
Potosky AL, Legler J, Albertsen PC. et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000 Oct 4;92(19):1582–1592. Not eligible exposure . [PubMed: 11018094]
527.
Potosky AL, Miller BA, Albertsen PC. et al. The role of increasing detection in the rising incidence of prostate cancer. Jama. 1995 Feb 15;273(7):548–552. Not eligible exposure . [PubMed: 7530782]
528.
Potosky AL, Warren JL. Radical prostatectomy: does higher volume lead to better quality? J Natl Cancer Inst. 1999 Nov 17;91(22):1906–1907. Comment . [PubMed: 10564667]
529.
Poulos CK, Daggy JK, Cheng L. Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens. Cancer. 2004 Aug 1;101(3):527–532. Not eligible exposure . [PubMed: 15274065]
530.
Pound CR, Walsh PC, Epstein JI. et al. Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. World J Urol. 1997;15(6):373–377. Not eligible exposure . [PubMed: 9436288]
531.
Powell IJ, Banerjee M, Sakr W. et al. Should African-American men be tested for prostate carcinoma at an earlier age than white men? Cancer. 1999 Jan 15;85(2):472–477. Not eligible exposure . [PubMed: 10023717]
532.
Prapotnich D, Fizazi K, Escudier B. et al. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol. 2003 Mar;43(3):233–239. discussion 239–240. Not eligible exposure. [PubMed: 12600425]
533.
Prepelica KL, Okeke Z, Murphy A. et al. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer. 2005 Apr 15;103(8):1625–1630. Not eligible exposure . [PubMed: 15747374]
534.
Prestidge BR, Prete JJ, Buchholz TA, et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. International Journal of Radiation Oncology*Biology*Physics. 1998/1/15 1998;40(2):461–465. Not eligible exposure. [PubMed: 9457836]
535.
Pruthi RS, Derksen JE, Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int. 2004 Feb;93(3):275–278. Not eligible exposure . [PubMed: 14764122]
536.
Pruthi RS, Johnstone I, Tu IP. et al. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology. 1997 May;49(5):737–742. Not eligible exposure . [PubMed: 9145980]
537.
Quaranta BP, Marks LB, Anscher MS. Prostatectomy vs brachytherapy for localized prostate cancer. Oncology (Williston Park) 2004 Nov;18(13):1582–1585. Comment . [PubMed: 15648292]
538.
Quaranta BP, Marks LB, Anscher MS. Comparing radical prostatectomy and brachytherapy for localized prostate cancer. Oncology (Williston Park) 2004 Sep;18(10):1289–1302. discussion 1302–1284, 1309. Review. [PubMed: 15526832]
539.
Queen J. Transperitoneal laparoscopic radical prostatectomy. Semin Perioper Nurs. 2001 Jan;10(1):24–28. Not eligible exposure . [PubMed: 15129502]
540.
Rabbani F, Stapleton AM, Kattan MW. et al. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000 Dec;164(6):1929–1934. Not eligible exposure . [PubMed: 11061884]
541.
Raboy A, Albert P, Ferzli G. Early experience with extraperitoneal endoscopic radical retropubic prostatectomy. Surg Endosc. 1998 Oct;12(10):1264–1267. Case report . [PubMed: 9745069]
542.
Ragde H, Korb LJ, Elgamal AA. et al. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer. 2000 Jul 1;89(1):135–141. Not eligible exposure . [PubMed: 10897010]
543.
Raina R, Lakin MM, Agarwal A. et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology. 2003 Jul;62(1):110–115. Not eligible exposure . [PubMed: 12837433]
544.
Rakozy C, Grignon DJ, Li Y. et al. p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis. Pathol Res Pract. 1999;195(3):129–135. Not eligible exposure . [PubMed: 10220791]
545.
Ramon J, Leandri P, Rossignol G. et al. Urinary continence following radical retropubic prostatectomy. Br J Urol. 1993 Jan;71(1):47–51. Not eligible exposure . [PubMed: 8435736]
546.
Rassweiler J, Frede T, Seemann O. et al. Telesurgical laparoscopic radical prostatectomy. Initial experience. Eur Urol. 2001 Jul;40(1):75–83. No provider characteristics . [PubMed: 11528180]
547.
Rassweiler J, Schulze M, Teber D. et al. Laparoscopic radical prostatectomy: functional and oncological outcomes. Curr Opin Urol. 2004 Mar;14(2):75–82. Review . [PubMed: 15075834]
548.
Rassweiler J, Sentker L, Seemann O. et al. Laparoscopic radical prostatectomy with the Heilbronn technique: an analysis of the first 180 cases. J Urol. 2001 Dec;166(6):2101–2108. No provider characteristics . [PubMed: 11696715]
549.
Rassweiler J, Sentker L, Seemann O. et al. Heilbronn laparoscopic radical prostatectomy. Technique and results after 100 cases. Eur Urol. 2001 Jul;40(1):54–64. No provider characteristics . [PubMed: 11528177]
550.
Rassweiler J, Stolzenburg J, Sulser T. et al. Laparoscopic radical prostatectomy—the experience of the German Laparoscopic Working Group. Eur Urol. 2006 Jan;49(1):113–119. No provider characteristics . [PubMed: 16337330]
551.
Ravery V, Chastang C, Toublanc M. et al. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1–T2 prostate cancer. Eur Urol. 2000 Apr;37(4):449–455. Not eligible exposure . [PubMed: 10765076]
552.
Ray ME, Dunn RL, Cooney KA. et al. Family history of prostate cancer and relapse after definitive external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):371–376. Not eligible exposure . [PubMed: 12957247]
553.
Razvi HA, Song TY, Denstedt JD. Management of vesical calculi: comparison of lithotripsy devices. J Endourol. 1996 Dec;10(6):559–563. Not eligible target population . [PubMed: 8972793]
554.
Rebillard X, Gelet A, Davin JL. et al. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer. J Endourol. 2005 Jul–Aug;19(6):693–701. Review . [PubMed: 16053358]
555.
Reeves MD, Myles PS. Does anaesthetic technique affect the outcome after transurethral resection of the prostate? BJU Int. 1999 Dec;84(9):982–986. Not eligible exposure . [PubMed: 10571624]
556.
Rehman J, Ragab MM, Venkatesh R. et al. Laparoscopic radical prostatectomy: Washington University initial experience and prospective evaluation of quality of life. J Endourol. 2004 Apr;18(3):277–287. No provider characteristics . [PubMed: 15225395]
557.
Remzi M, Klingler HC, Tinzl MV. et al. Morbidity of laparoscopic extraperitoneal versus transperitoneal radical prostatectomy verus open retropubic radical prostatectomy. Eur Urol. 2005 Jul;48(1):83–89. discussion 89. No provider characteristics. [PubMed: 15967256]
558.
Rhee AC, Olgac S, Ohori M. et al. Mucinous adenocarcinoma of the prostate: a case report of long-term disease-free survival and a review of the literature. Urology. 2004 Apr;63(4):779–780. Case report . [PubMed: 15072909]
559.
Rhee HK, Triaca V, Sorcini A. et al. Transperitoneal laparoscopic radical prostatectomy: descending technique. J Endourol. 2004 Sep;18(7):601–604. discussion 604. Not eligible exposure. [PubMed: 15597644]
560.
Rioux-Leclercq NC, Chan DY, Epstein JI. Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma. Urology. 2002 Oct;60(4):666–669. Not eligible exposure . [PubMed: 12385930]
561.
Risbridger GP, Shibata A, Ferguson KL. et al. Elevated expression of inhibin alpha in prostate cancer. J Urol. 2004 Jan;171(1):192–196. Not eligible exposure . [PubMed: 14665874]
562.
Roach M 3rd. Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer. Semin Urol Oncol. 1996 May;14(2 Suppl 2):32–37. discussion 38. Review. [PubMed: 8725889]
563.
Roach M 3rd, Chen A, Song J, Diaz A, Presti J Jr, Carroll P. Pretreatment prostate-specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer. Semin Urol Oncol. 2000 May;18(2):108–114. Not eligible exposure . [PubMed: 10875450]
564.
Robinson L, Hughes LC, Adler DC. et al. Describing the work of nursing: the case of postsurgical nursing interventions for men with prostate cancer. Res Nurs Health. 1999 Aug;22(4):321–328. Not eligible exposure . [PubMed: 10435549]
565.
Rogers CG, Trock BP, Walsh PC. Preservation of accessory pudendal arteries during radical retropubic prostatectomy: surgical technique and results. Urology. 2004 Jul;64(1):148–151. Not eligible exposure . [PubMed: 15245954]
566.
Rogers E, Ohori M, Kassabian VS. et al. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol. 1995 Jan;153(1):104–110. Not eligible exposure . [PubMed: 7526002]
567.
Rollins G. Most treatments for localized prostate cancer have equal cure rates. Rep Med Guidel Outcomes Res. Feb 6 2004;15(3):1, 5–6. News. [PubMed: 15000075]
568.
Roos NP, Ramsey EW. A population-based study of prostatectomy: outcomes associated with differing surgical approaches. J Urol. 1987 Jun;137(6):1184–1188. Not eligible target population . [PubMed: 3586151]
569.
Rosenberg J, Small EJ. Prostate cancer update. Curr Opin Oncol. 2003 May;15(3):217–221. Review . [PubMed: 12778015]
570.
Roumeguere T, Bollens R, Vanden Bossche M. et al. Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches. World J Urol. 2003 May;20(6):360–366. Not eligible exposure . [PubMed: 12682770]
571.
Rozet F, Arroyo C, Cathelineau X. et al. Extraperitoneal standard laparoscopic radical prostatectomy. J Endourol. 2004 Sep;18(7):605–609. discussion 609–610. Not eligible exposure. [PubMed: 15597645]
572.
Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology. 2003 Dec 29;62(Suppl 1):87–94. Not eligible exposure . [PubMed: 14747046]
573.
Saffrin R, Chou P, Ray V. et al. Suramin as adjuvant therapy with radical prostatectomy. Prostate. 1996 May;28(5):325–327. Not eligible exposure . [PubMed: 8610060]
574.
Sakai I, Harada K, Hara I. et al. Intussusception of the bladder neck does not promote early restoration to urinary continence after non-nerve-sparing radical retropubic prostatectomy. Int J Urol. 2005 Mar;12(3):275–279. Not eligible exposure . [PubMed: 15828955]
575.
Saliken JC, Donnelly BJ, Brasher P. et al. Outcome and safety of transrectal US-guided percutaneous cryotherapy for localized prostate cancer. J Vasc Interv Radiol. 1999 Feb;10(2 Pt 1):199–208. Not eligible exposure . [PubMed: 10082109]
576.
Salomon CG, Kalbhen CL, Dudiak CM. et al. Prostate carcinoma: transrectal US after cryosurgical ablation. Radiology. 1998 Feb;206(2):533–538. Not eligible exposure . [PubMed: 9457209]
577.
Salomon L, Anastasiadis A, Saint F. et al. Introducing a new, simple scoring system to evaluate oncological and functional outcome after radical prostatectomy. Scand J Urol Nephrol. 2003;37(5):392–395. Not eligible exposure . [PubMed: 14594687]
578.
Salomon L, Anastasiadis AG, Katz R. et al. Urinary continence and erectile function: a prospective evaluation of functional results after radical laparoscopic prostatectomy. Eur Urol. 2002 Oct;42(4):338–343. Not eligible exposure . [PubMed: 12361898]
579.
Salomon L, Levrel O, Anastasiadis AG. et al. Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach. Prostate Cancer Prostatic Dis. 2002;5(4):285–290. Not eligible exposure . [PubMed: 12627213]
580.
Salomon L, Levrel O, de la Taille A. et al. Radical prostatectomy by the retropubic, perineal and laparoscopic approach: 12 years of experience in one center. Eur Urol. 2002 Aug;42(2):104–110. discussion 110–101. Not eligible exposure. [PubMed: 12160579]
581.
Salomon L, Saint F, Anastasiadis AG. et al. Combined reporting of cancer control and functional results of radical prostatectomy. Eur Urol. 2003 Dec;44(6):656–660. Not eligible exposure . [PubMed: 14644116]
582.
Salonia A, Suardi N, Crescenti A. et al. Pfannenstiel versus vertical laparotomy in patients undergoing radical retropubic prostatectomy with spinal anesthesia: results of a prospective, randomized trial. Eur Urol. 2005 Feb;47(2):202–208. Not eligible exposure . [PubMed: 15661415]
583.
Sandhu DP, Mayor PE, Sambrook PA. et al. Outcome and prognostic factors in patients with advanced prostate cancer and obstructive uropathy. Br J Urol. 1992 Oct;70(4):412–416. Not eligible exposure . [PubMed: 1450851]
584.
Sanguineti G, Franzone P, Culp L. et al. Radiotherapy after prostatectomy. Tumori. 2002 Nov–Dec;88(6):445–452. Not eligible exposure . [PubMed: 12597135]
585.
Saranchuk JW, Kattan MW, Elkin E. et al. Achieving optimal outcomes after radical prostatectomy. J Clin Oncol. 2005 Jun 20;23(18):4146–4151. Not eligible exposure . [PubMed: 15961762]
586.
Sato K, Tsuchiya N, Habuchi T. et al. Total cystoprostatectomy in the treatment of locally advanced prostate carcinoma. Aktuelle Urol. 2003 Jul;34(4):259–261. Not eligible exposure . [PubMed: 14566679]
587.
Scardino PT, Carlton CE Jr. Re: Impact of transurethral resection on the long-term outcome of patients with prostatic carcinoma. J Urol. 1994 Sep;152(3):970. Comment . [PubMed: 8051773]
588.
Schaefer U, Witt F, Schueller P. et al. Prostate-specific antigen (PSA) in the monitoring of prostate cancer after radical prostatectomy and external beam radiation. Anticancer Res. 2000 Nov–Dec;20(6D):4989–4992. Not eligible exposure . [PubMed: 11326654]
589.
Schapira MM, Lawrence WF, Katz DA. et al. Effect of treatment on quality of life among men with clinically localized prostate cancer. Med Care. 2001 Mar;39(3):243–253. Not eligible exposure . [PubMed: 11242319]
590.
Schatzl G, Madersbacher S, Hofbauer J. et al. The impact of urinary extravasation after radical retropubic prostatectomy on urinary incontinence and anastomotic strictures. Eur Urol. 1999 Sep;36(3):187–190. Not eligible exposure . [PubMed: 10450000]
591.
Schild SE. Salvage radiotherapy for elevated PSA levels following prostatectomy. Cancer J. 2002 May–Jun;8(3):234–235. Comment . [PubMed: 12074320]
592.
Schild SE, Pisansky TM. The role of radiotherapy after radical prostatectomy. Urol Clin North Am. Aug 2001;28(3):629–637, x. Review. [PubMed: 11590818]
593.
Schild SE, Wong WW, Grado GL. et al. Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc. 1994 Jul;69(7):613–619. Not eligible exposure . [PubMed: 7516988]
594.
Schild SE, Wong WW, Grado GL. et al. The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):535–541. Not eligible exposure . [PubMed: 8621275]
595.
Schmidt JD, Doyle J, Larison S. Prostate cryoablation: update 1998. CA Cancer J Clin. 1998 Jul–Aug;48(4):239–253. Review . [PubMed: 9676539]
596.
Schonberger B, Giessing M, Vogler H. et al. Relevance and meaning of prostate cancer in kidney transplantation. Transplant Proc. 2002 Sep;34(6):2225–2226. Case report . [PubMed: 12270375]
597.
Schuessler WW, Schulam PG, Clayman RV. et al. Laparoscopic radical prostatectomy: initial short-term experience. Urology. 1997 Dec;50(6):854–857. Not eligible exposure . [PubMed: 9426713]
598.
Schulman CC, Altwein JE, Zlotta AR. Treatment options after failure of local curative treatments in prostate cancer: a controversial issue. BJU Int. 2000 Dec;86(9):1014–1022. Review . [PubMed: 11119094]
599.
Schulman CC, Wildschutz T, Zlotta AR. Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and open questions. Eur Urol. 1997;32(Suppl 3):41–47. Review . [PubMed: 9267784]
600.
Schulz RJ, Kagan AR. Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization. Cancer. 2004 Jul 1;101(1):208–209. author reply 209–210. Comment. [PubMed: 15222011]
601.
Sciarra A, Di Chiro C, Di Silverio F. Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer. World J Urol. 2000 Dec;18(6):392–400. Not eligible exposure . [PubMed: 11204257]
602.
Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol. 2000 Nov;164(5):1465–1472. Not eligible exposure . [PubMed: 11025684]
603.
Scott PA, Scott PA, Perkash I, Mode D. et al. Prostate cancer diagnosed in spinal cord-injured patients is more commonly advanced stage than in able-bodied patients. Urology. 2004 Mar;63(3):509–512. Not eligible exposure . [PubMed: 15028447]
604.
Seaman EK, Whang IS, Cooner W. et al. Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate. Urology. 1994 May;43(5):645–648. Not eligible exposure . [PubMed: 7513107]
605.
Secin FP, Carver B, Kattan MW. et al. Current recommendations for delaying renal transplantation after localized prostate cancer treatment: are they still appropriate? Transplantation. 2004 Sep 15;78(5):710–712. Not eligible exposure . [PubMed: 15371673]
606.
See WA. Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer. Curr Treat Options Oncol. 2003 Oct;4(5):351–362. Review . [PubMed: 12941195]
607.
Selek U, Lee A, Levy L. et al. Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):963–967. Not eligible exposure . [PubMed: 14575826]
608.
Shaffer DR, Scher HI. Prostate cancer: a dynamic illness with shifting targets. Lancet Oncol. 2003 Jul;4(7):407–414. Review . [PubMed: 12850191]
609.
Shah R, Bassily N, Wei J. et al. Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors. Urology. 2000 Nov 1;56(5):721–725. Not eligible exposure . [PubMed: 11068287]
610.
Shaheen A, Quinlan D. Feasibility of open simple prostatectomy with early vascular control. BJU Int. 2004 Feb;93(3):349–352. Not eligible target population . [PubMed: 14764135]
611.
Shanberg AM, Sawyer DE, Lee IS. et al. Depth of penetration of the neodymium: yttrium-aluminum-garnet laser in the human prostate and clinical results of high-dose laser energy in 50 patients. World J Urol. 1995;13(2):78–82. Not eligible exposure . [PubMed: 7627209]
612.
Shekarriz B, Upadhyay J, Pontes JE. Salvage radical prostatectomy. Urol Clin North Am. 2001 Aug;28(3):545–553. Review . [PubMed: 11590813]
613.
Shibata A, Ma J, Whittemore A. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst. August 19, 1998 1998;90(16):1230–1231. Review. [PubMed: 9719085]
614.
Shrader-Bogen CL, Kjellberg JL, McPherson CP. et al. Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. Cancer. 1997 May 15;79(10):1977–1986. Not eligible exposure . [PubMed: 9149026]
615.
Shulman MJ, Benaim EA. Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma. Cancer. 2005 Jun 1;103(11):2280–2286. Not eligible exposure. [PubMed: 15844202]
616.
Silber JH, Williams SV, Krakauer H. et al. Hospital and patient characteristics associated with death after surgery. A study of adverse occurrence and failure to rescue. Med Care. 1992 Jul;30(7):615–629. Not eligible outcomes . [PubMed: 1614231]
617.
Simonato A, Gregori A, Lissiani A. et al. Laparoscopic radical cystoprostatectomy: a technique illustrated step by step. Eur Urol. 2003 Jul;44(1):132–138. Not eligible target population . [PubMed: 12814689]
618.
Skinner EC, Glode LM. High-risk localized prostate cancer: primary surgery and adjuvant therapy. Urol Oncol. 2003 May–Jun;21(3):219–227. Review . [PubMed: 12810210]
619.
Small EJ. Prostate cancer, Incidence, management and outcomes. Drugs Aging. 1998 Jul;13(1):71–81. Review . [PubMed: 9679210]
620.
Small EJ, Roach M 3rd. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol. 2002 Jun;29(3):264–273. Review . [PubMed: 12063679]
621.
Smart R. Outcomes of transrectal ultrasound scan of the prostate with sector biopsies for 323 New Zealand men with suspicion of prostate cancer. N Z Med J. 1999 Dec 10;112(1101):465–469. Not eligible exposure . [PubMed: 10678211]
622.
Smith DS, Carvalhal GF, Schneider K. et al. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer. 2000 Mar 15;88(6):1454–1463. Not eligible exposure . [PubMed: 10717630]
623.
Smith DS, Krygiel J, Nease RF Jr. et al. Patient preferences for outcomes associated with surgical management of prostate cancer. J Urol. 2002 May;167(5):2117–2122. Not eligible exposure . [PubMed: 11956454]
624.
Smith JA Jr. Stage T1c prostate cancer: perspectives on clinical management. Semin Urol Oncol. 1995 Aug;13(3):238–244. Review . [PubMed: 8521137]
625.
Smith JA Jr. Outcome after radical prostatectomy depends on surgical technique but not approach. Curr Urol Rep. 2002 Jun;3(3):179–181. Review . [PubMed: 12084186]
626.
Smith JA Jr. Robotically assisted laparoscopic prostatectomy: an assessment of its contemporary role in the surgical management of localized prostate cancer. Am J Surg. 2004 Oct;188(4A Suppl):63S–67S. Not eligible exposure . [PubMed: 15476654]
627.
Smith MR, Manola J, Kaufman DS. et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004 Oct 1;101(7):1569–1574. Not eligible exposure . [PubMed: 15468186]
628.
Smith MR, McGovern FJ. Gonadotropin-releasing hormone agonist failure in a man with prostate cancer. J Urol. 2001 Jul;166(1):211. Not eligible exposure . [PubMed: 11435862]
629.
Smitt MC, Heltzel M. The results of radical prostatectomy at a community hospital during the prostate specific antigen era. Cancer. 1996 Mar 1;77(5):928–933. Not eligible exposure . [PubMed: 8608486]
630.
Soderdahl DW, Davis JW, Schellhammer PF. et al. Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer. J Endourol. 2005 Apr;19(3):318–326. Not eligible exposure . [PubMed: 15865521]
631.
Sodha S, Nagda S, Lackman RD, et al. Gamma probe assisted biopsy of suspected metastatic rib lesions. Clin Orthop Relat Res. May 2004(422):186–189. Not eligible target population. [PubMed: 15187855]
632.
Sohayda CJ, Kupelian PA, Altsman KA. et al. Race as an independent predictor of outcome after treatment for localized prostate cancer. J Urol. 1999 Oct;162(4):1331–1336. Not eligible exposure . [PubMed: 10492191]
633.
Solberg A, Angelsen A, Bergan U. et al. Frequency of lymphoceles after open and laparoscopic pelvic lymph node dissection in patients with prostate cancer. Scand J Urol Nephrol. 2003;37(3):218–221. Not eligible exposure . [PubMed: 12775280]
634.
Sole-Balcells F, Villavicencio H, Ortiz A. Postsurgical management of the patient undergoing radical prostatectomy. Br J Urol. 1992 Nov;70(Suppl 1):43–49. Not eligible exposure . [PubMed: 1467877]
635.
Soloway MS, Watson R. The role of induction androgen deprivation prior to radical prostatectomy. Eur Urol. 1996;29(Suppl 2):114–118. Review . [PubMed: 8717473]
636.
Speight JL, Shinohara K, Pickett B. et al. Prostate volume change after radioactive seed implantation: possible benefit of improved dose volume histogram with perioperative steroid. Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1461–1467. No provider characteristics . [PubMed: 11121649]
637.
Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med. 2002 Jan;27(1):11–17. Not eligible target population . [PubMed: 11805477]
638.
Srougi M, Paranhos M, Leite KM. et al. The influence of bladder neck mucosal eversion and early urinary extravasation on patient outcome after radical retropubic prostatectomy: a prospective controlled trial. BJU Int. 2005 Apr;95(6):757–760. Not eligible exposure . [PubMed: 15794777]
639.
Stamey TA. Lower limits of detection, biological detection limits, functional sensitivity, or residual cancer detection limit? Sensitivity reports on prostate-specific antigen assays mislead clinicians. Clin Chem. 1996 Jun;42(6 Pt 1):849–852. Not eligible exposure . [PubMed: 8665674]
640.
Stamey TA, Caldwell M, McNeal JE. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004 Oct;172(4 Pt 1):1297–1301. Not eligible exposure . [PubMed: 15371827]
641.
Stamey TA, McNeal JE, Yemoto CM. et al. Biological determinants of cancer progression in men with prostate cancer. Jama. 1999 Apr 21;281(15):1395–1400. Not eligible exposure . [PubMed: 10217055]
642.
Stamey TA, Yemoto CM, McNeal JE. et al. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol. 2000 Apr;163(4):1155–1160. Not eligible exposure . [PubMed: 10737486]
643.
Stanford JL, Feng Z, Hamilton AS. et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. Jama. 2000 Jan 19;283(3):354–360. Not eligible exposure . [PubMed: 10647798]
644.
Stattin P, Bergh A, Karlberg L. et al. Long-term outcome of conservative therapy in men presenting with voiding symptoms and prostate cancer. Eur Urol. 1997;32(4):404–409. Not eligible exposure . [PubMed: 9412796]
645.
Stav K, Rahimi-Levene N, Lindner A. et al. Retropubic radical prostatectomy: associated blood loss and transfusion requirements—a two-decade perspective review. Isr Med Assoc J. 2005 Feb;7(2):103–106. Review . [PubMed: 15729961]
646.
Stavridis S, Georgiev V, Popov Z. et al. Radical retropubic prostatectomy for prostate carcinoma; first results of the Clinic of Urology in Skopje. Acta Chir Iugosl. 2005;52(4):37–40. No provider characteristics . [PubMed: 16673592]
647.
Steinberg AP, Gill IS. Laparoscopic prostatectomy: a promising option in the treatment of prostate cancer. Cleve Clin J Med. Feb 2004;71(2):113–114, 117–121. Review. [PubMed: 14982194]
648.
Steiner MS. Current results and patient selection for nerve-sparing radical retropubic prostatectomy. Semin Urol Oncol. 1995 Aug;13(3):204–214. Review . [PubMed: 8521134]
649.
Steiner MS. Neoadjuvant androgen ablation before radical prostatectomy reduces positive margin rate, but has no effect on 36-month post-treatment biochemical failure. Curr Urol Rep. 2001 Jun;2(3):193–194. Not eligible exposure . [PubMed: 12084263]
650.
Stephenson AJ, Slawin KM, Bianco FJ Jr. et al. Perspectives on the natural history of recurrent prostate cancer after radical prostatectomy, based on the response to salvage radiotherapy. BJU Int. 2004 Dec;94(9):1210–1212. Not eligible exposure . [PubMed: 15610088]
651.
Stolzenburg JU, Do M, Pfeiffer H. et al. The endoscopic extraperitoneal radical prostatectomy (EERPE): technique and initial experience. World J Urol. 2002 May;20(1):48–55. Not eligible exposure . [PubMed: 12088191]
652.
Stolzenburg JU, Rabenalt R, Dietel A. et al. Hernia repair during endoscopic (laparoscopic) radical prostatectomy. J Laparoendosc Adv Surg Tech A. 2003 Feb;13(1):27–31. Not eligible exposure . [PubMed: 12676018]
653.
Stolzenburg JU, Truss MC, Bekos A. et al. Does the extraperitoneal laparoscopic approach improve the outcome of radical prostatectomy? Curr Urol Rep. 2004 Apr;5(2):115–122. Not eligible exposure . [PubMed: 15028203]
654.
Strom SS, Gu Y, Zhang H. et al. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate. 2004 Sep 1;60(4):343–351. Not eligible exposure . [PubMed: 15264247]
655.
Studer UE. Radical prostatectomy or deferred treatment? Semin Surg Oncol. 1995 Jan–Feb;11(1):46–49. Not eligible exposure . [PubMed: 7538694]
656.
Su LM, Link RE, Bhayani SB. et al. Nerve-sparing laparoscopic radical prostatectomy: replicating the open surgical technique. Urology. 2004 Jul;64(1):123–127. Not eligible exposure . [PubMed: 15245948]
657.
Sullivan LD, Weir MJ, Kinahan JF. et al. A comparison of the relative merits of radical perineal and radical retropubic prostatectomy. BJU Int. 2000 Jan;85(1):95–100. Not eligible exposure . [PubMed: 10619954]
658.
Summers JL. Reexamining interstitial radiotherapy for PCa. Contemp Urol. Apr 1994;6(4):17–24, 27. Review. [PubMed: 10147148]
659.
Sun GH, Fu YT, Wu CJ. et al. Povidone-iodine instillation for management of pelvic lymphocele after pelvic lymphadenectomy for staging prostate cancer. Arch Androl. 2003 Nov–Dec;49(6):463–466. Case report . [PubMed: 14555330]
660.
Svetec D, McCabe K, Peretsman S. et al. Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. J Urol. 1998 May;159(5):1606–1608. Not eligible exposure . [PubMed: 9554363]
661.
Swanson GP, Riggs MW, Earle JD. et al. Long-term follow-up of radical retropubic prostatectomy for prostate cancer. Eur Urol. 2002 Sep;42(3):212–216. Not eligible exposure . [PubMed: 12234504]
662.
Swindle PW, Kattan MW, Scardino PT. Markers and meaning of primary treatment failure. Urol Clin North Am. 2003 May;30(2):377–401. Review . [PubMed: 12735513]
663.
Talcott JA, Rieker P, Propert KJ. et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst. 1997 Aug 6;89(15):1117–1123. Not eligible exposure . [PubMed: 9262249]
664.
Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol. 2004 Nov;92(4):287–295. Review . [PubMed: 15663992]
665.
Tarcan T, Ozveri H, Biren T. et al. Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels. Int J Urol. 1997 Jul;4(4):362–367. Review . [PubMed: 9256325]
666.
Teloken C. Management of erectile dysfunction secondary to treatment for localized prostate cancer. Cancer Control. 2001 Nov–Dec;8(6):540–545. Review . [PubMed: 11807424]
667.
Tempany CM. MR staging of prostate cancer. How we can improve our accuracy with decisions aids and optimal techniques. Magn Reson Imaging Clin N Am. 1996 Aug;4(3):519–532. Review . [PubMed: 8873017]
668.
Tewari A, El-Hakim A, Horninger W. et al. Nerve-sparing during robotic radical prostatectomy: use of computer modeling and anatomic data to establish critical steps and maneuvers. Curr Urol Rep. 2005 Mar;6(2):126–128. Review . [PubMed: 15717970]
669.
Tewari A, El-Hakim A, Leung RA. Robotic prostatectomy: a pooled analysis of published literature. Expert Rev Anticancer Ther. 2006 Jan;6(1):11–20. Review . [PubMed: 16375639]
670.
Tewari A, Kaul S, Menon M. Robotic radical prostatectomy: a minimally invasive therapy for prostate cancer. Curr Urol Rep. 2005 Feb;6(1):45–48. Not eligible exposure . [PubMed: 15610696]
671.
Tewari A, Menon M. Vattikuti Institute prostatectomy: surgical technique and current results. Curr Urol Rep. 2003 Apr;4(2):119–123. Not eligible exposure . [PubMed: 12648428]
672.
Tewari A, Peabody J, Sarle R. et al. Technique of da Vinci robot-assisted anatomic radical prostatectomy. Urology. 2002 Oct;60(4):569–572. Not eligible exposure . [PubMed: 12385908]
673.
Tewari A, Srivasatava A, Menon M. A prospective comparison of radical retropubic and robot-assisted prostatectomy: experience in one institution. BJU Int. 2003 Aug;92(3):205–210. Not eligible exposure . [PubMed: 12887468]
674.
Thompson IM, Canby-Hagino E, Lucia MS. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst. 2005 Sep 7;97(17):1236–1237. Comment . [PubMed: 16145036]
675.
Thompson IM, Coltman CA. Screening for prostate cancer: opportunities for prevention. Semin Urol Oncol. 1996 May;14(2 Suppl 2):4–10. discussion 10–11. Review. [PubMed: 8725886]
676.
Thorpe AC, Cleary R, Coles J. et al. Nottingham health profile measurement in the assessment of clinical outcome after prostatectomy. Northern Regional Prostate Audit Group. Br J Urol. 1995 Oct;76(4):446–450. Not eligible exposure . [PubMed: 7551879]
677.
Tiguert R, Hurley PM, Gheiler EL. et al. Treatment outcome after radical prostatectomy is not adversely affected by a pre-existing penile prosthesis. Urology. 1998 Dec;52(6):1030–1033. Not eligible exposure . [PubMed: 9836550]
678.
Tiguert R, Rigaud J, Lacombe L. et al. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol. 2003 Aug;170(2 Pt 1):447–450. Not eligible exposure . [PubMed: 12853796]
679.
Tobias-Machado M, Lasmar MT, Medina JJ. et al. Preliminary experience with extraperitoneal endoscopic radical prostatectomy through duplication of the open technique. Int Braz J Urol. 2005 May–Jun;31(3):228–235. No provider characteristics . [PubMed: 15992425]
680.
Tol-Fakkar M, Hermansson CG, Hugosson J. et al. Radical prostatectomy—long-term oncological outcome from a community hospital. Scand J Urol Nephrol. 2003;37(5):376–381. Not eligible exposure . [PubMed: 14594684]
681.
Tombal B, Van Cangh PJ, Loric S. et al. Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate. 2003 Aug 1;56(3):163–170. Not eligible exposure . [PubMed: 12772185]
682.
Touijer AK, Guillonneau B. Laparoscopic radical prostatectomy. Urol Oncol. 2004 Mar–Apr;22(2):133–138. Review . [PubMed: 15082012]
683.
Touma NJ, Izawa JI, Chin JL. Current status of local salvage therapies following radiation failure for prostate cancer. J Urol. 2005 Feb;173(2):373–379. Not eligible exposure . [PubMed: 15643174]
684.
Trabulsi EJ, Guillonneau B. Laparoscopic radical prostatectomy. J Urol. 2005 Apr;173(4):1072–1079. Review . [PubMed: 15758704]
685.
Trabulsi EJ, Hassen WA, Touijer AK. et al. Laparoscopic radical prostatectomy: a review of techniques and results worldwide. Minerva Urol Nefrol. 2003 Dec;55(4):239–250. Review . [PubMed: 14765016]
686.
Trachtenberg J. Appraisal of current therapies for prostate cancer. Eur Urol. 1996;29(Suppl 2):110–113. Review . [PubMed: 8717472]
687.
Tse E, Knaus R. Laparoscopic radical prostatectomy - results of 200 consecutive cases in a Canadian medical institution. Can J Urol. 2004 Apr;11(2):2172–2185. No provider characteristics . [PubMed: 15182406]
688.
Tsien C, Griffith KA, Sandler HM. et al. Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy. Urology. 2003 Jul;62(1):93–98. Not eligible exposure . [PubMed: 12837430]
689.
Tsien C, Sandler H. Salvage radiotherapy in the treatment of prostate cancer. Urology. 2003 Dec 29;62(Suppl 1):63–68. Review . [PubMed: 14747043]
690.
Tsihlias J, Kapusta LR, DeBoer G. et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998 Feb 1;58(3):542–548. Not eligible exposure . [PubMed: 9458103]
691.
Tsui KH, Sun GH, Huang ST. et al. Minilaparotomy radical retropubic prostatectomy for prostate cancer. Arch Androl. 2004 Jan–Feb;50(1):23–25. Not eligible exposure . [PubMed: 14660167]
692.
Tucker RD. Use of interstitial temperature self-regulating thermal rods in the treatment of prostate cancer. J Endourol. 2003 Oct;17(8):601–607. Review . [PubMed: 14622479]
693.
Tunc M, Sanli O, Kandirali E. et al. Should high-grade prostatic intraepithelial neoplasia change our approach to infravesical obstruction? Urol Int. 2005;74(4):332–336. Not eligible exposure . [PubMed: 15897699]
694.
Turk I, Deger S, Winkelmann B. et al. Laparoscopic radical prostatectomy. Technical aspects and experience with 125 cases. Eur Urol. 2001 Jul;40(1):46–52. discussion 53. No provider characteristics. [PubMed: 11528176]
695.
Underwood W 3rd, Wei J, Rubin MA. et al. Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. Urol Oncol. 2004 Jan–Feb;22(1):20–24. Not eligible exposure . [PubMed: 14969799]
696.
Ung JO, Richie JP, Chen MH. et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology. 2002 Sep;60(3):458–463. Not eligible exposure . [PubMed: 12350484]
697.
Valeri A, Fromont G, Sakr W. et al. High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy. Urol Oncol. 2005 Mar–Apr;23(2):87–92. Not eligible exposure . [PubMed: 15869992]
698.
Valicenti RK, Chervoneva I, Gomella LG. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1093–1097. Not eligible exposure . [PubMed: 15001249]
699.
Valicenti RK, Gomella LG, El-Gabry EA. et al. The multidisciplinary clinic approach to prostate cancer counseling and treatment. Semin Urol Oncol. 2000 Aug;18(3):188–191. Not eligible exposure . [PubMed: 10975490]
700.
Valicenti RK, Gomella LG, Ismail M. et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):53–58. Not eligible exposure . [PubMed: 10477006]
701.
van den Brule FA, Waltregny D, Castronovo V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol. 2001 Jan;193(1):80–87. Not eligible exposure . [PubMed: 11169519]
702.
van den Ouden D, Hop WC, Kranse R. et al. Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol. 1997 Feb;79(2):203–211. Not eligible exposure . [PubMed: 9052471]
703.
van den Ouden D, Schroder FH. Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery. World J Urol. 2000 Jun;18(3):194–203. Review . [PubMed: 10926084]
704.
van der Kwast TH, Labrie F, Tetu B. Prostatic intraepithelial neoplasia and endocrine manipulation. Eur Urol. 1999;35(56):508–510. Not eligible exposure . [PubMed: 10325515]
705.
Van Poppel H, Boulanger SF, Joniau S. Quality assurance issues in radical prostatectomy. Eur J Surg Oncol. 2005 Aug;31(6):650–655. Review . [PubMed: 16023946]
706.
Van Poppel H, Vanuytsel L, Petrovich Z. et al. Is postoperative irradiation after radical prostatectomy necessary? Eur J Cancer. 1999 Dec;35(13):1763–1770. Review . [PubMed: 10673989]
707.
van Vulpen M, Raaymakers BW, Lagendijk JJ. et al. Three-dimensional controlled interstitial hyperthermia combined with radiotherapy for locally advanced prostate carcinoma—a feasibility study. Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):116–126. No provider characteristics . [PubMed: 12007949]
708.
Vanasupa BP, Miller TA, Schwartz BF. Diagnosis of prostate adenocarcinoma using transurethral resection of the prostate after multiple negative transrectal biopsies and persistently elevated prostate-specific antigen level. Urology. 2000 Dec 20;56(6):1056. Not eligible exposure . [PubMed: 11113765]
709.
Vanasupa BP, Paquette EL, Wu H. et al. The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL. Urol Oncol. 2002 Jul–Aug;7(4):167–172. Not eligible exposure . [PubMed: 12474533]
710.
Vargas C, Kestin LL, Weed DW. et al. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714–724. Not eligible exposure . [PubMed: 15708249]
711.
Varkarakis J, Pinggera GM, Sebe P. et al. Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program. Urology. 2004 Feb;63(2):337–341. Not eligible exposure . [PubMed: 14972485]
712.
Vassilikos EJ, Yu H, Trachtenberg J. et al. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clin Biochem. 2000 Mar;33(2):115–123. Not eligible exposure . [PubMed: 10751589]
713.
Vellet AD, Saliken J, Donnelly B. et al. Prostatic cryosurgery: use of MR imaging in evaluation of success and technical modifications. Radiology. 1997 Jun;203(3):653–659. Not eligible exposure . [PubMed: 9169684]
714.
Vesalainen S, Lipponen P, Nordling S. et al. Results of the primary treatment in T1–3M0 prostatic adenocarcinoma are dependent on tumour biology. Anticancer Res. 1995 Mar–Apr;15(2):569–573. Not eligible exposure . [PubMed: 7763039]
715.
Vicini FA, Ziaja EL, Kestin LL. et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology. 1999 Jul;54(1):111–117. Not eligible exposure . [PubMed: 10414736]
716.
Villa S, Bedini N, Fallai C. et al. External beam radiotherapy in elderly patients with clinically localized prostate adenocarcinoma: age is not a problem. Crit Rev Oncol Hematol. 2003 Nov;48(2):215–225. Not eligible exposure . [PubMed: 14607384]
717.
Vis AN, Noordzij MA, Fitoz K. et al. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol. 2000 Dec;164(6):2156–2161. Not eligible exposure . [PubMed: 11061947]
718.
Vodopija N, Zupancic M, Korsic L. et al. Laparoscopic radical prostatectomy—analysis of our first 100 consecutive cases. Coll Antropol. 2004 Jun;28(1):429–437. No provider characteristics . [PubMed: 15636102]
719.
Voges GE, Mottrie AM, Stockle M. et al. Hormone therapy prior to radical prostatectomy in patients with clinical stage C prostate cancer. Prostate Suppl. 1994;5:4–8. Not eligible exposure . [PubMed: 7513531]
720.
Volavsek M, Masera A, Ovcak Z. Incidental prostatic carcinoma. A predictive role of neoangiogenesis and comparison with other prognostic factors. Pathol Oncol Res. 2000;6(3):191–196. Not eligible exposure . [PubMed: 11033459]
721.
Vollmer RT, Humphrey PA. The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer. Am J Clin Pathol. 2001 Dec;116(6):864–870. Not eligible exposure . [PubMed: 11764075]
722.
Vollmer RT, Keetch DW, Humphrey PA. Predicting the pathology results of radical prostatectomy from preoperative information: a validation study. Cancer. 1998 Oct 15;83(8):1567–1580. Not eligible exposure . [PubMed: 9781951]
723.
Walsh IK, Williams SG, Mahendra V. et al. Artificial urinary sphincter implantation in the irradiated patient: safety, efficacy and satisfaction. BJU Int. 2002 Mar;89(4):364–368. Not eligible exposure . [PubMed: 11872025]
724.
Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol. 2000 Jun;163(6):1802–1807. Review . [PubMed: 10799186]
725.
Ward JF, Blute ML, Slezak J. et al. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003 Nov;170(5):1872–1876. Not eligible exposure . [PubMed: 14532796]
726.
Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May;15(3):181–186. Review . [PubMed: 15815195]
727.
Ward JF, Sebo TJ, Blute ML. et al. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol. 2005 Apr;173(4):1156–1160. Not eligible exposure . [PubMed: 15758726]
728.
Ward JF, Slezak JM, Blute ML. et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005 Apr;95(6):751–756. Not eligible exposure . [PubMed: 15794776]
729.
Warde P, Gospodarowicz MK. Progress in prostate cancer. Cmaj. 1997 Dec 15;157(12):1685–1686. Review . [PMC free article: PMC1228646] [PubMed: 9418660]
730.
Wasson J, Fleming C, Bruskewitz R. et al. The treatment of localized prostate cancer: what are we doing, what do we know, and what should we be doing? The Prostate Patient Outcome Research Team. Semin Urol. 1993 Feb;11(1):23–26. Not eligible exposure . [PubMed: 8465125]
731.
Watson R, Soloway MS. Is there a role for induction androgen deprivation prior to radical prostatectomy? Hematol Oncol Clin North Am. 1996 Jun;10(3):627–641. Review . [PubMed: 8773501]
732.
Watson RB, Soloway MS. Neoadjuvant hormonal treatment before radical prostatectomy. Semin Urol Oncol. 1996 May;14(2 Suppl 2):48–55. discussion 55–46. Review. [PubMed: 8725891]
733.
Weber BA, Roberts BL, Resnick M. et al. The effect of dyadic intervention on self-efficacy, social support, and depression for men with prostate cancer. Psychooncology. 2004 Jan;13(1):47–60. Not eligible exposure . [PubMed: 14745745]
734.
Weldon VE. Technique of modern radical perineal prostatectomy. Urology. 2002 Oct;60(4):689–694. Review . [PubMed: 12385936]
735.
Wennberg J. Some considerations in outcomes research. J Vasc Interv Radiol. 1995 Nov–Dec;6(6 Pt 2 Su):102S–103S. Not eligible exposure . [PubMed: 8770851]
736.
Whelan P. The case against radical prostatectomy. Ann R Coll Surg Engl. 2005 May;87(3):161–162. Comment . [PMC free article: PMC1963926] [PubMed: 15920789]
737.
Wiegel T, Bressel M. Stage D1 prostate cancer—is radiotherapy and early hormonal therapy equivalent to radical prostatectomy, radiotherapy, and early hormonal therapy? regarding Sands et al., IJROBP 31:13–19; 1995. Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):896–897. Comment . [PubMed: 7790281]
738.
Wiegel T, Hinkelbein W. Radiotherapy after radical prostatectomy in patients with prostate-specific antigen elevation. Front Radiat Ther Oncol. 2002;36:35–42. Review . [PubMed: 11842753]
739.
Wiegel T, Hinkelbein W. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2002 Jan;62(1):115. Not eligible exposure . [PubMed: 11830322]
740.
Wiig JN, Waehre H, Larsen SG. et al. Radical prostatectomy for locally advanced primary or recurrent rectal cancer. Eur J Surg Oncol. 2003 Jun;29(5):455–458. Not eligible exposure . [PubMed: 12798751]
741.
Wilder RB, Hsiang JY, Ji M. et al. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy. Am J Clin Oncol. 2000 Apr;23(2):176–180. Not eligible exposure . [PubMed: 10776980]
742.
Grant William B. Geographic variation of prostate cancer mortality rates in the United States: Implications for prostate cancer risk related to vitamin D. International Journal of Cancer. 2004;111(3):470–471. Comment . [PubMed: 15221981]
743.
Williams RD. Prostate cancer outcomes studies—the pathway to improvement. J Urol. 1998 Jan;159(1):172. Comment . [PubMed: 9400464]
744.
Willie Underwood JJ III, Wei John T, Dunn Rodney. et al. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer. 2005;103(3):538–545. Not eligible exposure . [PubMed: 15612083]
745.
Wilson LC, Kennett KM, Gilling PJ. Laparoscopic radical prostatectomy: early safety and efficacy. ANZ J Surg. 2004 Dec;74(12):1065–1068. Not eligible exposure . [PubMed: 15574150]
746.
Wilt T. Prostate cancer: non-metastatic Clin Evid. Jun 2002(7):812–823. Review. [PubMed: 12230707]
747.
Wilt TJ. Prostate cancer screening: practice what the evidence preaches. Am J Med. 1998 Jun;104(6):602–604. Comment . [PubMed: 9674725]
748.
Wilt TJ. Prostate carcinoma practice patterns: what do they tell us about the diagnosis, treatment, and outcomes of patients with prostate carcinoma? Cancer. 2000 Mar 15;88(6):1277–1281. Editorial . [PubMed: 10717606]
749.
Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol. 1994 Nov;152(5 Pt 2):1910–1914. Not eligible exposure . [PubMed: 7523736]
750.
Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial (PIVOT) Oncology (Williston Park) 1997 Aug;11(8):1133–1139. discussion 1139–1140, 1143. Review. [PubMed: 9268976]
751.
Winkler MH, Gillatt DA. Learning curve and stage migration of a radical retropubic prostatectomy series over a 10-y period. Prostate Cancer Prostatic Dis. 2004;7(3):258–262. No provider characteristics . [PubMed: 15224089]
752.
Wirth M, Tyrrell C, Delaere K. et al. Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer Prostatic Dis. 2005;8(2):194–200. Not eligible exposure . [PubMed: 15931272]
753.
Wirth MP, Froehner M. Perspectives in adjuvant treatment of prostate cancer. Urol Int. 2002;68(1):1–5. Review . [PubMed: 11803260]
754.
Wirth MP, Froehner M. Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program. Oncology. 2003;65(Suppl 1):1–4. Review . [PubMed: 12949426]
755.
Wirth MP, Weissbach L, Marx FJ. et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol. 2004 Mar;45(3):267–270. discussion 270. Not eligible exposure. [PubMed: 15036669]
756.
Wong WS, Chinn DO, Chinn M. et al. Cryosurgery as a treatment for prostate carcinoma: results and complications. Cancer. 1997 Mar 1;79(5):963–974. No provider characteristics . [PubMed: 9041159]
757.
Woo TC, Choo R, Jamieson M. et al. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer. 2005;51(1):32–36. Not eligible exposure . [PubMed: 15749627]
758.
Yang G, Timme TL, Frolov A. et al. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer. 2005 Mar 15;103(6):1186–1194. Not eligible exposure . [PubMed: 15712208]
759.
Yoon JH, Chen MH, Renshaw AA. et al. Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer. Urology. 2002 Sep;60(3):454–457. Not eligible exposure . [PubMed: 12350483]
760.
Yoshimura K, Arai Y, Ichioka K. et al. A 3-y prospective study of health-related and disease-specific quality of life in patients with nonmetastatic prostate cancer treated with radical prostatectomy or external beam radiotherapy. Prostate Cancer Prostatic Dis. 2004;7(2):144–151. Not eligible exposure . [PubMed: 15111981]
761.
Yoshimura K, Ichioka K, Terada N. et al. Use of complementary and alternative medicine by patients with localized prostate carcinoma: study at a single institute in Japan. Int J Clin Oncol. 2003 Feb;8(1):26–30. Not eligible exposure . [PubMed: 12601539]
762.
Yoshimura K, Sumiyoshi Y, Hashimura T. et al. Neoadjuvant flutamide monotherapy for locally confined prostate cancer. Int J Urol. 2003 Apr;10(4):190–195. Not eligible exposure . [PubMed: 12657097]
763.
Youssef E, Forman JD, Tekyi-Mensah S. et al. Therapeutic postprostatectomy irradiation. Clin Prostate Cancer. 2002 Jun;1(1):31–36. Not eligible exposure . [PubMed: 15046710]
764.
Yu KK, Hricak H, Grossfeld GD. et al. Prediction of patient outcome after radical prostatectomy by imaging: choice of outcome measure. Acad Radiol. 1998 Sep;5(Suppl 2):S347–348. Not eligible exposure . [PubMed: 9750850]
765.
Yu Y, Schell MC, Rubin P. Circumventing the learning curve of dose and volume in intravascular brachytherapy. Cardiovasc Radiat Med. 1999 Apr–Jun;1(2):170–171. Editorial . [PubMed: 11229551]
766.
Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer. 1993 Sep 1;72(5):1709–1725. Not eligible exposure . [PubMed: 7688659]
767.
Zelefsky MJ, Whitmore WF Jr, Leibel SA. et al. Impact of transurethral resection on the long-term outcome of patients with prostatic carcinoma. J Urol. 1993 Dec;150(6):1860–1864. Not eligible exposure . [PubMed: 8230519]
768.
Zhang Y, Glass A, Bennett N. et al. Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization. Cancer. 2004 Jan 15;100(2):300–307. Not eligible exposure . [PubMed: 14716764]
769.
Zhang Y, Zippe CD, Van Lente F. et al. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells. Clin Cancer Res. 1997 Jul;3(7):1215–1220. Not eligible exposure . [PubMed: 9815802]
770.
Ziada AM, Lisle TC, Snow PB. et al. Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network. Cancer. 2001 Apr 15;91(8 Suppl):1653–1660. Review . [PubMed: 11309764]
771.
Zietman AL, Edelstein RA, Coen JJ. et al. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology. 1994 Jun;43(6):828–833. Not eligible exposure . [PubMed: 7515206]
772.
Zietman AL, Shipley WU, Coen JJ. Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. J Urol. 1994 Nov;152(5 Pt 2):1806–1812. Review . [PubMed: 7523726]
773.
Zincke H. Radical prostatectomy and exenterative procedures for local failure after radiotherapy with curative intent: comparison of outcomes. J Urol. 1992 Mar;147(3 Pt 2):894–899. Not eligible exposure . [PubMed: 1538491]
774.
Zincke H, Oesterling JE, Blute ML. et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994 Nov;152(5 Pt 2):1850–1857. Not eligible exposure . [PubMed: 7523733]
775.
Zippe CD. Cryosurgery of the prostate: techniques and pitfalls. Urol Clin North Am. 1996 Feb;23(1):147–163. Review . [PubMed: 8677533]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (947K)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...